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Abstract 
Understanding the molecular mechanisms regulating cardiac cell proliferation during the 
embryonic, fetal and adult life holds a paramount importance in view of developing innovative 
strategies aimed at inducing myocardial regeneration after cardiac damage. Previous high 
throughput screening studies in our laboratory identified a series of microRNAs able to trigger 
cardiomyocyte proliferation and stimulate cardiac regeneration after myocardial infarction.  
In the first part of this project, we investigated the mechanism of action of the top ten most 
effective of these miRNAs, revealing an involvement of the Hippo-YAP pathway in their action. 
We found that all the investigated miRNAs activated YAP-mediated transcription, nuclear 
localization of active YAP and increased expression of YAP responsive genes. Of notice, miR-
199a-3p, one of the most effective miRNAs exerted its direct effect on two mRNA targets 
impinging on the Hippo pathway, the inhibitory kinase TAOK1 and the E3 ubiquitin ligase, 
β−TrCP. Most of the miRNAs inducing proliferation (including miR-199a-3p) also modulated the 
dynamics of the actin cytoskeleton in the treated cardiomyocytes, which displayed a rounded shape 
and gross bundles of actin fibers at the cytoplasm periphery. Consistent with these observations, we 
found that the Cofilin2 mRNA was a direct target of four of the investigated miRNAs and that 
downregulation of Cofilin2 itself was sufficient to promote cardiomyocyte proliferation, activate 
nuclear translocation of YAP and stimulate transcription of TEAD-responsive genes.  
The second part of the project was aimed at identifying small molecules exerting a mitogenic effect 
on neonatal cardiomyocytes through an unbiased high-throughput screening (HTS) of a library of 
780 FDA-registered drugs. The neuroactive alkaloid harmine was identified as the most powerful 
molecule at inducing cardiomyocyte proliferation in vitro and heart regeneration after myocardial 
infarction in vivo. Harmine exerted its activity through the inhibition of the dual specificity 
phosphorylation-regulated tyrosine kinase, Dyrk1a and, again, the activation of YAP nuclear 
translocation.  
Collectively, these results identify both YAP activation and actin cytoskeleton remodelling as 
major determinants of cardiomyocyte proliferation and establish the molecular basis for the 
development of pharmacological therapies to promote heart regeneration through the stimulation of 
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1.1 Introduction to cardiovascular diseases 
Therapeutic strategies for cardiovascular diseases have been the challenge of the last century. In 
fact, cardiovascular diseases are one of the leading causes of death worldwide. In USA only, 
ischemic cardiomyopathies affects 7.1 millions people and 4.5 millions patients suffer of cardiac 
insufficiency after myocardial infarction, associated with a mortality rate of more than 50% 
within the follow-up period of 5 years (Writing Group, Mozaffarian et al. 2016). 
Ischemic heart failure, as a consequence of myocardial infarction, occurs when cardiac tissue is 
deprived of oxygen, due to a coronary arterial obstruction. When the ischemic injury is severe 
enough to cause loss of critical amounts of cardiomyocytes, a series of sequential pathological 
events occur, including formation of a non-contractile scar, ventricular wall thinning, overload of 
blood flow that lead to ventricular remodeling, heart failure and most probably to death 
(Mahmoud and Porrello 2012). 
The therapies currently available for patients with myocardial infarction and heart failure, 
including treatment with ACE-inhibitors, diuretics and beta- blockers, aim at reducing the impact 
of fibrotic remodeling, thus improving the morphological and functional impairment of the 
injured heart. However, none of these therapies are able to solve the real critical problem of an 
infarcted heart, namely the dramatic depletion of cardiomyocytes causing a severe reduction of 
cardiac contractility and pump function. Therefore, there is a compelling need to explore 
alternative approaches and new therapeutic strategies aiming at regenerating the injured heart and 
increasing its physiological functions.  
1.2 Heart regeneration 
In the animal kingdom, the regenerative potential is not equally distributed among species. 
Invertebrates, such as insects, planarians and echinoderms, have a strong regenerative ability. 
Among vertebrates, Axolotl, zebrafish and newts are great examples of regeneration after damage 
of many different organs, such as limbs or fins. In mammals, this regenerative potential is very 
limited and restricted to minor parts of the body.  The peculiar ability of vertebrates to regenerate 
is closely related to their capacity to maintain the developmental transcriptional profile ready-to-
use. Understanding the peculiar mechanisms of regeneration remains a great challenge in 
regenerative medicine, especially to face damages to those tissues with poor proliferative 
capability, including the heart. In this respects, pioneering studies by Poss and Oberpriller 
reported examples of complete heart regeneration in salamander and zebrafish after heart 
resection of the left ventricular apex (Poss, Wilson et al. 2002) (Oberpriller and Oberpriller 1974). 
Regeneration is due to dedifferentiation of pre-existing cardiomyocytes adjacent to the resected 
area, a process sustained by sarcomere breakdown and cytoskeletal remodeling. A specific gene 
expression program drives cardiomyocyte differentiation, driven by GATA4 (Lepilina, Coon et 
al. 2006) and Hand2 (Schindler, Garske et al. 2014). Of note, the newly formed cardiomyocytes 
are fully able to functionally integrate into the preexisting myocardium. 
	 11	
 
Multiple recent evidence has demonstrated that the mammalian heart retains its proliferative 
potential during embryonic development and early post-natal period, while it rapidly looses it 
after birth (van Amerongen and Engel 2008). In humans, cardiomyocyte cell cycle withdrawal 
seems to arise around the first year of life, as concluded from recent findings (Li, Wang et al. 
1996, Mollova, Bersell et al. 2013) (Bergmann, Zdunek et al. 2015). 
A complete functional rescue of cardiac function after acute myocardial ischemia has been 
recently reported to occur in a two months-old baby with myocardial infarction (Haubner, 
Schneider et al. 2016). This evidence further strengthen previously published hypotheses, 
suggesting the possibility of heart regeneration in children and newborns, as observed in rodents 
(Macmahon 1937, Saker, Walsh-Sukys et al. 1997). In the adult life, injured myocardial tissue is 
largely replaced by a fibrotic scar, resulting from the lack of proliferative potential of adult 
cardiomyocytes. However, a limited capacity of cardiac renewal can still occur in adult animals, 
as demonstrated by using transgenic mice (Hsieh, Segers et al. 2007), the carbon-dating technique 
in humans (Bergmann, Bhardwaj et al. 2009) or the thymidine-labelling experiments in mice 
(Soonpaa and Field 1997). A fundamental question was to identify the cell types involved in this 
regeneration process. Pre-existing cardiomyocytes were identified as the main source of heart 
regeneration after injury in a model of apical resection in transgenic cmlc2:EGFP zebrafish 
(Jopling, Sleep et al. 2010) and in rodents (Hsieh, Segers et al. 2007, Senyo, Steinhauser et al. 
2013).  
In the rodent studies, cardiac cell turnover was estimated to be of 0.76% per year in young adult 
mice, which decreases with age. This rate resulted significantly increased (4 folds) in the infarct 
border zone, after myocardial injury. In humans, the measurement by mass spectrometry of 
carbon-14 incorporated in the DNA during the Cold War in the atomic weapon-testing period was 
used as a tool to date human cardiomyocytes. Exploiting this technique, it was estimated a 
cardiomyocyte renewal of about 1% per year in in young adults, which decreases to 0.45% in 
aged people (Bergmann, Bhardwaj et al. 2009). Although an innate cardiomyocyte turnover has 
been detected, this is clearly not sufficient to compensate for the critical cardiac cell loss after 
myocardial infarction. Therefore, understanding the molecular pathways determining the re-entry 
of cardiomyocytes into the cell cycle remains a critical goal of current research.  
 
1.2.1 Learning from evolution: filling the gap between amphibians and 
mammals 
1.2.1.1 Evolutionary and developmental adaptations in heart regeneration  
Morphological differences in heart among species are results of the adaptation from aquatic to 
terrestrial life. Since these differences correlate with a decreasing heart regeneration capability, it 
appears important to understand the morphological and physiological changes occurred during 
this transitions. 
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The differences between mammals and amphibians consist not only in cardiac chamber 
morphology, but also in the presence of a complex coronary vasculature, which is not present in 
amphibians (Reese, Mikawa et al. 2002, Perez-Pomares, Gonzalez-Rosa et al. 2009). Pressure, 
temperature, hypoxia, metabolism, immune response and blood clotting all parameters that 
significantly changed during the transition of life to earth. 
1.2.1.2 Pressure  
The conquest of terrestrial land forced the evolution to supply animals of a closed circulatory 
system. In the early stage of mammal life, a significant increase in blood pressure correlated with 
an increase of mechanical load on ventricular walls (Hillman, Kallapur et al. 2012), resulting in 
cardiomyocyte adaptive changes, with important consequences at the structural and metabolic 
levels. Recent evidence sustain the hypothesis that the increased mechanical load in adult human 
heart is responsible for cardiomyocyte cell cycle arrest, as ventricular unloading stimulates 
cardiomyocyte proliferation (Canseco, Kimura et al. 2015). According to this notion, mammals 
might have lost their heart regenerative capability to achieve a more functional pumping heart.  
1.2.1.3 Body temperature 
Another important factor, correlated to the loss of cardiac regeneration ability in vertebrates, is 
body temperature. In fact, it is known that neonatal mice, similar to fish and amphibians, do not 
have a thermoregulatory system. Interestingly, this peculiarity is somehow conserved in human 
infants, who still are not able to maintain constant the body temperature. Thermoregulation is 
achieved in adult organisms (Tourneux, Libert et al. 2009).  The environmental temperature 
seems to have an effect in many examples of regeneration. For limb regeneration, newts prefer a 
warmer environment (Tattersall, Tyson et al. 2012). Also in fish, the time frame necessary for 
completing fin regeneration seems to be dependent from temperature (Sirbulescu and Zupanc 
2010). Finally, an in vivo model of brain injury suggests an enhanced regeneration after cerebral 
ischemia in hypothermic conditions (Yenari and Han 2013). No specific data are currently 
available on temperature in cardiac tissue of various organisms, however, it appears reasonable to 
conclude that the thermoregulatory system, similar to metabolic efficiency, might have resulted as 
a consequence of an important evolutionary pressure. This might have influenced the loss of 
regenerative ability. 
1.2.1.4 Oxygen concentration 
Another key player in tissue regeneration is oxygen tension. Interestingly, the level of 
cardiomyocyte oxygenation dramatically changes from embryonic to post-natal life and mimics 
the shift in oxygen concentration happened in evolution when life moved from water to land. 
Interestingly, species with high regenerative ability live in a hypoxic habitat. Recent studies 
(Puente, Kimura et al. 2014) (Nakada, Canseco et al. 2017) have raised the possibility that high 
oxygen tension is involved in the cardiomyocyte cell cycle arrest, due to the induction of the 
DNA damage response because of reactive oxygen species. Moreover, it is well accepted that the 
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subpopulation of CMs responsible for cardiac renewal shows low metabolic activity and a gene 
expression profile typical of the one detected in hypoxic conditions (Kimura, Xiao et al. 2016). 
Of note, in the mammalian adult heart, the gradual exposure to a systemic hypoxemia reactivates 
the endogenous regenerative potential, unveiling the relevance of hypoxia in the regenerative 
process (Nakada, Canseco et al. 2017).   
1.2.1.5 Metabolism 
Adaptation of cardiac cells to an oxygen-rich environment triggered important metabolic changes. 
During fetal life, the glycolytic pathway is the main source of ATP. At birth, cardiomyocytes 
undergo profound metabolic changes resulting in a more efficient strategy to supply energy 
through the mitochondrial oxidative phosphorylation process (Gong, Song et al. 2015). Despite its 
higher efficiency, oxidative phosphorylation generates many reactive oxygen species (ROS), 
which trigger the activation of the DNA damage response and, consequently, the exit of 
cardiomyocytes from the cell cycle (Puente, Kimura et al. 2014). Gross metabolic changes occur 
also in case of heart failure. Since the oxygen tension in the case of ischemic heart damage is very 
similar to neonatal hypoxic conditions, in a mouse model of myocardial infarction a decrease of 
fatty acid oxidative phosphorylation has been detected parallel to an increase in glycolysis. These 
changes are theoretically favorable to regeneration, but, despite the decrease in oxidative 
phosphorylation, no significant changes in the glycolytic pathway are detected, nor a significant 
regeneration of the injured tissue (Nakada, Canseco et al. 2017). This evidence suggests that, in 
order to create a favorable environment for cardiomyocyte cell cycle re-entry, the metabolic 
switch per se is not sufficient, but it requires a complex regulation of different biochemical and 
biophysical processes, still under intense investigation. 
1.2.1.6 Immune system 
Another intriguing hypothesis inversely links the tissue regenerative potential along evolution to 
the development of a mature immune system. In non-mammalian vertebrates a specialized 
immune system is absent (Buchmann 2014) and, in neonatal mammals, the immune system has 
very weak pro-inflammatory activity (Sattler and Rosenthal 2016). 
The absence of the adaptive immune response in amphibians correlates with the great 
performance in regenerating limbs as if a more permissive immune surveillance would be 
required to allow regeneration to happen (Epelman, Liu et al. 2015). Of note, key effectors of the 
regenerative process in zebrafish, amphibians and in neonatal mice are macrophages (Godwin, 
Pinto et al. 2013) (Lavine, Epelman et al. 2014). Macrophages are massively recruited at the site 
of heart damage in both neonatal and adults, and are mainly involved in the neoangiogenesis 
process of the newly-formed tissue, without any direct role in cardiomyocyte proliferation 
(Lavine, Epelman et al. 2014). Therefore, even if the adaptive immunity is a potent weapon 
against infectious diseases, it might be detrimental for regeneration, since it is responsible for the 
localized inflammatory response at the site of injury, which triggers the release of many 
cytokines, possibly inhibiting cardiac cell proliferation. 
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1.2.1.7 Blood clotting 
The role of blood clotting is a controversial topic in the field of heart regeneration. . In some 
conditions, clotting factors are able to induce regeneration. Some examples are given by mouse 
liver regeneration and salamander lens: in these cases, platelet activation and other coagulation 
events are able to start the molecular signaling required for the regenerative response (Lesurtel, 
Graf et al. 2006). Thrombin is a clotting factor responsible for an opposite effect on lens 
regeneration in newt and axolotl, although it stimulates newt myocyte proliferation in vitro 
(Imokawa, Simon et al. 2004). A different molecule (PDGF-BB), secreted by platelets, induces 
epicardial cells to start neovascularization in a model of heart regeneration in zebrafish (Kim, Wu 
et al. 2010). However, since blood clotting is not only involved in tissue regeneration but also in 
repair, the mechanisms involved in these opposite events are still under debate. 
1.2.1.8 Structural organization of cardiac myocytes 
The contractile protein apparatus of cardiomyocytes greatly differs between mammalian and non-
mammalian vertebrates. A recent proteomic study highlights the differences at protein level 
between adult zebrafish and mouse hearts and their neonatal counterparts (Gomes, Skroblin et al. 
2016). The findings confirmed that neonatal hearts share a similar pattern of immature 
myofilaments, with a limited number of structural proteins, such as Myh6, Myl2 and Myoz2, 
expressed in mature cardiomyocytes (Gomes, Skroblin et al. 2016). The innate regenerative 
potential of zebrafish and mouse neonatal hearts is probably associated with an immature 
sarcomere structure which renders cardiac cells more prone to divide. Actually, it is well assessed 
that the ability to disassemble sarcomere is required for cardiomyocytes to proliferate (Ahuja, 
Perriard et al. 2004). Conversely, the structural rigidity of adult mammalian cardiac cells, 
acquired during adaptation to the increased workload, is a strong physical barrier for 
cardiomyocyte proliferation and therefore regeneration. 
1.2.1.9 Cardiomyocyte nucleation 
Another important feature shared by zebrafish, newt and fetal cardiac cells is the mono-nucleation 
of myocytes (Senyo, Lee et al. 2014). Among mammals, cardiomyocyte binucleation occurs 
during the first weeks after birth in rodents and at the end of gestation in sheep and humans 
(Jonker, Zhang et al. 2007). The rate of binucleation in humans is below the average observed in 
other species and, after birth, cardiac cells get polyploid, a feature of terminally differentiated 
cardiomyocytes (Mollova, Bersell et al. 2013). The meaning of this process is unclear: it might be 
due to the rapid growth occurring after birth in mammalian vertebrates, which results in an 
increased demand of transcriptional activity, connected to higher energetic requirements of the 
adult life.  
 
The analysis of the regenerative potential through evolution suggests that, in mammals, postnatal 
normoxic environment triggered a significant increase of ROS production and possibly the 
activation of the DNA damage response, might be responsible for the cell cycle arrest of adult 
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cardiac myocytes. Moreover, structural constrains seem to be greatly involved in the impairment 




FIGURE 1-1 CARDIAC REGENERATIVE CAPABILITY IN DIFFERENT SPECIES 
From zebrafish to humans, heart regenerative potential after injury is significantly diminished. Different 
pathways lead to recover the damaged tissue in different species. In blue are shown genes , promoting heart 
regeneration, in red those responsible for inhibition. A-V, atrial-ventricular; EMT, epithelial- mesenchymal 
transition; MI, myocardial infarction. Adapted from (Sahara, Santoro et al. 2015). 
1.2.2 Contributors to heart regeneration: all for one and one for all 
If the analysis of morphological and physiological changes of the heart along evolution can 
contribute to find the reason why heart regeneration does not occur in mammals, deep 
understanding of organogenesis during embryonic life can give important insight as well. The 
contribution of several cell types in the repair process strictly resembles the series of events 
occurring during organogenesis. Indeed, regeneration arises from a complex network of signaling 
networks aimed at organizing cell proliferation, migration, differentiation and functional 
integration. In the case of myocardial regeneration, four important processes have been reported 
as key players: angiogenesis, extracellular matrix signaling (ECM), immune response and 
innervation.  
1.2.2.1 Angiogenesis 
In the case of organ regeneration, a newly formed network of vessels is required, in order to give 
nutrients and oxygen supply to the regenerated tissue. This is the case of zebrafish	 (Lepilina, 
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Coon et al. 2006) and mouse heart regeneration, following different types of injury (Porrello, 
Mahmoud et al. 2011): neo-angiogenesis always parallels the tissutal regenerative response. If 
angiogenesis is impaired, cardiac regeneration fails (Epelman, 2015). Evidence in zebrafish exists 
showing a crosstalk through the Fibroblast Growth Factor (FGF) between cardiac and endothelial 
cells of the epicardium (Lepilina, Coon et al. 2006), having the effect of providing an efficient 
vascular network to the regenerated heart tissue. Several other growth factors are key regulators 
of neo-angiogenesis in the case of heart regeneration (Zangi, Lui et al. 2013), supporting the 
important role of the synergistic regulation of different pathways accomplish a complex process 
such as tissue regeneration. 
1.2.2.2 Extracellular matrix (ECM) 
Although the involvement of ECM in cardiac regeneration is still poorly understood, it is known 
that, in the case of myocardial ischemic injury, a massive ECM deposition followed by 
remodeling is responsible for fibrotic scar formation and, consequently, for impairment of cardiac 
function. Interestingly, recent evidence suggests a new role for the fibrotic scar, which not 
necessarily impairs cardiac regeneration. In zebrafish, if scar formation upon injury is impaired 
by inhibition of TGF-β signaling, heart tissue regeneration is completely blocked (Chablais and 
Jazwinska 2012). Moreover, since the cellular component of the connective tissue slightly 
changes during life, it is possible that different cell types make the tissue environment more 
permissive to the regenerative response (Chablais and Jazwinska 2012). Moreover, the ECM 
biochemical composition can impact the efficiency of regeneration, acting as a juxtacrine system 
to induce cardiac cell proliferation (Ieda, Tsuchihashi et al. 2009). 
1.2.2.3 Organ innervation  
As it happens for the vascular network, a proper innervation of the newly formed tissue is 
required to an organ in order to successfully accomplish the regenerative process. Recent data 
have demonstrated that specific pharmacological repression of cholinergic nerve function results 
in a reduction in cardiomyocyte proliferation in zebrafish and in neonatal murine heart 
(Mahmoud, O'Meara et al. 2015). Moreover, experimental evidence shows that, in the presence of 
mechanical denervation of the vagus nerve in different mouse models of myocardial injury, such 
as apical resection and myocardial infarction, heart fails to regenerate (Mahmoud, O'Meara et al. 
2015) (White, Gordon et al. 2015). Interestingly, regeneration can be partially restored by nerve 
growth factor (NGF) supply, suggesting that NGF is required to sustain heart regeneration.  
1.2.2.4 Immune response 
In case of myocardial infarction, an acute inflammatory response is activated, causing a series of 
pathological events resulting in scar remodeling and consequent heart failure. In this context, 
macrophages are responsible for massive production of pro-inflammatory cytokines, fibroblast 
activation and ECM remodeling. The immune response is closely linked to regeneration in 
injured hearts. Recent information from a model of macrophage depletion in neonatal mice has 
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demonstrated that monocytes and macrophages are required for both regeneration and neo-
angiogenesis in the heart (Aurora, Porrello et al. 2014). Of note, these authors found that the 
absence of macrophages after infarction did not affect cardiac myocyte proliferation directly, but 
rather the neo-vascularization of the regenerated tissue, because of the lack of pro-angiogenic 
cytokines. 
1.3.1 Cardiomyocyte identity: from transcriptional profile to structural 
barriers in development and regeneration 
A basic requirement for heart regeneration is the reactivation of an embryonic transcriptional 
program in cardiac cells, to make them dedifferentiate and be permissive to cell cycle re-entry. 
Importantly, specific gene expression programs characterize each step of cardiac cell 
differentiation; the transcription factors Nkx2-5 and ISL1, for example, are markers of cardiac 
progenitors (Ehrman and Yutzey 1999) (Cai, Liang et al. 2003), while Hopx expression 
characterizes a subpopulation of cardiac committed progenitors, known as cardiomyoblasts (Jain, 
Li et al. 2015). Indeed, from ChIP-seq studies on the murine embryonic heart at E9.5, emerged 
that Hopx localized close to genes related to the WNT signaling pathway. Other studies 
demonstrated that, Hopx promotes SMAD-mediated BMPs signaling and suppresses WNT 
signaling, enhancing cardiomyogenesis (Jain, Li et al. 2015). During embryonic heart 
development, GATA4 regulates the final steps of cardiomyocyte differentiation, driving the 
expression of a-myosin heavy chain and cardiac troponin C (Molkentin, Lin et al. 1997, Gupta, 
Gemberling et al. 2013). In the case of heart damage, its de novo expression drives de-
differentiation of cardiomyocytes, inducing a phenotype permissive for their division, 
characterized by less tight and de-structured sarcomeres (Jopling, Sleep et al. 2010). This 
phenotype is the result of deep changes at chromatin level in failing cardiomyocytes: recent 
evidences have established that dynamic methylation is a key feature during postnatal growth of 
cardiomyocytes and interestingly the methylation pattern of cardiac cells in case of injury is very 
similar to neonatal methylation pattern	(Gilsbach, Preissl et al. 2014) .	As it happens for GATA4, 
the fetal transcription factor Hand2 (the heart and neural crest derivatives-expressed protein 2), is 
re-expressed during heart regeneration (Schindler, Garske et al. 2014). Conversely, some 
transcriptional factors are involved in cardiomyocyte cell-cycle exit, as p38 kinase and Meis1. 
Indeed, Meis1 up-regulation during postnatal life is responsible for the activation of CDK 
inhibitors (p15, p16 and p21) and cardiomyocyte proliferative arrest (Mahmoud, Kocabas et al. 
2013). 
It is interesting to note that the peculiar transcriptional profile of cardiomyocytes involved in 
regeneration leads to a partial cell de-differentiation, mainly affecting the sarcomere structure and 
the actin cytoskeleton, responsible for the contractility and the rigidity of the mature cardiac cells 
(O'Meara, Wamstad et al. 2015).  
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1.3.2 Regulation of cardiomyocyte proliferation 
Several cell-cycle regulators are expressed during heart development and downregulated in the 
adulthood (reviewed in (Xin, Olson et al. 2013)). Genetic manipulation of these regulators 
promotes, to different extents, de-differentiation and proliferation of cardiac cells.  
1.3.2.1 FGF1 and inhibition of p38 pathway 
The p38 kinase belongs to the MAP kinase family and is a negative regulator of the cell cycle. 
The inhibition of p38 results in neonatal cardiomyocyte proliferation, while its overexpression has 
an opposite effect, blocking cardiac cells proliferative ability (Engel, Schebesta et al. 2005). In 
addition, it was observed that a combination of p38 inhibitors and FGF1, fibroblast growth factor 
1, increases mitotic events with an improvement of heart function in a mouse model of 
myocardial ischemia, due to the impairment of apoptosis at the site of injury (Engel, Hsieh et al. 
2006). FGF1 also promotes new vessel formation, while p38 inhibition is associated to the 
expression of genes involved in cell cycle regulation. However, despite these evidences, the 
increase in cardiac cell proliferation remains modest. 
1.3.2.2 Neuregulin-1 signaling 
Neuregulin1 (NRG1) is a growth factor involved in cardiac cell proliferation during embryonic 
life. NRG1 shows an agonist effect on the ErbB receptor family. It exerts its function binding 
ErbB4, inducing either ErbB2-ErbB4 or ErbB4-ErbB4 dimerization. Of note, NRG1 is able to 
induce proliferation only in mononucleated cardiac myocytes (Bersell, Arab et al. 2009). In adult 
cardiac myocytes, NGR1 treatment induces sarcomere breakdown and an immature sarcomere 
structure similar to the fetal one. Moreover, NGF1 not only promotes cardiomyocyte proliferation 
in adult hearts through PI3K activation, but its activation is also required during development for 
the complete maturation and final differentiation of CMs, under the control of BMP10 (Grego-
Bessa, Luna-Zurita et al. 2007).  
1.3.2.3 Notch signaling 
In Vertebrates, Notch signaling controls mesodermal commitment during development, playing a 
critical role in mammalian embryonic cardiogenesis; mice lacking the genes encoding either 
Notch receptors or their ligands show early embryonic lethality, mainly because of cardiovascular 
abnormalities (Penton, Leonard et al. 2012). In addition to its essential role in heart development 
and cardiac specification during embryogenesis, Notch regulates proliferation of immature 
cardiomyocytes during fetal and post-natal life (Collesi, Zentilin et al. 2008) (Campa, Gutierrez-
Lanza et al. 2008) (Croquelois, Domenighetti et al. 2008) and is essential for the maintenance of 
the heart structural and functional integrity after myocardial infarction  (Kratsios, Catela et al. 
2010) during the response to increased workload or during heart failure (Croquelois, 
Domenighetti et al. 2008) (Oie, Sandberg et al. 2010). In the species that efficiently regenerate the 
heart after damage, Notch is essential for postnatal cardiomyocyte proliferation (Raya, Koth et al. 
2003) (Zhang, Han et al. 2013), while recent evidence indicates that it is largely ineffective in 
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driving cardiac regeneration in adults, because of permanent epigenetic modification at main 
Notch-responsive promoters (Collesi, Zentilin et al. 2008)	(Felician, Collesi et al. 2014) .  
Among the pathways described as capable to stimulate cardiomyocytes proliferation, the YAP-
Hippo signaling pathway is considered the most potent driver in the regulation of cardiomyocyte 
proliferation. 
1.4. A path for regeneration: Hippo Signaling Pathway 
The Hippo Pathway was discovered through a genetic screening in Drosophila aimed at 
identifying genes involved in the control of organ size	(Xu, Wang et al. 1995)	(Justice, Zilian et 
al. 1995). It is highly conserved pathway, involved in the maintenance of tissue integrity through 
a intracellular signaling cascade whose inactivation, through genetic deletion of proteins such as 
Warts (Wts), Hippo (Hpo), Salvador (Sav) and Mats (Mts), results in a common phenotype of 
massive proliferation and an overgrowth of the interested tissue (Halder and Johnson 2011).  
In the past decade, the Hippo signaling pathway has been described to be involved not only in 
tissue growth, but also in stem cell pluripotency and cell fate determination (Lian, Kim et al. 
2010, Qin, Hejna et al. 2016, Britschgi, Duss et al. 2017). Moreover, it is involved in the control 
of the balance between proliferation and apoptosis, often associated to the development of solid 
cancer (Low, Pan et al. 2014). 
Actually, solid cancer cells often show a hyperactivation of the Yes-associated protein (YAP), 
which, together with TAZ, is the main regulator of the Hippo signaling cascade (Zhao, Li et al. 
2010). Since proliferation and apoptosis are key regulatory processes in both regenerative 
medicine and oncology, targeting this pathway has become an attractive clinical strategy for the 
development of new therapeutics. 
The Hippo transduction cascade has a high level of molecular complexity and redundancy, which 
reflects the importance of this signaling pathway in the regulations of critical cellular processes. 
Briefly, in humans, the STE20-like protein kinase 1/2 (MST1/2) (Hippo in Drosophila) was 
described as an upstream kinase, which phosphorylates large tumor suppressor homolog 1/2 
(Lats1/2) (Warts in Drosophila); these two kinases are able to directly interact through to the 
adaptor protein Sav1 (Salvador). MOB1A and MOB1B (Mats in Drosophila) enhance the kinase 
activity of Lats1/2. Lats1/2 are kinases able to directly regulate YAP/TAZ, the final effectors of 
the Hippo transduction signaling; upon activation, Lats1/2 phosphorylates the transcriptional co-
activator, Yes-associated protein YAP, and its paralogues PDZ-binding domain, TAZ (Yorkie in 
Drosophila). YAP phosphorylation on Ser127 has two major consequences: it stimulates its 
binding to the 14-3-3 protein family, preventing YAP translocation to the nucleus and it triggers 
phosphorylation of CK1d and the recruitment of beta-TRCP, resulting in YAP/TAZ proteasomal 
degradation (Hariharan 2006, Zhao, Li et al. 2010). 
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When the MST1/2 kinase cascade gets inactivated, YAP is no longer phosphorylated and 
translocates into the nucleus to activate the transcription of target genes, including CTGF, CyR61 
and Birc5 (Zhao, Ye et al. 2008) (Shimomura, Miyamura et al. 2014). 
Since YAP/TAZ are not able to directly bind DNA, their function is mediated by several 
transcription factors; among these are TEAD1-4 (TEA domain family member- Scalloped in 
Drosophila) (Zhao, Ye et al. 2008), Runx (Zaidi, Sullivan et al. 2004), FoxO1 (Shao, Zhai et al. 
2014), Tbx5 (Murakami, Nakagawa et al. 2005) and SMADs (Ferrigno, Lallemand et al. 2002) 
but their role in Hippo signaling activation is still not completely understood. The canonical 
inhibition of the Hippo cascade leads to TEAD1-4-mediated gene expression, preferentially 
repressed by VGLL4 repressor binding, which is lost in the presence of the YAP/TAZ co-
activators (Koontz, Liu-Chittenden et al. 2013). 
Consistently, mouse models of knockdown of genes representing the active core of the Hippo 
pathway, such as MST1/2, SAV1, MOB1A/B or LATS1/2, showed a significant increase of 
TEAD target gene expression, similar to YAP overexpression models	 (Dong, Feldmann et al. 
2007) (Camargo, Gokhale et al. 2007, Lee, Lee et al. 2010) (Nishio, Hamada et al. 2012).  
Downstream target genes of YAP/TAZ signaling were first identified in Drosophila: among them, 
cyclinE, diap1 and the microRNA bantam are all mediators of cell proliferation and survival (Wu, 
Liu et al. 2008). Other targets are p73 and ErbB-4; the former is a transcription factor involved in 
the stimulation of the apoptotic response and in DNA-damage signaling in association with YAP 
(Downward and Basu 2008); ErbB-4 is a tyrosine kinase receptor, which is able to induce a 
mitogenic signalling after YAP-mediated transactivation (Komuro, Nagai et al. 2003, Schuchardt, 
Bhat et al. 2014).  
 
 
FIGURE 1-2 SCHEMATIC REPRESENTATION OF THE CORE KINASES OF THE HIPPO SIGNALING PATHWAY 
A simplified view of the main regulatory kinases of the Hippo pathway are shown in orange (MST1/2 and 
LATS1/2). When the pathway is turned on, these kinases are activated and lead to downstream 
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phosphorylation of the final effector of the signaling pathway, YAP, to its consequent cytoplasmic retention 
or proteasome-dependent degradation. Conversely, when the pathway is turned off, YAP is no longer 
inhibited, it translocates into the nucleus and, in association with the TEAD transcription factors, induce cell 
cycle gene expression. 
 
1.4.1 YAP and TAZ protein structure 
Both YAP and TAZ show a very conserved protein structure. Both of them show a coiled-coiled 
and PDZ-binding domain, essential for nuclear translocation (Shimomura, Miyamura et al. 2014). 
Actually, it was found that the protein zona occludents 2 (ZO2) can bind this region and regulate 
YAP nuclear translocation via recruitment of some other regulators, or inducing conformational 
changes, critical for YAP activation (Oka, Schmitt et al. 2012). 
 
 
FIGURE 1-3 SCHEMATIC REPRESENTATION OF YAP AND TAZ STRUCTURE 
The functional domains of YAP/TAZ are represented, together with interacting proteins. The PDZ binding 
domain (PDZ BD) is located at the C-terminus, while the WW domains are in the central region. The TEAD 
binding domain allows YAP and TAZ to exert their function as transcription factors. The serine residue 
phosphorylated by upstream protein kinases are indicated in dark yellow, while those target of CK1 
phosphorylation are in a lighter yellow; the c-Abl binding site is in light blue. The lysine residue target of 
Set7 methylation is in pink.  Adapted from (Piccolo, Dupont et al. 2014). 
 
Moreover, both YAP and TAZ share other two important motifs: a WW domain in the central 
region of the protein and a transactivation domain in the C-terminal region (Fig.1-3). YAP only 
shows two interesting domains: the proline rich-domain at N-terminus mediates its interaction 
with the heterogeneous nuclear ribonuclear protein U (hnRNP U), while the SH3-binding motif, 
close to the second WW region, mediates its binding with the Yes tyrosine kinase (Sudol 1994, 
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Howell, Borchers et al. 2004).  
The phosphorylation of YAP by LATS on the five serine residues is one of the best-described 
modifications to regulate YAP activity. The S127A mutation was observed to increase YAP 
localization inside the nucleus (Basu, Totty et al. 2003). Phosphorylations on Ser127 of YAP and 
on Ser89 of TAZ create docking sites for 14-3-3 proteins, which promote their cytoplasmic 
retention (Yu, Zhao et al. 2012) (Basu, Totty et al. 2003). Conversely, phosphorylation on Ser381 
has a different functional role, leading to YAP proteasomal degradation (Kim, Kim et al. 2013). 
Several additional post-translational modifications can occur on YAP/TAZ, such as acetylation, 
methylation and sumoylation; however, the relevance of most of these modifications is still not 
completely understood. 
1.4.2 YAP signaling pathway: upstream activating stimuli  
Among the recently identified proteins involved in the direct regulation of YAP1, the NDR 
(nuclear Dbf2 related kinase) family members are able to inhibit YAP1/TAZ activation 
promoting their cytoplasmic retention (Zhang, Tang et al. 2015). NRD1/2 kinases, including 
LATS1/2, are AGC serine/threonine kinases (STK38/STK38L), which are characterized by a 
highly conserved NTR domain, the N-terminal regulatory portion, and the functional kinase 
segment, located between the subdomain VII and VIII (Hergovich, Stegert et al. 2006). NDR1/2 
are able to directly interact with MOB through their NTR domain, however different MOB 
isoforms preferentially interact either with NDR1/2 or with LATS1/2. Actually, MOB2 
preferentially binds NDR2, whereas MOB1A/B interact with both NDR1/2 and LATS1/2. 
Interestingly, their upstream activation can be mediated by MAPK4 and MST kinases via 
phosphorylation on Thr444/ Thr442 (Stegert, Hergovich et al. 2005) (Hergovich, Kohler et al. 
2009). NDR proteins can be functionally regulated by several mechanisms, including 
phosphorylation or changes in subcellular distribution. Even though the absence of NDR1/2 is 
associated with a strong increase of YAP activity, their role in the physiological cellular context 
is poorly understood. 
Other kinases have been described to modulate the Hippo pathway, such as the MAP4K family 
and TAOK1/3, which mediate LATS1/2 activation through phosphorylation (Meng, Moroishi et 
al. 2015) (Boggiano, Vanderzalm et al. 2011). Of note, TAOK activation can affect the Hippo 
transduction cascade at two different levels: upstream of MST1/2, mediating their 
phosphorylation and in parallel to MAP4 kinases and MST1/2, acting directly on LATS1/2 
activation (Plouffe, Meng et al. 2016). Moreover NF2, neurofibromatosis type 2, is involved in 
the activation of LATS1/2, carried out by MAP4Ks and TAOKs. Indeed, NF2 ablation triggers a 
more relevant decrease of YAP phosphorylation than the absence of MST1/2 (Plouffe, Meng et 
al. 2016). NF2, is a protein belonging to the FERM domain protein superfamily, whose 
expression is very abundant in the “zonula adherens”, responsible, together with tight junctions, 
for tissue architecture and integrity (Lallemand, Curto et al. 2003). In this peculiar cellular 
microenvironment, NF2 and other proteins such as AMOT, Expanded and α-Catenin, are also 
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involved in the regulation of the Hippo signaling cascade, recruiting LATS at the junctions and 
consequently inhibiting YAP.  
Several different stimuli can modulate the Hippo pathway through G-protein-coupled receptor 
activation (GPCRs), a class of cell surface receptors able to influence a plethora of biological 
functions. Due to the different G-proteins, which can be recruited by these receptors, GPCRs are 
able either to promote or block the Hippo-signaling pathway. In fact, G12/G13, Gq/11 and Gi-
coupled receptors inhibit LATS1/2 function, resulting in a positive effect on cell proliferation 
coherent with YAP activation, while Gs-coupled receptors activate LATS1/2 kinases. 
Furthermore, Ga proteins exert their effect on Rho GTPases and cytoskeleton remodeling, but 
how this is linked to LATS activity remains quite obscure (Yu, Zhao et al. 2012). 
1.4.3 YAP/ TAZ as mechanosensors 
As previously discussed, ECM properties and mechanical cues assume a fundamental role in 
organ structure development, by influencing cellular transcriptional profiles in adult tissues. At 
the cellular level, this implies a tight regulation of intra- and extracellular signals, resulting in a 
dynamic remodeling of actin cytoskeleton. Any alteration of the mechanical forces on cells can 
actively contribute to the development of pathological conditions such as cancer transformation 
or fibrosis.  
Despite the relevance of cellular mechanoresponse is widely recognized, little information is 
available on the mechanism of intracellular transduction of these stimuli. In this context, our 
current knowledge on YAP/TAZ function upon mechanical inputs is also shedding lights on cell 
mechanobiology. 
Actually, YAP and TAZ are mainly regulated by their localization; stiffness of the extracellular 
matrix or cytoskeletal tension are responsible for their nuclear distribution, which represents their 
functional activation, while soft substrates induce YAP and TAZ retention inside the cytosol 
(Aragona, Panciera et al. 2013). Actin cytoskeleton is essential for YAP/TAZ 
mechanotransduction: indeed, the inhibition of actin polymerization results in YAP/TAZ nuclear 
exclusion (Dupont, Morsut et al. 2011). These findings have been further supported by evidences 
obtained using F-actin inhibitory proteins, as CAPZ, ADF/Cofilin, demonstrating YAP activation 
upon a specific disposition of polymerized actin (Aragona, Panciera et al. 2013). Interestingly, the 
link between YAP/TAZ activation and changes in cellular geometry seems to be Hippo-
independent, implying alternative regulations of YAP/TAZ signaling (Wada, Itoga et al. 2011). 
FAK, SRC and RHO proteins have been described as molecular links between the extracellular 
signals (either from other cells or from the ECM) and the intracellular environment, possibly 
leading to YAP/TAZ activation. The YAP response to mechanical cues is to generate intracellular 
forces; this implies the formation of contractile actomyosin structures leading to cytoskeleton 
reorganization. Since in the heart several mechanical cues together with important cell-contact 
interactions are responsible for tissue integrity and myocardial functionality, the Hippo pathway 
holds a fundamental role in cardiac development as well as in heart homeostasis. 
	 24	
1.4.4 YAP signaling: between cancer and regeneration 
YAP/TAZ involvement in regulation of cell proliferation makes them interesting targets for 
therapeutic strategies in oncology and regenerative medicine. In non-small-cell-lung-cancer 
(NSCLC), patients showing high expression of YAP/TAZ have a poor prognosis; however, 
eventhough YAP/TAZ presence is essential for malignant progression, it is not sufficient to 
promote the development of NSCL cancer, as well as glioblastoma (Bhat, Salazar et al. 2011) In 
other types of malignancies, as in colorectal and liver tumors, YAP is required for malignant 
transformation; in colon and lung cancers arising from K-RAS mutation, both YAP and K-RAS 
regulate the EMT-related genetic program (Shao, Xue et al. 2014). Moreover, K-RAS is able to 
promote YAP transcriptional activation, therefore supporting the concept of a Hippo-independent 
mechanism.  
Intriguingly, elevated YAP levels provide several advantages to cancer cells, including enhanced 
resistance to chemotherapeutic treatments, as observed in breast cancer (reviewed in: (Harvey, 
Zhang et al. 2013). Moreover, recent findings demonstrate that YAP/TAZ activation, in certain 
cases, sustains the resistance to oncogene-targeted therapy; elevated levels of YAP correlate with 
a poor response to RAF and MEK inhibitors in treatment cancer histotypes bearing a BRAF-
mutation, acting as a survival stimulus for tumor cells (Lin, Sabnis et al. 2015). Since cell cycle 
regulation is a crucial process not only in tumor development, but also for organ regeneration, the 
role of YAP was explored in this context as well. Indeed, the regenerative process occurring in 
mammalian liver upon different kinds of injury is mediated by Hippo pathway inactivation, 
specifically by inhibition of Mst1/2 and Lats1/2, associated with a GA-binding protein- dependent 
YAP overexpression (Wu, Xiao et al. 2013). Neuromuscular junction (NMJ) regeneration is also 
mediated by YAP activity. Defective NMJ formation was observed in YAP KO mice, with deficit 
in pre- and postsynaptic distribution and size (Zhao, Shen et al. 2017). Furthermore, YAP absence 
inhibits muscle re-innervation, again highlighting the fundamental role of YAP in NMJ 
regeneration. Interestingly, YAP-/- mice showed a decrease in β-catenin levels, suggesting a role 
of WNT signaling in NMJ regeneration. However, induction of WNT signaling in YAP-/- mice 
ameliorated, but not completely rescued, the de novo formation of NMJ, demonstrating that β-
catenin is not the only player downstream of YAP-mediated NMJ regeneration (Zhao, Shen et al. 
2017). 
Intestine regeneration requires YAP functional activity too. In fact, a decreased level of cell 
proliferation was observed in the crypts of YAP KO mice, demonstrating that YAP regulation of 
intestinal stem cell cycle affects intestinal regeneration. Besides the role of YAP in the 
regenerative gut response after damage (Gregorieff, Liu et al. 2015) (Barry, Morikawa et al. 
2013), the involvement of WNT signaling in intestinal regeneration is commonly accepted. 
Another example of the pivotal role of YAP in the regeneration process is bone regenerative 
response. A dichotomous behavior of YAP in chondrocyte differentiation was described (Deng, 
Wu et al. 2016). Indeed, YAP is both responsible for early chondrocyte proliferation, through 
TEAD mediated Sox6 expression, and block of chondrocyte maturation, due to Col10a1 
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expression inhibition, mediated by Runx2. In addition, YAP drives the early phases of fracture 
repair, through the suppression of the development of cartilaginous callus tissue. 
Finally, YAP was identified as a key player in cardiac regeneration, as discussed below in details. 
1.4.5 Hippo pathway: the heart issue  
Heart development is a complex process requiring the integration of spatial-temporal signaling 
pathways and the interaction of different cell types (Brade, Pane et al. 2013). A network of 
interconnected signaling pathways flow into the nucleus, triggering the activation of a specific set 
of transcription factors, among which is Tbx5, a major regulator of the gene expression program 
leading to heart development. The finding that Tbx5 is activated by YAP raised the intriguing 
possibility that the Hippo pathway might be involved in embryonic cardiac development 
(Murakami, Nakagawa et al. 2005). Several studies have been performed to better understand the 
role of the Hippo kinase cascade in the heart. Data suggest that a deficiency of the Hippo pathway 
during heart development causes cardiac overgrowth; in fact, selective cardiac inactivation of 
Mst1/2, Sav1, and Lats2, which negatively affect YAP activation, led to marked myocardium 
enlargement due to an increase in cardiomyocyte number and trabecular expansion (Heallen, 
Zhang et al. 2011). 
The role of YAP in cardiac growth has been investigated using either gain or loss-of-function 
models (Xin, Kim et al. 2013) (von Gise, Lin et al. 2012). YAP1 activation is fundamental and 
sufficient to induce proliferation of embryonic cardiomyocytes and is also responsible for the 
physiological enlargement of the heart during development, via hyperplastic more than 
hypertrophic growth. These findings suggest that YAP is sufficient to promote cardiomyocyte cell 
cycle activity. On the contrary, YAP cardiac-specific inactivation, in early stages of the heart 
development (at E10.5), is lethal, because of a marked reduction of cardiomyocyte number and 
dramatic hypoplasia (Xin, Kim et al. 2011). Of note, in the heart, YAP signaling is transduced by 
canonical transcription factors, TEAD1-4, which are fundamental for YAP mitogenic activity in 
cardiomyocytes (Wu, Liu et al. 2008) (Zhao, Ye et al. 2008). Indeed, lack of expression of 
TEAD1 results in E11-12 embryonic death, a critical time frame for heart development. 
Conversely, TEAD1 overexpression in the heart during postnatal period promotes cardiac 
pathological remodeling, responsible for heart failure (Chen, Friedrich et al. 1994).  
Mice overexpressing TEAD1 show age-dependent cardiac dysfunction, associated with. an 
increase in GSK3β activation associated with decrease levels of both nuclear β-catenin and 
NFATc3/c4 (Tsika, Ma et al. 2010). These studies show that increased TEAD1 can promote the 
development of heart defects, typically present in cardiac remodeling following heart failure. 
Since, in mammals, both YAP and its paralogue are present, TAZ cardiac-specific KO mice were 
generated. Surprisingly, postnatal cardiac TAZ deletion did not show any specific phenotype and 
did not alter mouse lifespan, demonstrating that the role of TAZ in heart development and 
function is dispensable, compared to YAP (Xin, Kim et al. 2013).  
Cardiac-specific Mst1 overexpression sustains a massive cardiomyocyte apoptosis, responsible 
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for animal death due to dilated cardiomyopathy. Indeed, a dominant-negative MST1 protein 
exerts a protective function against remodeling in a model of MI (Yamamoto, Yang et al. 2003). 
Besides its critical role during heart development, Yap exerts a critical function in heart 
regeneration upon injury. In a mouse model of myocardial infarction, increased levels of YAP not 
only prevent cardiac cell loss but also fibrotic scar formation. Consistently, constitutive activation 
of YAP1 is able to extend the regeneration window, triggering an improvement of cardiac 
function (Xin, Kim et al. 2013). In a heart-inducible YAP transgenic mouse model, in case of 
myocardial infarction, YAP activation significantly reduced scar size, with a net improvement of 
myocardium functionality. These effects were due to adult cardiomyocyte cell cycle re-entry, 
driven by YAP activation. Of note, sustained expression of YAP triggered significant 
downregulation of specific genes associated with terminal differentiation of cardiac cells (such as 
muscle- and oxidative metabolism-related genes), while cell cycle gene expression increased, 
suggesting that YAP induces a genetic program leading to a less differentiated phenotype, in 
order to make proliferation possible (Xin, Kim et al. 2013). Hippo signaling deficiency leads to 
increased cardiomyocyte proliferation and myocardial protection after MI. In fact, Sav1 KO mice 
show improved cardiac function and smaller scar size after MI (Heallen, Morikawa et al. 2013). 
These findings suggest that YAP is fundamental for adult heart homeostasis and has a strong 
cardioprotective function, probably due to its ability to promote both cardiac cell survival and 
proliferation in response to injury. Recent literature shows a strong interconnection between Yap 
signaling and other intracellular signal transduction pathways, acting synergistically in the 
regeneration process (Shao, Zhai et al. 2014)	(Lin, Zhou et al. 2015). 
Several published studies have analyzed the complex role of YAP in cardiac regeneration and 
have thus expanded our knowledge on the interaction of YAP-Hippo signaling with other 
intracellular signal transduction pathways and with the different cellular processes occurring after 
injury.  
An interesting study was performed in conditional cardiac specific Salvador KO mice bearing a 
dystrophin loss-of-function (Mdx background), in order to explore the link between the Hippo 
pathway and the dystrophin glycoprotein complex (DGC) (Morikawa, Heallen et al. 2017). Both 
Salv KO, and Salv;Mdx DKO mice were able to regenerate the apex after heart apical resection. 
Interestingly, DKO mice were able to repair the resected heart showing an impressive cardiac 
overgrowth, often resulting in the formation of a second apex. These findings suggest that the 
Hippo pathway and DGC proteins are both responsible to restrict cell growth after damage, 
suggesting a key role of the DGC in arraying proliferating cardiomyocytes in a 3D space. When 
the same mice were analyzed in a TAC model of hypertrophy, the Salv; Mdx DKO myocardium 
showed milder cardiac fibrotic features than the mdx control mice, associated with a contained 
dilatation and physiological parameters similar to the Salv KO controls. Moreover, both Salv KO 
and DKO shared an increased level of nuclear YAP, demonstrating that the cardiomyopathy of 
mdx mice was abolished by Salvador depletion, resulting in YAP activation, with a consequent 
boost of cardiomyocyte proliferation and protection from apoptosis (Morikawa, Heallen et al. 
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2017).  
The use of innovative tools, as translating ribosomal affinity purification (TRAP), has allowed the 
recovery and analysis of cardiomyocyte transcripts in several mouse models. Cardiomyocytes 
purified from Salv-depleted infarcted hearts express pro-proliferative genes, as well as genes 
related to vasculogenesis (FGFs and EGFs) and, more importantly, stress-related genes. Among 
these genes there is Parkin2 (Park2), involved in the quality control of mitochondria, which was 
also described to be important in cardiac repair, suggesting the need of mitochondrial quality 
control in the cardiac regenerative process. Park2 is involved in mitochondrial maturation and 
plays a key role in the cardiomyocyte metabolic transition from the embryonic to the adult age 
(Dorn 2016). Its absence in Salv KO mice negatively affected heart function, suggesting that 
Park2 is required not only for myocardial function but also for the resolution of the fibrotic scar 
(Leach, Heallen et al. 2017). 
Recent studies have identified multiple molecular mechanisms exploited by YAP to control heart 
growth and cardiomyocyte proliferation. In Sav1 KO mice, Sav inactivation triggers β-catenin 
translocation into the nucleus leading to up-regulation of WNT pathway target genes (Heallen, 
Zhang et al. 2011). Consistent with these findings, YAP overexpression in fetal hearts caused an 
increase of WNT signaling (Xin, Kim et al. 2013). 
Insulin-like growth factor (IGF) signaling is involved in Yap-dependent cardiomyocyte 
proliferation as well. Indeed, in a model of YAP constitutive activation, increased levels of IGF1 
receptor were detected, with consequent GSK3β functional inhibition. Inactivation of GSK3β 
stabilizes β-catenin, a final effector of the WNT pathway, resulting in the activation of pro-
proliferative genes (Xin, Kim et al. 2011). Moreover, YAP activation in neonatal cardiomyocytes 
resulted in upregulation of cell cycle regulators such as cyclin D, demonstrating a direct link 
between cell cycle genes and YAP itself (von Gise, Lin et al. 2012). 
Recently, the PI3K-AKT signaling pathway was described to cooperate with YAP-signaling in 
the control of cardiac cell growth and survival. Through a genome-wide screening approach 
aimed at identifying genes responsible for YAP-induced pro- proliferative effects, it was found 
that YAP induces the expression of Pik3cb, the phosphatidilinositol-3phosphate kinase catalytic 
subunit which is highly expressed during embryonic development and drastically decreases in 
adulthood. Interestingly, the pattern of expression of Pik3cb superimposes to the one of YAP 
itself. Strong in vivo evidence supports the requirement of YAP to promote PI3K-AKT mediated 
cardiomyocyte proliferation. AAV-mediated Pik3cb overexpression in YAP cKO mice after MI 
triggered a net increase in cardiac function, inducing a net cardiomyocyte proliferative response, 
paralleled by a reduction of apoptosis (Lin, Zhou et al. 2015). 
Collectively, multiple evidence unequivocally demonstrates the pivotal role of YAP as a master 
gene in cardiac biology. Its effect lasts from embryonic to adult life, since it regulates fetal heart 
development, induces proliferation in neonatal and adult cardiomyocytes and strengthens the 
regenerative potential in adult hearts after ischemic injury. Given its central role in heart 
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regenerative biology, the Hippo-YAP signaling pathway is an attractive target for heart 
regenerative therapies. 
1.4.6 microRNAs targeting YAP1 
Cellular processes need a multilayered regulation in order to be straightly modulated. Among the 
adopted strategies for post-transcriptional regulation of gene expression, microRNAs exploit a 
pivotal role, given the pleiotropic effect of their action. Several microRNAs have recently been 
involved in the regulation of the Hippo pathway cascade, mainly as key regulators of tumorigenic 
transformation. An example is miR-135b in lung cancer, responsible of the metastatic phenotype, 
given its property to target LATS2, MOB1B and NDR2. Thus, the use of an antagomir, which 
suppresses miR-135b expression, reduces metastasis and tumor growth (Lin, Chang et al. 2013). 
Similarly, overexpression of miR-31, a commonly upregulated miRNA in several tumors (Liu, 
Sempere et al. 2010), is also able to target LATS2, directly binding its 3’UTR as observed in 
endometrial cancer cell lines (Mitamura, Watari et al. 2014).  
Other important miRNAs targeting Hippo pathway members belong to the miR-130 family, 
whose overexpression has been observed in different cancers, such as bladder, gastric cancer and 
glioblastoma (Zhu, Wang et al. 2015, Egawa, Jingushi et al. 2016). Of note, YAP exerts a positive 
feedback on miR-130 expression, which in turn represses VGLL4, an inhibitor of YAP-TEAD 
complex in hepatocellular carcinoma (Shen, Guo et al. 2015). Interestingly, miR-130a displays a 
similar function of the fruitfly miRNA bantam, which inhibits the homolog of VGLL4 SdBP/Tgi, 
further unveiling the evolutionary conservation of YAP molecular signaling. Moreover, 
upregulation of mir-130b preserves cancer stem cells in glioblastoma, targeting MST1 and SAV1 
(Zhu, Wang et al. 2015). On the contrary, both miR-195-5p and miR-186 seem to target YAP 
with beneficial effects in tumor suppression, specifically on colorectal and hepatic cancer, 
respectively (Ruan, He et al. 2016, Sun, Song et al. 2017).  
Other important insights into the regulation of YAP signaling by miRNAs derived from findings 
in hepatocellular carcinoma (Liu, Zhang et al. 2015). PreS, a HBV transactivator protein, is able 
to induce TAZ overexpression by suppressing miR-338-3p. Thus, downregulation of this miRNA, 
in the presence of preS, causes a reduction in TAZ suppression, resulting in TAZ-mediated 
promotion of cancer growth (Liu, Zhang et al. 2015). Recently, miR-125a was described to target 
TAZ in glioblastoma and miR-141 in gastric cancer (Yuan, Xiao et al. 2015, Zuo, Zhang et al. 
2015). 
A different example is the miR-29 family, upregulated upon YAP overexpression. In this case the 
pro-proliferative effect is achieved by targeting the 3’UTR of the PTEN transcript. Since PTEN is 
responsible for inhibition of mTOR, downregulation of PTEN results in mTOR activation and 
induction of cell proliferation (Tumaneng, Schlegelmilch et al. 2012).  
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1.5. Gene therapy to promote heart regeneration 
Several strategies have been proposed to promote cardiac regeneration. Great excitement was 
raised in the first decade of this century by the possibility that cells from various derivation might 
perform as stem cells for cardiac regeneration. This was the case of c-kit-positive cells from the 
bone marrow	 (Orlic, Kajstura et al. 2001) and the heart itself	 (Beltrami, Barlucchi et al. 2003), 
mesenchymal stromal cells from the bone marrow	(Hatzistergos, Quevedo et al. 2010) and heart-
derived cardiosphere-forming cells	(Smith, Barile et al. 2007). However, when all these cell types 
have been used for clinical experimentation, the results achieved turned out to be highly 
disappointing. To date, there is no proof that any cell type with putative stem cell capacity, once 
injected into the heart, induces real cardiac regeneration (commented in: (Eschenhagen, Bolli et 
al. 2017) In most instances, implantation of exogenous cells into the heart provides a modest and 
transitory beneficial effect through the paracrine secretion of factors improving cardiac function, 
preventing cardiomyocyte apoptosis or inducing neoangiogenesis. 
Generation of new myocardial tissue can instead be achieved by the implantation of 
cardiomyocytes obtained in vitro from ES or iPS cells, as originally shown by the Murry 
laboratory	(Kadota, Pabon et al. 2017). This approach, however, requires the generation of at least 
one billion cardiomyocytes in culture and their bulk implantation in vivo, with consequent 
problems related to the electrical and mechanical integration of these cells with the surviving 
myocardial tissue. An alternative approach would consist in the stimulation of the endogenous 
capacity of myocardial myocytes to undergo division, therefore achieving endogenous cardiac 
regeneration. This goal might be achieved by gene therapy. 
Gene therapy exploits the idea of modifying cell behavior by delivering nucleic acids. Early 
attempts of cardiac gene transfer started in ‘90s, with the delivery of angiogenic genes through 
adenoviral vectors, able to transduce cardiomyocytes at high efficiency and to express high levels 
of the encoded transgenes. Despite preliminary positive results, most of these studies were 
prematurely terminated due to the intense inflammatory response and immune rejection elicited 
by adenoviral vectors (Hedman, Hartikainen et al. 2011). Subsequent attention of the gene 
therapy community thus turned to the Adeno-Associated Virus (AAV) as a powerful tool for 
cardiac gene transfer, due to the peculiar tropism of this virus for post-mitotic cells, including 
cardiomyocytes and the long term episomal persistence of its genome in the infected cells 
(reviewed in (Zacchigna, Zentilin et al. 2014)) Over 100 clinical trials with AAV vectors have 
been performed to date (http://www.abedia.com/wiley/), of which one for a cardiac application 
(AAV1-Serca2a for heart failure	(Hulot, Salem et al. 2017). 
While the use of viral vectors is essential to transfer large genes into the heart, shorter nucleic 
acids could be delivered through simple chemical methods. This is the case of the delivery of 
short interfering RNAs (siRNAs), miRNA mimics and inhibitors, which are currently largely 
used in RNAi-based therapeutics (Zhou, Zhang et al. 2014) (Fig.1-4). Inded, microRNAs might 
also play a role in cardiac regeneration (Eulalio, Mano et al. 2012) and are key regulators of heart 
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remodelling, representing a new class of therapeutic targets in heart failure patients (Philippen, 
Dirkx et al. 2015). 
 
 
FIGURE 1-4 SCHEMATIC OVERVIEW OF STRATEGIES AVAILABLE FOR HEART REGENERATIVE THERAPY 
On the top, cell-free therapies are represented by the use of chemical compounds, cytokines, growth factors 
and microRNAs. At the bottom, cell-based therapies are based on the use of cardiomyocytes derived from 
different sources such as embryonic stem cells (ESCs), cardiac progenitor cells (CPCs) and induced 
pluripotent stem cells (iPSCs). Adapted from (Sahara, Santoro et al. 2015). 
 
1.5.1 Biological compounds for heart regeneration: microRNAs, as 
regulators of gene expression 
Among all non-coding RNAs, microRNAs (miRNAs) are endogenous -22nt long RNA molecules 
which act as post-transcriptional regulators of gene expression in plants and animals (Bartel 
2004). They exert their function by binding the 3’ UTR of target messenger RNA, leading to 
either its degradation or the inhibition of protein translation (Humphreys, Westman et al. 2005). 
MiRNA target recognition is restricted to a short sequence, known as the “seed” sequence 
(Rhoades, Reinhart et al. 2002, Vasudevan and Steitz 2007) shared by all micro-RNAs belonging 
to the same family. Interestingly, the length of 3’ UTRs correlates with the number of miRNA-
binding sites, therefore with the complexity of gene expression modulation (Osada and Takahashi 
2007) (Cheng, Bhardwaj et al. 2009). Moreover, a single miRNA can control the expression of 
several target mRNAs, therefore enabling the modulation of an entire signaling pathway (van 
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Rooij and Kauppinen 2014). 
1.5.1.1 MicroRNA biosynthesis and processing 
MicroRNAs have several peculiar features if compared to other functional RNA species in the 
cell. Most of them are encoded by polycistronic transcripts, suggesting that members of the same 
family evolved as a cluster (Du and Zamore 2005). In eukaryotic cells, microRNAs are processed 
in a sequence of steps (reviewed by (Cai, Hagedorn et al. 2004)  (Du and Zamore 2005). 
The precursor microRNA, also known as pre-microRNA, is an approximately 60 nt long hairpin 
RNA generated by excision from the primary transcript by Drosha (Lee, Ahn et al. 2003) Drosha 
is a class III endonucleases, which produces duplex RNA products containing a 5' phosphate and 
a 3'-OH, with usually a 2 nt overhang at the 3' end (Zeng, Yi et al. 2005). Drosha exhibits low 
enzymatic efficiency, therefore a regulatory subunit, DGCR8, helps the enzyme in the recognition 




FIGURE 1-5 BIOGENESIS OF MICRORNAS, PROCESSING AND MATURATION. 
A primary miRNA transcript is produced by RNA polymerase II or III and is cleaved by the Drosha–
DGCR8 complex in the nucleus. Exportin-5–Ran-GTP mediates the export of the pre-miRNA to the 
cytoplasm, where Dicer, in complex with TRBP, further processes it to a mature miRNA. The functional 
strand is then loaded with Argonaute (Ago2) into the RNA-induced silencing complex (miRISC). RISC is 
guided to silence target mRNAs and to induce mRNA cleavage or translational repression. miRNA 
function can be artificially mimicked using double-stranded miRNA mimics or inhibited by single-stranded 













































Once pre-miRNAs are produced, exportin5 (Exp5) is responsible for their export into the 
cytoplasm (Khvorova, Reynolds et al. 2003), where Dicer, a RNaseIII-type enzyme, recognize the 
3' overhang via its PAZ domain and produces a duplex intermediate miRNA; usually only one of 
the two strands can be detected in cells, while the other is degraded. How the choice is 
mechanistically achieved is not known, although it likely involves differential binding and 
retention of one of the two RNA strands by Dicer and its associated proteins (Tomari, Matranga 
et al. 2004). The functional strand is bound by Argonaute and loaded into the RNA-induced 
silencing complex (RISC) (Meister, Landthaler et al. 2004). RISC is guided to silence target 
mRNAs and to induce mRNA cleavage or translational repression (Fig.1-5). 
1.5.1.2 miRNAs controlling cardiomyocyte proliferation 
Several microRNAs have been described as powerful regulators of different biological processes. 
During zebrafish heart regeneration, both mir-99 and mir-100 are downregulated	 (Aguirre, 
Montserrat et al. 2014). Interestingly, they both target Smarca5 and Fntb, key factors involved in 
dedifferentiation and proliferation of adult cardiomyocytes, suggesting that miR-99 and 100 are 
involved in cardiac cell cycle withdrawal. Other examples are the miR-1 and miR-133 families, 
part of the same bi-cistronic transcript and both regulators of cardiac cell proliferation. Actually, 
miR-1 and miR-133a are specifically expressed in cardiac and skeletal muscle, while miR-133b is 
expressed in skeletal muscle only. Multiple evidence strongly supports a fundamental role for this 
miRNA cluster during heart development(Zhao, Samal et al. 2005). In fact, Hand2, a crucial 
transcription factor in cardiac morphogenesis, is a direct miR-1 target. Of note, when an altered 
expression of miR-1 and miR-133 occurs in adult cardiac tissue, heart failure arises both in mice 
and humans. This finding can be explained by the fact that miR-133 silencing results in the 
suppression of genes as Cdc42 and RhoA, which induce the cardiac hypertrophic phenotype 
(Care, Catalucci et al. 2007). Similar function is exerted by miR-1, whose overexpression 
decreases cell death and fibrotic cardiac remodeling (Karakikes, Chaanine et al. 2013). MiR-133-
1 and miR-133-2 are inhibitors of cardiomyocyte proliferation, since they both target Cyclin D1 
and SRF. MiR-133 also regulates the expression of Mps1, a kinase involved in several cell cycle 
checkpoints, as the mitotic spindle-assembly checkpoint (Mattison, Stumpff et al. 2011). 
The miR-15 family is also involved in cardiomyocyte cell cycle withdrawal. MiR-195 targets 
Chek1, a checkpoint kinase known to negatively regulate cell cycle progression. As a 
consequence, miR-15 suppression boosts cardiac cell proliferation and improves cardiac function 
after MI (Porrello, Mahmoud et al. 2013). 
Other microRNAs exert their function in cardiac myocyte differentiation during embryonic heart 
development, as is the case of the miR-17-92 cluster. The expression of this cluster is under BMP 
regulation and its direct targets are Isl1 and Tbx1. In mice, their overexpression is sufficient to 
promote cell cycle entry of cardiac cells and tissue protection in case of MI (Chen, Huang et al. 
2013).  
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Taken together, these findings support the use of miRNA as therapeutic tools to target multiple 
genes at the same time, in light of the final goal to force cardiomyocyte cell cycle re-entry. In this 
context, a high-throughput screening performed in our laboratory revealed several human 
miRNAs able to induce cardiomyocyte proliferation. Among them, hsa-miR 199a-3p and hsa-
miR 590-3p were able to induce cardiac regeneration after myocardial infarction, by boosting 
cardiomyocyte proliferation in vivo (Eulalio, Mano et al. 2012).  
1.5.1.3 MicroRNAs in heart regeneration: the role of YAP 
The Morrisey’s group (Tian, Liu et al. 2015) recently described the miR-302~367 cluster, which 
is early expressed during cardiac development in mice and plays an important role in cardiac 
myocyte proliferation during heart embryogenesis. Main targets of this cluster of miRNAs are 
several proteins of the Hippo pathway. The sustained expression of miR-302~367 in a transgenic 
mouse model induced long lasting cardiomyocyte proliferation, finally leading to cardiomegaly 
and heart failure. Conversely, transient in vivo overexpression of this cluster using miR-302~367 
mimics induced heart regeneration, with a significant improvement of cardiac function (Tian, Liu 
et al. 2015). These observations further support the role of the Hippo pathway as a master 
regulator of cardiomyocyte proliferation and heart regeneration and validate the use of miRNA 
mimics as tools to reproduce the effects of specific miRNAs in vivo in a limited time frame, 
avoiding the adverse effects of their prolonged overexpression. 
1.5.2 Chemical compounds for heart regeneration 
Parallel to the significant advances in the understanding of key regulatory processes leading to 
cardiac regeneration, an increasing interest is focused on the development of new, small 
molecules to be used as therapeutic tools in heart regenerative medicine. Small chemical 
compounds would significantly improve the impact of heart therapy, with a net reduction in costs 
and increase of benefits, since already approved drugs have been tested for safety and 
pharmacokinetics in patients, and they have established manufacturing and distribution networks.  
To date, only a few chemical compounds have been studied in order to stimulate heart muscle 
repair. The isoxazole family (Isx) was described to promote cardiac repair after myocardial 
infarction, activating Notch signaling in progenitors of epicardial origin. Moreover, these organic 
compounds were able to protect cardiomyocytes after myocardial infarction by inhibiting the 
proton sensing GPCR-68, a highly controlled receptor during cardiac ischemia. These preliminary 
encouraging results were not paralleled by a rescue in cardiac function, suggesting a role of Isx in 
the protection from cardiac remodeling after infarction, rather than in the acute phase of the 
ischemic damage (Russell, Goetsch et al. 2012). 
Another pathway deeply studied as a potential therapeutic target for heart regeneration is the 
WNT/β-catenin pathway because of its involvement in the cell cycle regulation in the embryonic 
cardiac precursors (Ueno, Weidinger et al. 2007). ICG-001 is a small WNT modulator molecule, 
which selectively disrupts the interaction of β-catenin with CREB binding protein (CBP) 
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(Willems, Spiering et al. 2011). However, ICG-001 ability of improving the cardiac contractile 
function in an in vivo model of myocardial infarction is mainly associated with its effect on 
epicardial cells rather then on ventricular cardiomyocytes (Sasaki, Hwang et al. 2013).  
More recently, MSI-1436, a strong allosteric inhibitor of the protein tyrosine phosphatase 1B 
(PTP1b), was also described as a promising candidate for heart regeneration. This small 
molecule, also known as Trodusquemine, showed good tolerance in patients in phase 1 clinical 
trials for type-2 diabetes and for the treatment of obesity (ClinicalTrials.gov identifier NCT 
number: NCT00606112). Besides these applications, MSI-1436 is able to successfully induce 
cardiac muscle regeneration in a mouse model of myocardial infarction, with no detectable side 
effects at a dosage well below the minimum dose tolerated by patients (Smith, Maguire-Nguyen 
et al. 2017). The regenerative effect of this compound was also observed during regeneration of 
other tissues, as the caudal fin of zebrafish. This evidence suggests that MSI-1436 could act as a 
powerful trigger of tissue regeneration in a broad spectrum of putative targets (Smith, Maguire-
Nguyen et al. 2017).  
Last, but not least, harmine is a compound showing a regenerative effect on pancreatic beta cells; 
it is a FDA-registered compound, which shares with MSI-1436 the peculiar property to act on 
many tissues with relevant beneficial effects as discussed below in details.  
1.5.2.1 Harmine: a versatile compound  
The 7-methoxy-1-methyl-9H-pyrido[3, 4-b] indole, also known as harmine, is a tricyclic beta-
carboline alkaloid, found in many plants. It was originally extracted from the seeds and root of 
Peganum harmala, a plant broadly used in North Africa, Middle East and Central Asia. It is also 
present in the stem of the Banisteriopsis Caapi vine, the main component of the ayahusca, a 
hallucinogen infusion prepared in Brazilian Amazon during tribal spiritual ceremonies.  
Harmine is not only present in the vegetable kingdom but also in marine organisms, insects and 
mammals, as well as in human tissues and fluids. It was traditionally used as a drug with a broad 
spectrum of features, including antimicrobial, anti-inflammatory, antimycotic, anti-oxidative, 
antitumor, anti-depressive and analgesic effects (Moloudizargari, Mikaili et al. 2013) (Patel, 
Gadewar et al. 2012). 
1.5.2.3 Harmine in biology and its potential therapeutic value 
The molecular mechanism of action of harmine is only partially described. It is known that this 
drug binds type A receptors of the gamma-aminobutyric acid (GABA) in the same site used by 
benzodiazepine, but with an opposite effect. These chemicals are also known as MAO Inhibitors, 
due to their ability to inhibit a metabolic enzyme, the monoamine oxidase (MAO), in order to 
prevent direct activation of monoamine receptors (Farzin, Haghparast et al. 2011).  
MAO is responsible for the oxidative deamination of amines and is directly involved in the 
metabolism of vasoactive and neuroactive amines in many tissues. MAO exists in two different 
isoforms: MAO-A and MAO-B. Both isoenzymes are able to oxidize dopamine, but MAO-A 
preferentially acts on serotonin and norepinephrine, while MAO-B on phenylethylamine (Shih, 
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Chen et al. 1999). In particular, harmala alkaloids reversibly bind the enzymatic site of MAO, 
resulting in an enhanced and prolonged effect of neurotransmitters, due to the fact that MAO 
physiological function is to degrade endogenous neurotransmitters and dietary amines. Indeed, at 
the periphery, MAOs catalyze the oxidative catabolism of circulating amines, blocking the effect 
of dietary amines. In the central nervous system, MAOs inactivate amine neurotransmitters, 
guaranteeing the protection of neurons from exogenous amines and monitoring the intracellular 
reservoir of amines. Genetic depletion of MAO genes results in higher reactivity in stress 
conditions (Grimsby, Toth et al. 1997). Interestingly, MAO-A-deficient animals show cognitive 
deficit and reduced control of impulses with behavior disturbances, while a deficiency of MAO-B 
is not associated with any evident clinical defect, indicating that MAO-A has a more relevant role 
in amine metabolism (Lenders, Eisenhofer et al. 1996). 
Harmine is also a potent inhibitor of a dual specificity tyrosine-phosphorylation-regulated kinase 
(Dyrk1a), which regulates cell proliferation, apoptosis and brain development (Matsuki, Hori et 
al. 2005). Dyrk1a belongs to a family of kinases (Dyrk1b, Dyrk2, Dyrk3, Dyrk4a and Dyrk4b), 
which share the same activation mechanism (Walte, Ruben et al. 2013); they undergo auto-
phosphorylation on residue Y321 in order to achieve full activation and phosphorylate their 
substrates on serines and threonines (Himpel, Panzer et al. 2001). Dyrk1a is also overexpressed in 
several cancers, such as glioblastoma and lung cancer (Pozo, Zahonero et al. 2013) (Gao, Zheng 
et al. 2009). A complete overview of Dyrk1a’s downstream molecular mechanism remains a topic 
of debate.  
1.5.2.3.1 Cardiovascular responses 
Harmala compounds have a strong impact on the cardiovascular apparatus: bradycardia, 
alterations in arterial blood pressure and in myocardial contractile force are just a few of several 
effects on heart and blood vessels. 
The vasorelaxant effect induced by harmala drugs is due to their effect on the alpha 1-adrenergic 
receptors of the vascular smooth muscle cells, and to the increased NO levels, produced by 
endothelial cells because of the increased levels of external Ca2+. In fact, both harmine and 
harmaline (10^-6 to 3x10^-4 M) are able to inhibit muscle contractile response in a concentration-
dependent manner in the presence of stimulatory agents (Berrougui, Martin-Cordero et al. 2006). 
However, neither harmine nor harmaline showed any effect on the endothelium-independent 
relaxation. 
Interestingly, hamaline and harmine are able to reduce free radicals generated by DPPH, 
suggesting that the decrease in oxidative stress correlates with an increase of the relaxation effect 
on aortic rings. Indeed, harmine as well as harmaline are able to reduce the arterial pressure 
systemically and vascular resistance in peripheral tissues (Berrougui, Martin-Cordero et al. 2006). 
Little is known about the direct effect of harmine on the myocardium. Pioneering studies 
described a ionotropic effect and induced reduction in cardiac contractility (Aarons, Rossi et al. 
1977). Interestingly, the short time frame of cardiovascular effects is not compatible with the 
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timing of MAO inhibition by harmala alkaloids, therefore suggesting a MAO-independent 
mechanism of action (Aarons, Rossi et al. 1977). 
Another interesting feature of harmine is its strong anti-angiogenic action in tumors both in vivo 
and in vitro, in a model of gastric cancer, through the downregulation of COX-2 and NO synthase 
(Hamsa and Kuttan 2010). Harmine is able to inhibit endothelial cell proliferation and induce the 
production of pro-angiogenic cytochines (VEGF, NO and cytokines such as IL-1b and TNF-a) in 
a dose-dependent manner. These anti-angiogenic effects were detected at micromolar 
concentrations (2 µM), supporting the potential therapeutic use of harmine at low dosage. 
1.5.2.3.2 Nervous System responses 
Traditionally, harmala alkaloids have been described to have psychoactive properties with a broad 
spectrum of effects on both the central and peripheral nervous system. In addition to their effect 
on MAO inhibition, described above, another important feature of these compounds is related to 
their anti-depressant effect. Indeed, the acute administration of harmine at 15 mg/kg body weight, 
in rat hippocampal neurons induced a massive secretion of brain-derived neurotrophic factor 
(BDNF) (Fortunato, Reus et al. 2009), the levels of which are dramatically reduced in depressed 
patients.   
In the beginning of 1920s, multiple findings brought to evidence the involvement of beta-
carboline in Parkinson’s disease development. In particular, patients affected by Parkinson’s 
disease showed increased levels of β-carbolines with dopaminergic cytotoxicity mediated by 
DAT (dopaminergic active transporter) (Storch, Hwang et al. 2004). Another neurodegenerative 
disorder, Alzheimer’s disease, has recently been linked to both MAO activation and Dyrk1a 
kinase activity. In fact, Dyrk1a contributes to Tau phosphorylation (on Ser396) and consequently 
to the formation of the neurotoxic tau aggregates (Frost, Meechoovet et al. 2011), responsible for 
the pathological progression of Alzheimer’s disease. In this context, harmine treatment was 
shown to inhibit the formation of these aggregates, due to its suppressing activity on MAO and 
Dyrk1a (Frost, Meechoovet et al. 2011). 
1.5.2.3.3 Anti-cancer properties 
In Iran and Morocco, traditional medicine preparations for the treatment of many tumors were 
based on P. harmala seeds. These habits raised the interest of many researchers to understanding 
the properties of these seeds and, specifically, of β-carboline alkaloid compounds, which are 
supposed to be partially responsible for the inhibition of cancer cell proliferation. Additionally, 
their cytotoxic action was also linked to the ability to interact with nucleic acids, therefore 
inhibiting DNA synthesis (Chen, Chao et al. 2005). Actually, in vitro, harmine shows a very 
strong effect on the inhibition of DNA topoisomerase I purified from human placenta (Sobhani, 
Ebrahimi et al. 2002). Moreover, harmine mediates DNA conformational changes that interfere 
with DNA synthesis, resulting in proliferation arrest and genotoxic effect in budding yeast (Li, 
Liang et al. 2007). 
To further strengthen the role of harmine in cell-cycle related processes, recent findings have 
	 37	
shown that, in colon cancer cells, harmine decreases cyclin D1 expression levels, with an opposite 
increase of cyclin A, E2 and B1 levels as well as of the levels of CDK1/cdc2, myt-1 and p-cdc2. 
This expression profile is a hallmark of an S-G2/M phase arrest. Moreover, in this model, 
harmine led to activation of both caspase 3 and PARP and the downregulation of Bcl-2 and Mcl-
1; all these events are typically associated with apoptotic death mediated by mitochondrial 
pathway activation and by inhibition of both Akt and ERK signaling (Liu, Li et al. 2016). In 
hepatic cancer cell lines, harmine was shown to inhibit Rad51 recruitment, affecting homologous 
recombination and inhibiting double-strand breaks repair, with consequent cytotoxicity (Zhang, 
Zhang et al. 2015). This work identified novel potential targets in the homologous recombination 
pathway to optimize cancer therapy and arrest cancer cell proliferation. Of note, it seems that 
harmine is able to specifically target proliferating cells, as in hepatoma cell lines, with minimal 
side effect on post-mitotic cells.  
Another example of tumor cells sensitive to harmine treatment is head and neck squamous cell 
carcinoma (HNSCC). In this model, harmine-mediated inhibition of Dyrk1a decreases 
phosphorylation of the transcription factor Foxo3a, thus promoting cell death (Radhakrishnan, 
Nanjappa et al. 2016).  
The aforementioned examples are just a few of the several ones supporting harmine as an 
anticancer drug. Its cytotoxic effect is further strengthened by its anti-angiogenic and anti-
inflammatory properties (discussed above), which supported the patent on harmine-anti-tumor 
effect registered in 2001 (code: CN1358720A). 
1.5.2.3.4 Osteogenic effects 
The increasing need of new drugs to treat bone-destructive diseases led to the investigation of the 
properties of natural compounds in bone reabsorption. In this setting, harmine acts on osteoclast 
progenitors but not on osteoblasts, inhibiting osteoclastogenesis. In particular, harmine 
downregulates c-Fos and Nfatc1 expression, targeting nuclear factor kappa-B ligand (RANKL) 
signaling pathway and preventing osteoclast precursor differentiation (Yonezawa, Hasegawa et 
al. 2011). As a net result, harmine acts on osteoblast differentiation stimulating the activation of 
Runx2 and BMPs signaling. As in the case of its anti-tumoral effect, a patent for the use of alkyl-
amine harmine derivatives to promote bone repair was registered in 2014 (code: EP2968284A2).  
1.5.2.3.5 Anti-diabetic actions 
Among the alkaloids present in P. harmala, harmine is the main responsible of its anti-diabetic 
effects. Interesting findings show that this compound has an important metabolic effect, 
promoting the specific expression of PPARγ in adipocytes, resulting in an improvement of 
glucose metabolism (Waki, Park et al. 2007). Furthermore, harmine is also able to attenuate the 
expression of pro-inflammatory genes and diminishes macrophage recruitment in the adipose 
tissue, which is linked to the insulin resistance induced by obesity. The action of harmine on 
adipocyte metabolism can partially be explained by the inhibition of WNT signaling pathway 
(Waki, Park et al. 2007).  
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Since the deficiency of functional pancreatic beta-cells represents the cause of type 1 diabetes, 
harmine represents a promising therapeutic agent, as it is able to promote beta-cell proliferation, 
increase islet mass and improve glucose metabolism in in vivo models. The inhibition of Dyrk1a 
and the NFAT transcription factors were reported to be responsible for the harmine pro-




2 Thesis Aim 
The work presented in this Thesis was aimed at identifying the molecular mechanisms by which a 
few microRNAs and one small molecule are capable to stimulate cardiomyocyte proliferation ex 
vivo and cardiac regeneration after myocardial infarction in vivo.  
First, I concentrated my attention on the effect of 10 microRNAs that had been previously 
identified by the laboratory for their capacity to stimulate proliferation of neonatal rodent 
cardiomyocytes. For 6 of these microRNAs, I determined the transcriptional profile induced by 
their transfection into cardiomyocytes, observing that they all impinge on the Hippo/YAP pathway 
and determine remodelling of the actin cytoskeleton by targeting one or more of the proteins that 
control actin polymerization.  
Next, I screened a library of FDA-registered drugs in search for small molecules able to activate 
cardiomyocyte proliferation. I discovered that the neuroactive alkaloid harmine exerted a powerful 
pro-proliferative effect, which was mediated by the inhibition of the cellular Dyrk1a kinase. 
Similar to the investigated microRNAs, activation of YAP was also essential to mediate the pro-
proliferative effect of harmine.  
These findings are discussed in the context of the possibility of inducing cardiac regeneration after 














3 Materials and Methods 
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3.1. Cell culture methods 
3.1.1 Cell lines: HeLa   
HeLa cells (ATCC® Cells were taken in a Dulbecco’s modified Eagle medium with 1 g/l glucose 
(DMEM, Life Technologies) supplemented with 10% FBS and 100 U/ml penicillin and 100 mg/ml 
streptomycin (Sigma). 
3.1.2 Primary cells: isolation of ventricular cardiac myocytes from 
neonatal rats 
Ventricular CMs were isolated from neonatal rat as previously described	 (Collesi, Zentilin et al. 
2008). In brief, ventricles from neonatal (P0) rats were separated from the atria, cut into pieces and 
dissociated in calcium and bicarbonate-free Hanks with Hepes (CBFHH), using mechanical and 
physical stirring. CBFHH buffer contains 1.75 mg/ml trypsin (BD Difco) and 10 mg/ml DNase II 
(Sigma). Tissue digestion was performed at room temperature in ten minute steps, with collection 
of the supernatant to fetal bovine serum (FBS, Life Technologies) after each step. In order to pellet 
cells, collected supernatant was centrifuged and cardiac cells were then resuspended in Dulbecco’s 
modified Eagle medium 4.5 g/l glucose (DMEM, Life Technologies) supplemented with 5% FBS, 
20 mg/ml vitamin B12 (Sigma) and 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma). The 
collected cells were filtered using a cell strainer (40 mm, BD Falcon) and finally seeded onto four 
100-mm plastic dishes for 2 hr at 37°C in 5% CO2 and humidified atmosphere. CMs in the 
supernatant were then collected, counted and plated at the appropriate density into BD Matrigel 
Matrix Growth Factor Reduced (356230 BD Bioscience) pre-coated Primaria 96-well plates (BD 
Falcon) or matrigel-coated Primaria 35-mm dishes (BD Falcon). 
 
Number of cardiac cells seed for each plate/dish: 
96-multiwell plate: 15*10^3 cells/ well 
35 cm dishes: 5*10^5 cells/ dish 
60 cm dishes: 1*10^6 cells/ dish 
 
3.1.3 microRNA/siRNA transfection and EdU incorporation 
MicroRNAs and siRNAs (SMARTpool) were obtained from Dharmacon, Thermo Scientific and 
transfected into neonatal rat CMs using a standard reverse transfection protocol	 (Eulalio, Mano et 
al. 2012). Cardiomyocyte transfection efficiency with miRNAs/siRNAs is >90% using 
Lipofectamine RNAiMAX as lipids.  In brief, transfection lipids (Lipofectamine RNAiMAX, Life 
Technologies) were incubated with OPTIMEM (Life Technologies) for 5 min at RT and added to 
miRNAs, siRNAs or a combination of the two (at a final concentration of 25 nM each nucleic 
acid), arrayed on 96-well plates; 30 min later, 1x10^4 cells were seeded in each well. Twenty-four 
hours after transfection, culture medium was replaced by fresh medium; 28 h later (52 h after 
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plating), the culture medium was supplementaed with 5 mM 5- ethynyl-29-deoxyuridine (EdU, 
Life Technologies) for 20 h. Cells were fixed at 72 h after plating and processed for 
immunofluorescence. Experiments were performed in quadruplicate. 
 
Oligonucleotides 
siRNA targeting sequence:  
YAP1  NM_001034002.2  
 
sequences: siRNA YAP1sense 5'- 
GGAGAAGUUUACUACAUAA [dT] [dT] -3'  

















siRNA against rat STK38L  Sigma ID: SASI 
Rn02_00208859  
 
siRNA against rat Dyrk1a Ambion ID: s129286 
siRNA against rat Dyrk2 Ambion ID: s163537 
siRNA against rat Dyrk3 Ambion ID: s156275 
siRNA against rat Dyrk4 Ambion ID: s161980 
siRNA negative control Ambion  
siRNA negative control Sigma  





Harmine, harmaline, harmane (Sigma-Aldrich) were dissolved in DMSO and further diluted in 
culture media at the final concentration of 10 µM. 
CytochalasinD (sc_201442, Santa Cruz) was added to CM culture medium at the final 
concentration of 0.1 µM. 
3.1.5 TEAD reporter assay  
For luciferase assays, CMs were plated at the concentration of 1.5x105 (day 0) in a double-matrigel 
coated 96-Multiwell plate and, the day after, were transfected with the selected miRNAs 
(Dharmacon). At day 3 of culture, cells were transfected with 100 ng of both synthetic TEAD 
reporter firefly luciferase plasmid (p8xGTIIC-Lux, Plasmid #34615, Addgene) and a renilla 
luciferase plasmid. The day after transfection, firefly and renilla luciferase activities were measured 
using the Dual Luciferase Reporter Assay System (Promega), according to the manufacturer’s 
instructions. 
3.1.6 Luciferase 3′-UTR reporter assays  
Constructs coding for rat 3′-UTR of Cfl2, TAOK1, β-TrCP or STK38L (gBlock) were obtained by 
gene synthesis from Biomatik (3’UTR-Cfl2) or Genewiz (3’UTR- β- TrCP and 3’UTR-TAOK1) 
and subcloned into psiCHECK2.1 vector (Promega). HeLa cells were transfected with 100 ng of 
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the reporter constructs or psiCHECK2 vector (control) using FuGENE HD transfection reagent 
(Promega). Twenty-four hours later, cells were transfected with the miRNA under investigation at 
a final concentration of 50 nM in 96-well plates, using a standard forward transfection protocol 
similar to that described above. Each condition was tested in quadruplicates. 
Firefly and renilla luciferase activities were measured 48 hr after plasmid transfection using the 
Dual Luciferase Reporter Assay System (Promega), according to the manufacturer’s instructions. 
3.1.61 mutated UTR-luciferase reporters: construct generation  
The mutated 3’-UTR of β-TrC and TAOK1 were obtained by gene synthesis (gBlocks) from IDT 
(Integrated DNA Technology) and sub-cloned into the psiCHECK2.1 vector. The gBlocks terminal 
regions were implemented with enzymatic restriction sites for XhoI and NotI in addition to 
flanking regions of stuffer-DNA to increase cut efficiency. 
The gBlocks were digested with XhoI and Not-HF (New England Biolabs) as well as the wt UTR-
luciferase reporter plasmids. 
Briefly, 500 ng of gBlock or 2µg of the vectors were digested with 0.1µl/0.5µl of XhoI 
(10000U/ml) and 0.1µl/0.5µl of NotI-HF (10000U/ml) in presence of 2µl/3µl of 10x Buffer 2.1 and 
H20 to final volume of 20 µl/30µl and incubated at 37° for 2 hours; then, heat inactivation for 15’ 
at 65°C.  
Both digested vectors were submitted into DNA gel electrophoresis. 1% agarose gel was prepared, 
placed into an electrophoresis chamber and rinsed in TBE (Tris-Borate-EDTA buffer; Sigma). 
Samples were loaded into pre-cast wells and placed in an electric field where due to the negatively 
uniform mass/charge ratio of nucleic acids, DNA fragments migrated according to their molecular 
weight and secondary structure. The linearized vectors were excised and purified from gel using 
Wizard SV Gel and PCR Clean-Up System (Promega) according to manufacturer’s instruction. 
Also the digested gBlocks were purified, using the same kit. Finally, the linearized vectors and the 
digested gBlocks (mutated 3’UTR of β-TrC and TAOK1, respectively) were ligated and 
transformed into XL10 Gold (Stratagene) recombination deficient bacteria. Colonies were screened 
for ampicillin resistance as well as insert size by restriction enzyme digestion. 
Before using the ligation products to perform the 3’UTR-luciferase assay, we checked the sequence 







FIGURE 3-1 SCHEMATIC REPRESENTATION OF THE 3’UTR OF TAOK1 AND β-TRC TRANSCRIPTS  
The 3’UTR of TAOK1 and bTrC mRNA were mutated as shown in the miR-199a-3p recognized region (in 
blue). In green the seed sequence of miR-199a-3p. 
 
Recombinant DNA 
p8xGTIIC-Lux plasmid  Gift from S. Piccolo Lab Addgene, 
Cat#34615 
pRL Renilla Luciferase control plasmid Promega cat# E2261 
5SA-YAP1 in pCSII-EF-MCS plasmid Gift from S. Piccolo Lab, Dupont 
et al. Nature 2011 
 
psiCheck2.1 plasmid Promega Cat# C8021 
3’UTR-Cfl2 plasmid Biomatik Clone ID 
T4545-1 




3’UTR-mut Taok1 plasmid QuikChange II XL Site-Directed 
Mutagenesis Kit 
 
3’UTR-mut b-Trc plasmid QuikChange II XL Site-Directed 
Mutagenesis Kit 
 
3’UTR-Stk38L plasmid IDT gblock  
 
 
3.1.7 High-throughput screening: FDA-registered compound screening 
The miRNA mimics corresponding to hsa-miR-590-3p, hsa-miR-199a-3p were obtained from 
Dharmacon, Thermo Scientific. For miRNA transfection in rat CMs, miRNAs were robotically 
transferred from stock library plates to Primaria 384-well plates (BD Falcon) leaving columns 1 
and 24 empty for addition of controls (buffer, cel-miR-67). MiRNAs were transfected into neonatal 
rat CMs using a standard reverse transfection protocol, at a final miRNA concentration of 25 nM. 
Briefly, the transfection reagent (Lipofectamine RNAiMAX, Life Technologies) was diluted in 
OPTI-MEM (Life Technologies) and added to miRNAs on the 384-well plates; 30 min later, 5.000 
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cells/well were seeded. Twenty-four hours after transfection, culture medium was replaced by fresh 
medium; 24 h later, that is, 48 h after plating, FDA-registered compounds, 10 mM (or DMSO as 
control) were robotically arrayed on the 384-well plates and 52h after plating 5 µM 5-ethynyl-2′-
deoxyuridine (EdU, Life Technologies) was added for 20 h. Cells were fixed at 48 h after plating 
and processed for immunofluorescence. Screening was performed in duplicate. Cells were stained 
according to IF standard protocol as described later. 
 
3.1.8 Immuno-staining: immunofluorescence on primary cell cultures 
CMs were fixed with 4% PFA for 10 min, permeabilized with 0.5% Triton X-100 in PBS for 10 
min, followed by 1 hr blocking in 2% BSA (Roche). CMs were then stained overnight at 4°C with 
mouse monoclonal antibody against sarcomeric α-actinin (Abcam) diluted in blocking solution. 
Cells were washed with PBS and incubated for 2 hr with the secondary antibody conjugated to 
Alexa Fluor-488 (LifeTechnologies). Cells were further processed using the Click-IT EdU 555 
Imaging kit (Life Technologies) to reveal EdU incorporation, according to the manufacturer’s 
instructions, and stained with Hoechst 33342. 
3.1.8.1 Image acquisition  
In screening experiments, image acquisition was performed using an ImageXpress Micro 
automated high-content screening fluorescence microscope at ×10 magnification; a total of 16 
images were acquired per wavelength, well and replicate, corresponding to approximately 2.500 
cells analyzed per condition and replicate. Image analysis was performed using the ‘Multi-
Wavelenght Cell Scoring’ application module implemented in MetaXpress software (Molecular 
Devices). Cells were scored as proliferating only if positive for the proliferation marker EdU. In all 
quantifications, CMs were distinguished from other cells present in the primary cultures by their 
positivity for sarcomeric α-actinin. 
3.2 Biochemistry 
3.2.1 Nuclear/cytoplasmic fractionation  
1x106 neonatal rat cardiac myocytes were plated on matrigel-coated Primaria 60-mm dishes (BD 
Falcon) as described above. miRNAs were transfected by a standard forward transfection protocol. 
Seventy-two hr after transfection, cells were washed with ice-cold PBS and harvested in 80 µl of 
hypotonic buffer (50 mM Tris pH7.5, 10 mM NaCl, 3 mM MgCl2, 10% glycerol) supplemented 
with protease inhibitors (complete tablets, Mini EDTA-free, Roche) and phosphatase inhibitors 
(cocktail 3 Sigma, 2mM orthovanadate, 1 mM NaF). After 1 min, cells were scraped and NP40 was 
added at 0.1% final concentration. After 5 min on ice, cells were centrifuged at 4000 rpm for 5 min 
at 4ºC; the supernatant and cytosolic fractions were then recovered. Pellets were resuspended in 70 
µl IPLS buffer (50 mM Tris pH 7.5, 120 mM NaCl, 1 mM EDTA, 0.5% NP40, supplemented with 
the same inhibitors as above) and sonicated with 3 pulses of 10 min each (30 sec on/30sec off) on 
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ice in a Bioruptor™ Plus (Biosense). Nuclear lysates were centrifuged at 16,000 rpm for 20 min at 
4ºC and the supernatant was recovered as nuclear fraction. Concentration of cytoplasmic and 
nuclear lysates were measured using the Bradford assay (Protein Assay Dye Reagent Concentrate, 
Bio Rad). Lysates (10 to 20 µg) were loaded for protein separation and subsequent blotting onto a 
PVDF membrane (Amersham™ Hybond™ PVDF, GE Healthcare). 
3.2.2 Antibodies 
The following antibodies were used for western blotting analysis. 
 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit polyclonal anti-YAP Cell Signaling Tecnology Cat# 4912S RRID:AB_10694682 
 
Rabbit polyclonal anti-Phospho 
YAP (Ser 127) 
Cell Signaling Tecnology Cat# 4911S RRID:AB_2218913 
 
Rabbit polyclonal anti-Cofilin 2 Millipore Cat# 07-300 RRID:AB_2080926 
 
Mouse monoclonal anti-F actin Abcam Cat# ab205 RRID:AB_302794 
Clone NH3 
Rabbit polyclonal anti-actin Cytoskeleton 
 
Cat# AAN01 also AAN01-
B,AAN01-A RRID:AB_10708070 





Santa Cruz Biotechnology 
 
Cat# sc-15354 RRID:AB_2065916 
 





Rabbit polyclonal anti-PARP-1 Enzo Life Sciences Cat# ALX-210-302 
RRID:AB_2160732 
 
Mouse monoclonal anti-p84 Abcam Cat# ab487 RRID:AB_304696 
Clone 5E10 
Mouse monoclonal anti-Sarcomeric 
Alpha Actinin 
Abcam Cat# ab9465 RRID:AB_307264 
 
Alexa fluor 488 phalloidin Thermo Fisher Scientific 
 
Cat# A12379 also A-
12379 
RRID:AB_2315147 
rabbit monoclonal anti-Dyrk1a Cell Signaling #2771 
Mouse monoclonal anti-Dyrk2 Santa Cruz  sc-293487 
 
3.2.3  G/F actin separation and immunoblotting 
The amount of G-actin and F-actin in CMs was quantified using G-actin/F-actin in vivo assay kit 
(Cytoskeleton Inc.) according to the manufacturer's instructions. Briefly, cells were lysed in pre-
warmed lysis/F-actin stabilizing buffer supplemented with protease inhibitor and ATP. The cell 
lysate was centrifuged for 5 min at 350°—g to remove debris. A 100 µl aliquot was then 
ultracentrifuged at 100,000xg for 1hr at 37°C to pellet F-actin, with G-actin remaining in the 
supernatant. The pellet was resuspended in 100 µl of F-actin destabilizing buffer on ice for 1 hr 
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with frequent pipetting. Equal volumes of G-actin and F-actin fractions were mixed with 5x 
loading buffer and run on SDS-PAGE. Western blot analysis was performed using the anti α-actin 
antibody provided in the kit. Densitometry analysis was performed using the ImageJ software. 
3.3 Molecular Biology Methods 
3.3.1 RNA isolation and quantitative Real-Time PCR  
Total mRNA was isolated from CMs 72 hr after transfection, or at different time points after 
cytochalasin D treatment, using a standard TRIZOL RNA isolation protocol. The RNA obtained (1 
µg) was reverse-transcribed using MLV-RT (Invitrogen) with random hexamers (10 µM) in a 20 µl 
reaction, following the manufacturer’s instructions. mRNA levels for CTGF, CyR61, BIRC5 and 
GAPDH were measured by Real-Time PCR using pre-designed TaqMan assays (Thermofisher) 
and iQ™Supermix (Bio-Rad) according to the manufacturer’s instruction. 
TaqMan Probes are listed in the table. 
 
Real Time-PCR probes SOURCE ID 
CTGF  TaqMan Gene Expression Assays Thermo Scientific Assay ID 
Rn01537279_g1 
CyR61 TaqMan Gene Expression Assays Thermo Scientific Assay ID 
Rn00580055_m1 
Birc5   TaqMan Gene Expression Assays Thermo Scientific Assay ID 
Rn00574012_m1 
Taok1 TaqMan Gene Expression Assays Thermo Scientific Assay ID 
Rn00597907_m1 
bTrc    TaqMan Gene Expression Assays Thermo Scientific Assay ID 
Rn01413748_m1 
Cfl2    TaqMan Gene Expression Assays Thermo Scientific Assay ID 
Rn01472820_g1 
Stk38l    TaqMan Gene Expression Assays Thermo Scientific Assay ID 
Rn01472820_g1 
Dyrk2   TaqMan Gene Expression Assays Thermo Scientific Assay ID 
Rn01472820_g1 
Dyrk3    TaqMan Gene Expression Assays Thermo Scientific Assay ID 
Rn01472820_g1 
Dyrk4   TaqMan Gene Expression Assays Thermo Scientific Assay ID 
Rn01472820_g1 
Dyrk1a  TaqMan Gene Expression Assays 
 
Thermo Scientific Assay ID 
Rn00562940_m1 
 
3.3.2  Transcriptomic analysis  
Deep-sequencing of total neonatal rat CM RNA was performed 72 hr after transfection of 
microRNAs by IGA Technology Services, Udine, Italy as in ref.	 (Eulalio, Mano et al. 2012). 
Briefly, RNA purity, integrity and concentration were determined using an Agilent 2100 
Bioanalyzer (Agilent Technologies). Only RNA with a RIN value >7 and an rRNA 28S/18S ratio 
>2 was taken forward for sample preparation. Two µg of total RNA (minimum concentration of 
200 ng/µl) per sample were sequenced on an Illumina HiSeq2000. Two lanes in 7-plex were run 
obtaining 2 millions of single-reads per sample, 50-bp long. The raw sequencing data discussed in 
this thesis have been deposited in NCBI's Sequence Read Archive (SRA) and are accessible 
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through SRA STUDY accession SUB2866022. 
Real-time image analysis, base calling, de-multiplexing and production of FASTQ sequence files 
were performed on the HiSeq2000 instrument using the HiSeq Software. Raw sequence files were 
quality checked using FASTQC software (www.bioinformatics.babraham.ac.uk/projects/fastqc) 
and trimmed to remove Illumina adaptor using Cutadapt software (Martin, 2011). RNA-seq reads 
were mapped to Rattus norvegicus reference genome (GCF_000001895.5 Rnor 6.0.82) and to 
known mature miRNAs using STAR software (Dobin et al., 2013). Rounded Gene counts were 
used as input and transformed to rpkm using Bioconductor package edgeR rpkm function 
(McCarthy, Chen et al. 2012) . The CLC Bio Genomic Workbench (Mortazavi et al., 2008) was 
used to quantify gene expression levels. In particular, sequenced RNA fragments were mapped 
against the NCBI Rnor_6.0 annotation release 106 (GCF_000001895.5) RefGene genome 
annotation	 (O'Leary, Wright et al. 2016). The resulting gene expression levels were then 
normalized in RPKM (reads per kilobase of exon model per million mapped reads). In case of 
transfection of a pro-proliferative miRNA, genes whose RPKM values were greater than 1.00 in 
both miRNA and cel-miR-67 control-transfected rat CMs were considered as expressed. Fold 
changes were taken with respect to the expression of cel-miR-67 control. Genes whose fold 
changes were greater than 1.3 (both upregulated and downregulated) were considered as 
differentially expressed. 
3.3.3 Clustering of fold change expression levels  
Cluster analysis was performed on the basis of the log2-fold changes in gene expression in respect 
to cel-miR-67 to classify the pro-proliferative miRNAs according to their effects on CMs upon 
transfection. In brief, the correlation between the log2-fold changes for all pairs of miRNA was 
calculated. Clusters were then hierarchically identified using the average linkage criterion with a 
Euclidean distance metric as implemented in the clustering package of SciPy v0.18.1 
(http://www.scipy.org). Dendrograms were then generated to visualize the arrangement of the 
resulting cluster. 
3.3.4 Bioinformatic target prediction 
To the best of our knowledge, bioinformatic predictions of seed sequence interactions with rat 
transcripts are not available. With this constraint, we compiled a list of rat miRNA-gene 
interactions from mouse predictions. In particular, predicted mouse gene targets of the seed 
sequences (corresponding to miRNA families) of pro-proliferative miRNAs were collected from 
TargetScanMouse Release 7.1	(Agarwal, Bell et al. 2015). The mouse genes were then converted to 
their corresponding rat genes via homology using the HomoloGene database	(Coordinators 2016). 
The list of miRNA-gene interactions was filtered to only include genes that were downregulated by 
the miRNA upon transfection to CMs according to the transcriptomic data. 
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3.4 Animal models 
Wistar rats and CD1 mice were purchased from Charles River Laboratories Italia Srl. Animal care 
and treatments were conducted in conformity with institutional guidelines in compliance with 
national and international laws and policies (EEC Council Directive 86/609, OJL 358, 12 
December 1987). 
Dyrk1a F/F mice were were received by Prof. John D Crispino from the Robert H Lurie Medical 
Research Center and MHC-MCM-Dyrk1a F/F mice were generated by breeding Dyrk1a F/F mice 
and MHC-MCM- mice, which are available in ICGEB Animal House Facility. 
3.4.1 Myocardial infarction 
Myocardial infarction was produced in adult female CD1 mice (8–12 weeks old), by permanent left 
anterior descending (LAD) coronary artery ligation. Briefly, mice were anesthetized with an 
intraperitoneal injection of ketamine and xylazine, endotracheally intubated and placed on a rodent 
ventilator. Body temperature was maintained at 37°C on a heating pad. Beating heart was accessed 
via a left thoracotomy. After removing the pericardium, a descending branch of the LAD coronary 
artery was visualized with a stereomicroscope (Leica) and occluded with a nylon suture. Ligation 
was confirmed by the whitening of a region of the left ventricle, immediately post-ligation. EdU 
was administered intraperitoneally (500 µg per animal) every 2 days, for a period of ten days.  
3.4.2 Echocardiographical analyses  
To evaluate left ventricular function and dimensions, transthoracic two-dimensional 
echocardiography was performed on mice sedated with 5% isoflurane at 12, 30 and 60 days after 
myocardial infarction, using a Visual Sonics Vevo 2400 Ultrasound (Visual Sonics) equipped with 
a 30-MHz linear array transducer. M-mode tracings in parasternal short axis view were used to 
measure left ventricular anterior and posterior wall thickness and left ventricular internal diameter 
at end-systole and end-diastole, which were used to calculate left ventricular fractional shortening 
and ejection fraction. Echocardiography analysis was performed at week 1, 2, 4 and 8 after 
infarction (in harmine-treated animals) or after the induction of the phenotype (Dyrk1a KO mice) 
and hearts were collected at 8 week after infarction (n= 6 animals per group). 
3.4.3 Heart collection and histological analysis 
At the end of the studies, animals were anaesthetized with 5% isoflurane and then killed by 
injection of 10% KCl, to stop the heart in diastolic phase. The heart was excised, briefly washed in 
PBS, weighted, fixed in 10% formalin at room temperature, embedded in paraffin and further 
processed for histology or immunofluorescence. PicusSirius-Red staining were performed 
according to standard procedures and analyzed for morphology and extent of fibrosis. 
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3.5 Statistical analysis 
Unless otherwise indicated, all data are expressed as mean ± standard error of the mean (SEM). 
One-way ANOVA followed by post-hoc analysis with the Bonferroni’s Multiple Comparison Test 
































4.1 Activation of the YAP transcriptional coactivator mediates 
function of miRNAs inducing cardiomyocyte proliferation 
We wanted to explore the involvement of the YAP-Hippo signaling pathway in the biological 
effect of a series of human microRNAs previously identified to promote cardiac cell 
proliferation (Eulalio et al 2012). To this aim, we evaluate TEAD activation rate by transfecting 
neonatal rat cardiomyocytes with a TEAD-responsive reporter plasmid (p8xGTII-Lux) together 
with the top 10 of microRNAs characterized in our previous work for their pro-proliferative 
ability (Fig. 4-1A). These included human miR-590-3p (the most effective in our original 
screening in rat cells), miR-199a-3p (the most effective in mouse cells), miR-1825, miR-302c, 
miR-302d and miR-373 (two miRNAs known to be enriched in embryonic stem cells (Barroso-
del Jesus et al., 2009), miR-33b*, miR-18a*, miR-1248, miR-30e*. C. elegans cel-miR-67 was 
used as a negative control, while constitutively activated YAP (YAP5SA) was used as a positive 
control. We found that TEAD-luciferase reporter activity was significantly increased upon 
treatment with all the selected microRNAs compared to the control cel-miR-67 (Fig. 4-1B).
 
 
FIGURE 4-1. YAP ACTIVATION IN NEONATAL RAT CARDIOMYOCYTE UPON TREATMENT WITH PRO-PROLIFERATIVE 
MICRORNAS  
A. Experimental scheme to test activation of TEAD-dependent transcription. B.TEAD luciferase reporter analysis of 
CMs transfected with the indicated miRNA mimics. Transfection efficiency was standardized over a constitutively 
expressed Renilla luciferase reporter.  Transfection of a constitutively activated YAP plasmid (pYAP5SA) was used as a 
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positive control. Data are mean ±SEM (n=5 independent experiments); *P<0.05, **P<0.01;  one-way ANOVA C. 
Increase in YAP nuclear level by CM treatment with proproliferative miRNAs. Western blot of a representative 
experiment show the levels of nuclear and cytoplasmic YAP1 and phospho-YAP1 (P-YAP1) 72hr after transfection. 
PARP1 and GAPDH were used for loading control of the nuclear and cytoplasmic fractions respectively. D. 
Quantification of the increase in YAP nuclear level in CMs after miRNA mimics transfection. Results are shown as a 




To verify that detected TEAD activation corresponded to an increase of nuclear YAP, we 
investigated YAP1 levels in both cytoplasmic and nuclear fractions of cardiac cells treated with 
the 10 pro-proliferative microRNAs. In line with the previous evidence, we found that, in all 
cases, there was a correlation between cell treatment with the pro-proliferative microRNAs and 
the increase in YAP1 levels in the nucleus as shown in Fig. 4-1C and 4-1D. Finally, to 
understand whether YAP activation was a crucial event for CM proliferation mediated by these 
miRNAs, we knocked down YAP1 using a specific siRNA (YAP1 knock down >85% is shown 
in Fig. 4-2A) and simultaneously treated CMs with the investigated miRNAs. We analyzed EdU 
incorporation level as a marker for cell proliferation and we found that YAP1 knockdown 
prevented the pro-proliferative effect of all the microRNAs under investigation, as shown in Fig. 
4-2B. Representative images are shown in Fig. 4-2C.  
From these results, we conclude that the increase in nuclear YAP activation is a common key 




FIGURE 4-2. YAP IS CRUCIAL TO SUSTAIN CARDIOMYOCYTE PRO-PROLIFERATIVE EFFECT EXERTED BY THE MICRORNAS 
UNDER INVESTIGATION  
A. Efficacy of YAP1 downregulation using a specific siRNA. On the left side, representative western blotting. On the 
right side, quantification of 3 independent experiments. Data are mean ±SEM; **P<0.01; t-test B. Induction of CM 
proliferation by miRNA mimics is blunted by YAP knockdown. CMs were transfected with pro-proliferative microRNAs 
alone or in combination with an anti-YAP siRNA. The graph shows the percentage of sarcomeric α-actinin-positive cells 
that incorporated EdU. Data are mean ±SEM (n=4 independent experiments); *P<0.05, **P<0.01; one-way ANOVA C. 
Representative images of CMs treated with the indicated miRNAs with out without a siRNA against YAP. CMs are 
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visualized in green as sarcomere α-actinin-positive cells. Hoechst staining was used for nuclei (blue). EdU incorporation 
is visualized in red (bottom panels). The arrows indicate example of proliferating CMs. Scale bar: 100 µM. 
 
4.2. Common regulatory pathways mediate the activity of pro-
proliferative miRNAs  
Next, to understand the mechanisms used by the microRNAs of interest to obtain YAP 
activation, we first analyzed the transcriptional feature of neonatal rat cardiomyocytes treated 
with six of these microRNAs, namely human miR-590-3p, miR-199a-3p, miR-1825, miR-302d, 
miR-373 and miR-33b*; C. elegans cel-miR-67 was used as a negative control.  RNA from 
miRNA-transfected cardiac myocytes was isolated and used for transcriptomic RNA sequencing 
followed by computational analysis (Fig. 4-4A and -4B). Cluster analysis was performed on the 
obtained results, showing that miR-302d and miR-373-3p had similar effects on target gene 




FIGURE 4.3. MIRNA SEQUENCE AND CHROMOSOMAL LOCALIZATION 
Sequence, miRBase accession number, miRBase ID and chromosomal localization of the human miRNAs under 
investigation. The miRNA seed sequence is in red. 
 
Fig. 4-4A schematically shows the number of genes from NCBI database that were differentially 
regulated by the miRNAs: a total of 3734 genes were downregulated by at least 1 miRNA (at 1.0 
RPKM cutoff and 1.30 fold-change cutoff), while 3326 were upregulated. Next, we performed a 
pathway analysis using IPA software (Build version: 389077M, Content version: 27821452, 
08/08/2016), considering all the tested miRNAs as replicates of the common CM proliferative 
phenotype. The results showed that the network with the higher score (34) was the cell cycle- 
cancer  and cardiovascular system development and function network, followed by the embryonic -
organismal-tissue development network with a score of 22.  
Given the involvement of the YAP-Hippo signaling pathway on the regulation of cardiomyocyte 
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proliferation during embryonic development (Xiao et al., 2016), we focused our attention on 
genes linked to this pathway. To this aim, we generated an update catalogue of the genes known 
to have a role in the regulation of YAP-Hippo signaling pathway (203 genes). For each gene we 
reported fold changes in gene expression for each miRNA treatment along the bioinformatics 
prediction of miRNA targeting (TargetScan software) (Table 1).  
A summary of all this information is reported in Fig. 4-4D; the level of each transcripts is 
indicated by its fold difference over control (green: downregulated genes; red: upregulated 
genes). Interestingly, five out of six microRNAs upregulated TEAD2 levels, the final effector of 
the Hippo pathway. Moreover, all the selected microRNAs targeted either LATS1/2 or STK38L 
kinases, which blunt CM proliferation via YAP1 inactivation (Hergovich, 2016).  
Together, these bioinformatics findings on RNA sequencing data indicate that there is a 
signature of Hippo pathway involvement upon treatment of cardiomyocytes with the six 
analyzed pro-proliferative microRNAs. 
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FIGURE 4-4. EXPRESSION PROFILE OF GENES IN NEONATAL CMS UPON TREATMENT WITH PRO-PROLIFERATIVE MIRNAS 
Total neonatal rat CM RNAs were deep-sequenced and quantified using standard protocols. The gene expression profile 
mapped on Rattus norvegicus reference genome (GCF_000001895.5 Rnor 6.0.82) was then normalized by RPKM. Fold-
changes in gene expression upon transfection of pro-proliferating miRNA were taken with respect to cel-miR-67 
(negative control). A. Schematic representation of RNAseq experiment. Neonatal rat CMs were reverse transfected with 
the indicated miRNAs and RNA was analyzed by Next Generation Sequencing (NGS). B. Heatmap showing 
differentially expressed genes in response to all 6 miRNAs; downregulated genes are in green, upregulated genes in red.  
C. Cluster analysis was performed on the basis of log2 (fold-change over control, cel-miR-67). The dendrogram shows 
the arrangement upon hierarchically clustering using an average linkage criterion with a Euclidean distance as a metric. 
D. Common regulatory pathways mediate activity of miRNAs inducing CM proliferation, among which Hippo and F-
acting polymerization pathways. Upregulated genes are in red, downregulated genes in green. 
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4.3. Hippo pathway downregulation activates CM proliferation 
Interestingly, miR-199a-3p, one of the most effective miRNAs in boosting CM proliferation, 
lead to the downregulation of three mRNA targets indirectly involved in the Hippo pathway, 
namely those coding for the TAO kinase1 (TAOK1), the E3 ubiquitin-ligase β-transducing 
repeat containing protein (β-TrCP) and the serine/threonine kinase, STK38L. TAOK1/3 was 
described to activate MST1/2 via phosphorylation (Boggiano et al., 2011), as well as LATS1/2 
(Plouffe et al., 2016; Poon et al., 2011); β-TrCP mediates YAP ubiquitination and consequently 
leads to its degradation (Zhao et al., 2010). STK38L, a kinase belonging to the same AGC 
serine/threonine kinase family as LATS1/2, directly inactivates YAP via phosphorylation 
(Hergovich, Stegert et al. 2006) (Fig. 4-5A). In order to validate these targets and the direct 
binding of their 3’UTR by the studied miRNAs, we cloned the 3’UTRs of TAOK1, β-TrCP and 
STK38L mRNAs downstream the firefly luciferase gene and transfected these plasmids into 
HeLa cells treated with the 10 pro-proproliferative miRNAs (Fig. 4-5B). Co-transfection of a 
Renilla luciferase plasmid served as a control of transfection, while the cloning plasmid 
(psiCheck2.1) was used for normalization. Analysis of the luciferase activity 48 hours after 
transfection revealed that only TAOK1 and β-TrCP, but not STK38L, were 3’UTR-direct targets 
of miR-199a-3p (Figs. 4-5C, -5D and -5E respectively). The mutated counterparts were no 
longer able to bind miR-199a-3p as shown in Fig. 4-5F and -5G. In the case of STK38L, we 
found a downregulation of its transcript upon miR-199a-3p, miR-302d and miR-373 treatment, 
possibly due either to an indirect effect or to the binding of miRNAs outside the 3’UTR (western 
blotting analysis and protein quantification are reported in 4-5M and -5N). To complete this 
functional characterization, the downregulation of both TAOK1 and the β-TrCP by miR-199a-3p 
transfection was detected both at protein and mRNA levels (Fig. 4-5H, -5I and -5J show 












FIGURE 4-5. MECHANISM FOR YAP ACTIVATION BY MIR-199A-3P AND OTHER MIRNAS  
A. Schematic representation of the Hippo pathway, with the indication of the predicted target proteins according the 
TargetScan software. B. Experimental flow chart of 3'UTR luciferase assays. Fluc and Rluc: firefly and Renilla luciferase 
genes, respectively. 3'UTR luciferase assays with the 10 pro-proliferative miRNAs. C. TAOK1 and  β−TrCP (D) 3’-
UTRs are direct targets of miR-199a-3p, while STK38L is not (E). F-G Mutated 3’-UTR luciferase assay of both 
TAOK1 (F) and β−TrCP (G). All the Renilla (Rluc) values were normalized over firefly luciferase (Fluc) values. Control 
refers to transfection of a firefly luciferase gene with no 3'UTR. H-J. Representative western blots showing 
downregulation of TAOK1 and β−TrCP proteins in cells treated with miR-199a-3p mimic (H) and the relative 
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quantifications (I-J). K-L. Real-time RT-PCR quantification of TAOK1 and β−TrCP mRNAs in CMs treated with miR-
199a-3p mimic. Data are mean ±SEM (n=3 independent experiments); *P<0.05; t-test. M. Western blot showing 
STK38L levels upon treatment with miR-199a-3p. A siRNA targeting STK38L was used as a negative control. N. Protein 
quantification of western blot shown in panel M. Data are mean ±SEM (n=3 independent experiments); *P<0.05; t-test. 
O. RT-PCR quantification of STK38L upon pro-proliferative miRNA transfection. Data are mean ±SEM (n=3 
independent experiments); *P<0.05, **P<0.01; one-way ANOVA. 
 
 
Next we investigated whether the specific silencing of TAOK1, β-TrCP and STK38L had a 
direct impact on CM proliferation. We co-transfected neonatal CMs with a TEAD luciferase 
plasmid and with siRNAs targeting TAOK1, β-TrCP or STK38L (Fig.4-6C). SiRNA 
downregulation of each of these targets was evaluated at the protein level; β-TrCP expression 
was silenced >70% (Fig. 4-6A); TAOK1 expression >90% (Fig. 4-6B); and STK38L >65% 
(Fig. 4-5N), compared to control. Silencing of these proteins resulted in the transcriptional 
response of the TEAD-responsive promoter, as shown in Fig. 4-6C-6D.  
Then, we analysed the effect of TAOK1, STK38L and β-TrCP downregulation on CM 
proliferation. Of notice, siRNAs against both TAOK1 and β-TrCP significantly enhanced EdU 
incorporation and this effect was abolished when these siRNAs were combined with the specific 
silencing of YAP; in contrast, the downregulation of STK38l had no impact on cell proliferation 
(Fig. 4-6E-F).  
Taken together, these results demonstrate that the mechanism exploited by miR-199a-3p to 
induce CM proliferation involves the direct targeting of two proteins, TAOK1 and β-TrCP, 
which regulate YAP activation via different mechanisms. Further analysis, such as rescue 
experiments in which CM proliferation is evaluated after miR-199a-3p treatment in presence of 
TAOK1 and β-TrCP overexpression, will clarify the relevance of these miR-199a-3p targets 









FIGURE 4-6. MECHANISM FOR YAP ACTIVATION BY MIR-199A-3P.  
A-B. Representative western blots of β−TrCP and TAOK1 after CM treatment withe the respective siRNAs. Data are 
mean ±SEM (n=3 independent experiments); *P<0.05, **P<0.01; t-test. C-D. Downregulation of TAOK1, β−TrCP and 
STK38L stimulate TEAD transcriptional activity. CMs were transfected with siRNAs against TAOK1, β-TrCP or 
STK38L in combination with a TEAD luciferase reporter. The results were normalized to those obtained by a 
constitutively expressed Renilla luciferase plasmid. Data were normalized over a non-targeting (NT) siRNA. Data are 
mean ±SEM (n=5 independent experiments); *P<0.05; one-way ANOVA. E. Representative images of CMs stained for 
sarcomeric a-actinin, EdU incorporation and Hoechst  (nuclei) after treatment with siRNAs against TAOk1 and β−TrCP 
transcripts with a siRNA against YAP or a siRNA NT. Scale bar: 100 µm F. Percentage of sarcomeric α-actinin-positive 
cells that had incorporated EdU were analyzed 72 hr after treatment with specific siRNAs in combination with an anti-







4.4. Modulation of the actin cytoskeleton by Cofilin-2 regulates 
cardiomyocyte proliferation 
Transfection of neonatal CMs with the selected microRNAs often resulted in relevant cellular 
morphological changes, including rounding of the cell surface, as shown in Fig. 4-2C. 
Consistent with this observation, our RNAseq study revealed that many differentially expressed 
genes were involved in actin cytoskeleton remodeling (a list of 79 genes known to be involved in 
the actin cytoskeleton remodeling is shown in Table 2, along with the fold changes upon each 
miRNAs transfection). Fig. 6-4B shows the genes differentially regulated upon miRNA 
treatment. Several of the downregulated genes encoded for proteins able to directly bind G-actin 
and prevent actin polymerization (Xue and Robinson, 2013). In particular, Cofilin2 was 
downregulated by 5 out of 6 investigated miRNAs; Twinfilin1 (Twf1) by 4 miRNAs and 
Twinfilin2 (Twf2) by all 6 miRNAs; Thymosin β4 (Tmsb4x) by one miRNA and Profilin2 
(Pfn2) by 3 miRNAs. Moreover, 5 out of 6 miRNAs also dowregulated Csrp3, a LIM-only 
domain family protein previously described to be able to bind Cofilin2, enhancing its activity in 
F-actin depolymerization (Papalouka et al., 2009). Another downregulated target of 4 out of 6 
miRNAs is Mical3, a member of the Mical family of proteins also involved in actin 
depolymerization (Fremont et al., 2017). Finally, Aurora A kinase (Aurka) a serine/threonine 
kinase playing a critical role during early mitotic stages and spindle formation, known to 
regulate actin cytoskeleton remodeling through Cofilin phosphorylation (Ritchey and 
Chakrabarti, 2014), was commonly upregulated by all the investigated miRNAs. Fig. 4-7A 
shows the actin-related proteins that were also predicted as miRNA direct targets according to 
the TargetScan software.  
In particular, we noticed that the Cofilin2 transcript was downregulated by all the miRNAs under 
investigation, with the exception of miR-590-3p. Furthermore, Cofilin2 was the predicted target 
of 4 of these miRNAs (miR-199a-3p, miR-1825, miR-302d and miR-373; Fig. 4-7A). We 
demonstrated that all these 4 miRNAs were able to directly bind the Cofilin2 3’UTR in UTR-
luciferase assays (Fig. 4-7B). Accordingly, from the quantification of Cofilin2 transcript levels 
in neonatal rat CMs upon miRNA-treatment, a significant downregulation of Cofilin2 transcript 
was experimentally detected in CMs treated with these 4 miRNAs, in addition to CMs also 
treated with miR-33b* (Fig. 4-7C). Downregulation of Cofilin2 by miR-33b* might be due to an 
indirect effect, or an effect mediated by the miRNA binding to Cofilin2 transcript outside the 
3’UTR. Analysis of Cofilin 2 protein levels in miRNA-treated CMs provided consistent results 
showing downregulation of this factor after treatment with miR-199a-3p, miR-1825, miR-302d 
and miR-373 (Fig. 4-7D). 
Collectively, these results indicate that proteins that regulate the actin cytoskeleton dynamics 
and, in particular, the inhibitor of F-actin polymerization by Cofilin2, are frequently targeted, 
either directly or indirectly, by miRNAs inducing CM proliferation. 
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FIGURE 4-7. COFILIN2 IS A COMMON TARGET OF PRO-PROLIFERATIVE MIRNAS.  
A. Schematic overview of proteins involved in actin cytoskeleton remodeling which are predicted targets of the pro-
proliferative miRNAs B. Results of 3'UTR-luciferase assay to evaluate direct targeting of Cofilin2 (Cfl2) by the miRNAs 
under investigation. Experiments were performed as in Fig. 4-5C-E. Data are mean ±SEM (n=3 independent 
experiments): *P<0.05, **P<0.01; one-way ANOVA. C. Real-time RT-PCR quantification of the Cofilin2 expression in 
cardiac cells after miRNA-treatment. A siRNA against Cofilin2 (siCfl2) was used as a positive control. Data are 
mean±SEM (n=3 independent experiments); *P<0.05, **P<0.01; one-way ANOVA. D. Effect of miRNAs on Cofilin2 
protein levels in neonatal rat CMs. Representative western blot shows downregulation of Cfl2 upon pro-proliferative 
miRNAs. In the lower panel: quantification of Cfl2 levels. Data are mean±SEM (n=3 independent experiments); 




4.5. Remodeling of the actin cytoskeleton in proliferating 
cardiac myocytes 
The actin-severing protein, Cofilin2, regulates actin cytoskeleton dynamics by inducing 
polymerized actin (F-actin) conversion back into its monomeric form (G-actin). We thus 
evaluated the ratio between G- and F-actin in cardiomyocytes treated with selected pro-
proliferative miRNAs or with a siRNA against Cofilin2; in the presence of this siRNA we 
obtained a silencing of its target protein of >60% in CMs, which correlated with an upregulation 
of the levels of F-actin, as shown in Fig. 4-8A. The G/F ratio decreased in all the considered 
miRNA-treated CMs. Importantly, this ratio reached statistical significance for miR-199a-3p, 
miR-373, miR-302d and miR-33b* when compared to the negative control. The G/F ratio was 
also decreased in presence of the Cofilin2 silencing, as shown in Fig. 4-8B and Fig. 4-8C for 
representative blots and quantification respectively. 
Next, we wanted to visualize actin cytoskeleton remodeling in cells treated with some of the pro-
proliferative miRNAs or with the anti-Cofilin2 siRNA. For this purpose, we performed 
immunofluorescence staining using a fluorescein-tagged phalloidin to display F-actin (green). In 
Fig. 4-8E, in control CMs treated with the C. elegans miR-67, actin organization was detected in 
long threads throughout the cytoplasm, overlapping with those of the cardiac specific, α-actinin 
(red). In contrast, a round-shaped morphology ì, with actin fibers assembled in gross, round 
bundles at the cytosol periphery, characterized cells treated with miR-199a-3p and miR-373; 
these bundles of cortical actin were marked also in α-actinin-negative cells (fibroblasts). CMs 
treated with the two miRNAs also showed a decreased level of sarcomere organization. On the 
contrary, no evident morphological effect was detected in cells treated with miR-590-3p. Of 
notice, the same pattern of F-actin distribution also characterized cells treated with the siRNA 
against Cofilin2, as shown in Fig. 4-8D. Round-shaped CMs after miRNA and siRNA 
treatments were evaluated using the cell counter tool of the ImageJ software and the relative 
quantification are presented in Fig. 4-8F. 
Together, these data are consistent with the conclusion that the pro-proliferative miR-199a-3p 
and miR-373 determine actin cytoskeleton remodeling and, consequently, CM morphology 




FIGURE 4-8. MIRNA TREATMENT OF CARDIOMYOCYTES INDUCES REMODELLING OF THE ACTIN CYTOSKELETON 
A. Representative blots indicating that the downregulation of Cofilin2 changes the G/F actin ratio in favour of the actin 
polymerized form (F-actin). siRNA NT: non-targeting siRNA control B. Quantification of the G-actin/F-actin ratio in 
CMs upon pro-proliferative miRNAs or anti-Cofilin2 siRNA treatment. Representative western blots, using an anti-a-
actin antibody, of supernatants (containing G-actin) and pellets (F-actin) obtained by ultracentrifugation of lysates from 
the treated CMs. The G/F ratio is shown at the bottom of each band pair. The positive (+) control was provided by the kit 
manufacturer's. C. Quantification of the G/F actin ratio (percentage) obtained as in panel B. Data are mean ±SEM (n=3 
independent experiments); *P<0.05, **P<0.01; one-way ANOVA. D. Percentage of CMs with a rounded shape (as in 
the representative images in Panels E and F after treatment of CMs with miR-199a-3p or Cofilin 2 siRNA). Data are from 
the analysis of over 400 (n=4 independent experiments); shown are mean ±SEM; **P<0.01; one-way ANOVA. E. 
Immunofluorescence images showing remodelling of the actin cytoskeleton upon miRNA treatment. Fluorescent 
phalloidin staining (green) marks F-actin, CMs are visualized with an anti-a-actinin antibody (red), nuclei with Hoechst 
(blue). F indicates fibroblasts (a-actinin negative cells) F. Same as in panel E in CMs treated with an anti-Cofilin2 siRNA 
or with a nontargeting (NT) siRNA control. Scale bar: 65 µm; Scale bar: 33µm  
 
To evaluate cell cycle progression in cells treated with miR-199a-3p, miR-590-3p, miR-373 or 
the anti-Cofilin2 siRNA, we performed a phospho-histone H3 staining, as shown in the 
representative pictures in Fig. 4-9A for the miRNAs and Fig. 4-9B for the siRNA. As shown in 
in Fig. 4-9C, all miRNA treatments induced 5-9% of the cells to move through the G2/M phase. 
Importantly, mitotic cardiomyocytes showed disruption of the sarcomeric architecture, as 
concluded from the diffused staining with α-actinin shown in Fig. 4-9D. Finally, different 
mitotic stages are shown in Fig. 4-9E; CMs are stained with α-actinin. 
Together, these data show significant morphological changes in CM architecture during cell 






FIGURE 4-9. SARCOMERIC ARCHITECTURE WAS DISRUPTED IN PROLIFERATING CARDIOMYOCYTES UPON BOTH MIR-
199A-3P AND COFILIN2 SIRNA TREATMENT 
A-B. Representative images showing cells in G2/M phase treated with miR-199a-3p (A) or siRNA against Cofilin2 (B), 
showing nuclear staining of phospho-histone H3 (phospho-H3 (S10), red) and diffused cytosolic staining for α-actin 
(green). Nuclei are visualized with Hoechst 33342 (blue). C. Percentage of pH3 (S10)+, α-actinin+ cells (CMs) after 
treatment with the selected miRNAs or anti-Cofilin2 siRNA. Cel-miR-67 and a non-targeting (NT) siRNA served as 
negative controls for miRNA and siRNA respectively. Data results from the evaluation of over 400 CMs from four 
different experiments; shown are mean±SEM;**P<0.01, *P<0.01 one-way ANOVA D. Representative images of G2/M 
cardiomyocytes (defined as in C), showing nuclear positivity for phospho-histone H3 (pH3(S10), green) and disruption 
of the sarcomeric architecture, as suggested by the diffused α-actinin staining (red). Nuclei are counterstained with 






4.6. Downregulation of Cofilin2 activates cardiomyocyte 
proliferation through YAP activation 
We wondered whether cardiac cell proliferation mediated by Cofilin2 inhibition and actin 
cytoskeleton rearrangements might require YAP activation. In accordance with this possibility, 
we found that, in CMs, silencing of Cofilin2 mediated by RNAi determined activation of the 
TEAD-luciferase reporter as shown in Fig. 4-10A. In line, cardiomyocyte treatment with anti-
Cofilin2 siRNA resulted in a marked upregulation of the transcript levels of two well-established 
YAP-responsive genes, CTGF and CyR61 (Zhao et al., 2008) as shown in Fig. 4-10B. 
Moreover, co-transfection of CMs with a siRNA against YAP abolished the pro-proliferative 
effect exerted by Cofilin2 silencing, similar to the inhibitory effect observed in the presence of 
miR-199a-3p (Fig. 4-10C; representative IF images showing reduction EdU incorporation rate in 
Fig. 4-10D). The obtained data are indicative of a correlation between the actin polymerization 
process, which is increased by Cofilin2 inhibition, and YAP activation. To investigate this link, 
we suppressed actin polymerization using cytochalasin D and analysed the levels of both 
cytosolic and nuclear YAP1. CMs treated with this drug reduced the levels of nuclear YAP1 in a 
time-dependent manner, whereas increased the amounts of the cytoplasmic, phosphorylated 
YAP1 (representative western blots in Fig. 4-10E and quantification in Fig. 4-10F). This effect 
resulted in the drastic abolishment of the levels of the CTFG and CyR61 gene mRNAs (Fig. 4-
10G). 
Together, these results demonstrate that, in CMs, the extent of actin polymerization regulates 
YAP nuclear activity and, as a consequence, controls the levels of proliferating cells. 
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FIGURE 4-10. PERTURBATION OF THE ACTIN CYTOSKELETON ACTIVATES YAP NUCLEAR TRANSLOCATION AND ACTIVITY 
A. Downregulation of Cofilin2 activates TEAD reporter activity. The graph reports the results of TEAD-firefly luciferase 
reporter analysis of CMs transfected with miR-199a-3p and Cofilin2 siRNA. Experiments were performed as in Fig.1C. 
Transfection efficiency was standardized over a Renilla luciferase reporter. Data are mean±SEM (n=4 independent 
experiments); *P<0.05, **P<0.01; one-way ANOVA B. Real-time RT-PCR analysis of the levels of the two TEAD 
responsive genes CTFG and CyR61 in CMs transfected with anti-Cofilin2 siRNA Data are mean±SEM (n=4 independent 
experiments); **P<0.01; t-test. C. Downregulation of Cofilin2 activates CM replication in a YAP-dependent manner. 
The graph shows the percentage of α-actinin-positive cells that have incorporated EdU after 72 h-treatment with anti-
Cofilin2 siRNA or miR-199a-3p mimic alone or in combination with an anti-YAP siRNA. D. Representative pictures 
showing CMs incorporating EdU after treatment with an anti-Cofilin2 siRNA as in Panel B in the absence or presence of 
an anti-YAP siRNA. Scale bar: 100µm E. Treatment of CMs with cytochalasin D blocks nuclear translocation of YAP. 
Representative blots showing the levels of nuclear and cytoplasmic YAP1 and phospho-YAP1 (P-YAP1) in CMs treated 
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with cytochalasin D for the indicated time points. GAPDH and p84 were used for loading controls of cytoplasmic and 
nuclear fractions respectively. F. Quantification of YAP nuclear translocation in CMs treated with cyochalasin D. Data 
are mean±SEM (n=3 independent experiments); **P<0.01; one-way ANOVA. G. Treatment with cytochalasin D blocks 
transcription of YAP- responsive genes. The graph shows the levels of the CTFG and CyR61 mRNAs, measured by real-
time RT-PCR, in CMs treated with cyochalasin D for the indicated time points. Data are mean±SEM (n=3 independent 
experiments). 
 
4.7. High throughput screening of FDA-registered drugs 
identifies the neuroactive alkaloid harmine as a powerful 
inducer of cardiomyocyte proliferation 
In addition to mIRNAs, we wondered whether some existing small chemical compounds might 
also be able to boost CM proliferation, alone or in combination with the pro-proliferative 
miRNAs miR-199a-3p and miR590-3p. For this aim, we selected a library of 780 FDA-
registered compounds (Enzo Life Sciences), which was assembled by the vendor to maximize 
chemical diversity and thus cover the current full spectrum of pharmacologically active 
molecules (Table 3). 
We performed a high-throughput, fluorescence-microscopy-based, screening in neonatal rat 
CMs to test these molecules for their ability to induce CM proliferation (Fig. 4-11A). Primary rat 
neonatal cardiac cells were prepared with a purity about 90% and reverse transfected with miR-
199a-3p and miR-590-3p (or cel-miR-67 as a negative control). After 24 h of transfection, 
CMs were treated with the library of FDA-registered drugs. Each compound was 
administered at the final concentration of 10 µM (DMSO was used as a control). After 48 h 
from plating, cells were fixed and stained using the sarcomeric α-actinin to visualize CMs 
(green), Hoechst for nuclei (blue) and EdU incorporation (red nuclei) was evaluated as read-out 
of proliferation. The screening was performed in duplicate. 
The most effective molecule in boosting cardiac proliferation was the alkaloid harmine, a 
component of several psychoactive plant extracts (Fig 4- 11B, -11C and -11D). Of notice, 
harmine treatment was able to promote CM proliferation by itself, in the absence of miRNA 
co-treatment, reaching even higher proliferation levels than miR-199a-3p and miR-590-3p. 
Simultaneous treatment of cells with harmine and miR-199a-3p did not have synergistic 
effects; on the contrary, harmine and miR-590-3p treatment determined over 50% of CMs to 
become EdU-positive (Fig. 4-11E). This is in line with the notion, ensuing from our previous 
experiments, that miR-199a-3p and miR-590-3p act through largely different pathways. 
Representative images of CMs after harmine treatment are shown in Fig 4-11G, -11H and -
11I demonstrating a significant increase of the total number of CMs as well as EdU 
incorporation in CM nuclei. The screening results (Fig.11B-11D) are presented using the Z-
score, which shows the distance between the raw score and the population mean in units of 
standard deviation. When the raw score is below the mean, Z is negative, while it becomes 
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positive when the raw score is above the mean. 
 
 
FIGURE 4-11. HIGH THROUGHPUT SCREENING OF SMALL MOLECULES IDENTIFIES THE NEUROACTIVE ALKALOID 
HARMINE AS A POWERFUL INDUCER OF CM PROLIFERATION 
A. Schematic overview of the experimental procedure. A library of 780 FDA-registered compounds was screened in 
neonatal rat CMs for their ability to induce CM proliferation. Primary cardiac cells were reverse transfected with miR-
199a-3p and miR-590-3p (or cel-miR-67 as a control). Twenty-four hour after transfection, CMs were treated with the 
library of FDA- registered drugs. B-D. Results of the screening are presented in the plot as Z-scores (x axis), in which the 
Z score represents the distance between the raw score and the population mean in units of the standard deviation. Z is 
negative when the raw score is below the mean, positive when above. Each dot represents a different drug. E. EdU 
quantification (%) of in neonatal rat CMs are reported in the graph. Data are mean ±SEM (n=3 independent 
experiments); *P<0.05; one-way ANOVA F. The Total number of CMs was increased after harmine treatment as shown 
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in the graph. G-I. Representative images showing CMs visualized using an anti-a-actinin antibody (green); Hoechst 
identifies nuclei (blue) and EdU detects DNA synthesis (red). Scale bar: 100µm. 
 
 
4.8. Harmine treatment induces CM proliferation in vivo 
Next, we investigated the pro-proliferative effect of harmine on cardiac myocytes in vivo. Harmine 
or physiological solution were administrated via intraperitoneal injections in neonatal CD1 mice 
(P1) for 12 days at the dosage of 1 mg/kg body weight. After 10 days, a single dose of EdU was 
injected and, 48 hours later, mice were sacrificed and hearts collected for further analyses (Fig. 4-
12A). Immunofluorescence staining was performed on the total hearts, as shown in Fig. 4-12B: 
EdU incorporation was significant increase in CMs of mice treated with harmine in comparison 
with the control group (6.7 % EdU+CMs treated mice; 2.5% EdU+CMs controls; **P<0.01; t-test). 
Of note, the presence of increased septum and left ventricular posterior wall thickness, observed in 
the harmine-injected mice, was an indication of an increase in cardiac mass. Consistent with effect, 
there was a trend for an increase in cells positive for the proliferation marker phospho-histone 3 
(Fig. 4-12C). Quantification of phospho-H3 positivity is shown in Fig. 12D. 
 
    
 
FIGURE 4-12. HARMINE TREATMENT INDUCES CM PROLIFERATION IN VIVO  
A. Neonatal mice at postnatal day 1 (p1) were injected with harmine or PBS (control) for 5 times, followed by EdU 
injection at day 10. Hearts were collected after 12 days and stained for EdU. B. EdU and a-actinin staining of murine 
hearts injected with harmine or PBS. Scale bars, 1mm. C. Phospho-H3 (green), tropomyosin (red) positive cells in 
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paraffin sections of hearts treated with harmine or PBS identify proliferating cardiomyocytes. Relative quantification are 
shown in panel D. Data are mean ±SEM (n=6 mice: 3 controls and 3 treated mice). Hoechst marks nuclei (blue). Bar 
scale: 250 um 
 
 
4.9 Harmine promotes heart regeneration in an in vivo model of 
myocardial infarction 
Next, we wanted to assess the regenerative potential of harmine in an in vivo model of 
myocardial infarction (MI). For this purpose, PBS or harmine (10 mg/kg body weight) were 
injected in CD1 mice, which were then monitored for a two-month period (Fig. 4-13A). 
Importantly, since harmine is a neuroactive compound, the drug was administered starting from 
one week before the permanent ligation of left anterior descending coronary artery, in order for 
the animals to get exposed to it in advance of treatment.   
Two months after MI, harmine-treated mice showed a marked improvement in cardiac 
contractile function compared to the control group, as shown by a higher left ventricular ejection 
fraction (LVEF) measured by echocardiography (Fig. 4-13C). Consistent with this finding, 
infarct size in the harmine-treated mice was smaller (1.8 fold reduction in comparison with the 
control mice, according to ImageJ software measurements), as shown in representative Sirius 
Red-stained cardiac cross-sections (Fig. 4-13B). Furthermore, the left ventricles of these mice 
showed a trend toward reduced levels of dilatation as concluded from the echocardiographic 
analysis of left ventricle volume at the end of systole and diastole (Figs. 4-13D, -13E). 
 
FIGURE 4-13. THE ALKALOIDE HARMINE PROMOTES HEART REGENERATION IN AN IN VIVO MODEL OF MYOCARDIAL 
INFARCTION 
A. Schematic overview of the in vivo experiment. PBS or harmine (10 mg/kg body weight) were injected in CD1 mice, 
starting from one week before myocardial infarction (MI) and monitored for a period of two months. B. Representative 
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PicusSirius Red-stained cross-sections of hearts at 8 weeks after MI in control and harmine-treated hearts are shown, to 
evaluate infarct size and fibrotic scar compared to the control hearts. The arrowheads indicate the infarcted area. C. From 
echocardiographic data, % LVEF (left ventricular ejection fraction) was evaluated at 1, 2, 4 and 8 weeks after surgery. D-
E. Left ventricle dilatation was evaluated by LVESV and LVEDV (left ventricle volume at the end of systole/ diastole) 
in uL at 0, 1, 2, 4 and 8 weeks. 
 
 
4.10 Yap-dependent harmine proliferation in neonatal rat CMs 
Since from the FDA-registered drug screening it emerged that miR-199a-3p and harmine 
treatment do not show additive effect on CM proliferation, we reasoned that these molecules 
might share the same molecular mechanism to promote CM cell cycling. We therefore wondered 
whether YAP activation was an essential element for harmine to induce CM proliferation. To 
test this hypothesis, we transfected neonatal rat CMs with the siRNA against YAP1 which was 
already described above to knockdown the YAP1 transcript. Twenty-four hours before fixing the 
cells, we treated CMs with harmine and, 4 hours later, with EdU. Analysis of EdU incorporation 
revealed that the absence of YAP1 in harmine-treated CMs significantly reduced their 
proliferative ability (Fig. 4-14A and -B), demonstrating the essential role of YAP in CM 
cytokinesis mediated by harmine. Representative images of proliferating cardiomyocytes upon 
harmine administration and their inhibition upon YAP downregulation are shown in Fig. 4-14A. 
Since harmine is a compound belonging to the alkaloid family, we next wondered whether other 
alkaloids of the same class, such as harmane and harmaline (Fig. 4-14E), share the same pro-
proliferative capacity. We found that the most potent compound inducing cardiomyocyte 
proliferation was harmine, as shown in Fig. 4-14C and -14D, although a modest increase in 
cardiac myocyte proliferation was also observed in harmaline-treated cells. The effect of 
harmaline on CM proliferation can be explained by the similar molecular structure of these two 
drugs, which both have a methoxy and a methyl group that are not present in harmane (Fig. 4-
14E). Finally, we also tested whether these members of the alkaloid family are also able to 
induce YAP activity, using a TEAD-luciferase reporter assay. The results obtained 
demonstrated that only harmine promotes YAP activation in CMs (Fig. 4-14F) reaching 






FIGURE 4-14. YAP-DEPENDENT HARMINE-INDUCED PROLIFERATION IN NEONATAL RAT CMS 
A. Representative images showing proliferating cells transfected with siRNA anti-Yap1 or a non-targeting (NT) siRNA 
in the presence of harmine treatment. Cells were stained for a-actinin (green) to visualize CMs, EdU staining (red) to 
identify proliferating cells. Nuclei are visualized with Hoechst 33342 (blue). B. Quantifications of EdU+ CMs (%) are 
shown in the graph. Data are mean ±SEM (n=3 independent experiments); *P<0.05; t-test. Scale bar: 100µm C-E. 
Harmine analogues, harmaline and harmane (molecules structure in E), were tested for their ability to induce CM 
proliferation (C). Quantification of EdU+ CMs (%) are shown in the graph D. Data are mean ±SEM (n=3 independent 
experiments); **P<0.01; one-way ANOVA. F. CMs were treated with harmine analogues in combination with a TEAD 






4.12 Dyrk1a inhibition and Yap activation mediate the pro-
proliferative effect of harmine in cardiomyocytes 
It is known that harmine is also able to inhibit the dual specificity tyrosine phosphorylation 
regulated kinase (Dyrk1a), while both harmane and harmaline specifically inhibit MAO-A	
(Herraiz, Gonzalez et al. 2010)	(Herraiz and Chaparro 2006) .We therefore investigated whether 
the mechanism by which harmine induces CM proliferation might require Dyrk1a kinase 
inhibition.  
To investigate the role of Dyrk1a in the harmine-mediated CM proliferation, we silenced 
Dyrk1a (>90% protein downregulation; Fig. 4-15C) using a specific siRNA against its 
mRNA and evaluated EdU incorporation in cardiac myocytes. The results obtained showed 
that suppression of Dyrk1a was sufficient to induce CM proliferation (Fig. 4-15A), as 
concluded by the increase in EdU incorporation observed upon Dyrk1a silencing (Figs. 4-
15A and -15B). On the contrary, we found that adenovirus-mediated overexpression of 
Dyrk1a reduced proliferation by approximately 50% (Fig. 4-15D and -15E), correlating with 
a 50% decreased level of TEAD reporter activity (Fig. 4-15I). The overexpression of Dyrk1a 
mediated by adenovirus was confirmed by the evaluation of Dyrk1a protein level (2.5 fold 
changes over control) as shown in the Fig. 4-14F. An adenovirus carrying GFP was used as a 
control for these experiments. Of notice, TEAD activation levels, boosted by harmine 
treatment, was markedly reduced when cells were co-treated with harmine and Adeno-Dyrk1a 
(Fig. 4-15I).  
Next, we wanted to understand whether the increased proliferation observed after Dyrk1a 
silencing was mediated by YAP1. For this aim, we analyzed EdU incorporation in cardiac 
myocyctes after treatment with siRNA Dyrk1a in combination with a siRNA against YAP1. 
As shown in Figs.4-15G and 4-15H, YAP1 inhibition reduced the CM proliferation induced 
by Dyrk1a silencing.   
Collectively, these data show that Dyrk1a inhibition is responsible for the boost of 
proliferation triggered by harmine treatment in CMs. 
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FIGURE 4-15. DYRK1A INHIBITION AND YAP ACTIVATION MEDIATE PRO-PROLIFERATIVE HARMINE EFFECTS IN CMS  
A. Representative images of CM proliferation mediated by siRNA-silencing of Dyrk1a. CMs were transfected with a 
specific siRNA against Dyrk1a or non-coding siRNA (siRNA nc). CMs are visualized in green as α-actinin-positive cells. 
Hoechst staining was used for nuclei (blue). EdU incorporation is visualized in red. Scale bar: 100µm B. The graph 
shows the percentage of sarcomeric α-actinin-positive cells that have incorporated EdU. Data are mean ±SEM (n=3 
independent experiments); *P<0.01; t-test. C. Western blot showing siRNA-mediated Dyrk1a downregulation. GAPDH 
was used as loading control. D. Representative images of CMs upon overexpression of Dyrk1a mediated by an 
adenovirus (AdDyrk1a). An adenovirus carrying GFP, adGFP, was used as a control. CMs are stained same as in A. E. 
Percentage of sarcomeric α-actinin-positive cells (green) that have incorporated EdU (red nuclei) are reported in the 
graph. F. Western blot showing overexpression of Dyrk1a protein mediated by the adenovirus G. Representative images 
of CMs transfected with siRNA against Dyrk1a or a non-coding siRNA (siRNA nc) in the presence of Yap1 knockdown. 
H. The graph shows the percentage of sarcomeric α-actinin-positive cells that have incorporated EdU. Data are mean 
±SEM (n=3 independent experiments); *P<0.01; one-way ANOVA. I. CMs treated with adDyrk1a alone and in 
combination with harmine treatment were transfected with a TEAD luciferase reporter. A constitutively expressed 
Renilla luciferase plasmid was used to normalize the results. Data are mean ±SEM (n=5 independent experiments); 
*P<0.01; one-way ANOVA. 
 
 
4.13 The role of the Dyrk family in promoting CM proliferation 
To understand whether other Dyrk-family members (Fig. 4-16A) had the same capability of 
Dyrk1a in promoting CM cell cycle activity, we analysed CM proliferation upon transfection 
with siRNAs against each member of the Dyrk family (Dyrk1a, Dyrk2, Dyrk3, Dyrk4). CMs 
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were visualized with α-actinin staining (green), EdU staining (red) was used to identify 
proliferating cells and nuclei were stained with Hoechst 33342 (blue) as shown in Fig. 4-16C. 
The specific silencing of Dyrk1a was the only treatment able to significantly promote an 
increase in cardiac myocyte proliferation (Fig. 4-16B). 
Next, CMs treated with siRNAs against Dyrk1a, Dyrk2, Dyrk3 and Dyrk4 were transfected with 
a TEAD luciferase reporter. The results were normalized to those obtained by a constitutively 
expressed Renilla luciferase plasmid and calculated as fold over control (non-coding siRNA). 
Even though Dyrk1a alone was able to induce CM proliferation, it was not the only one able to 
increase Yap-mediated TEAD activity. Indeed, Dyrk2 also seems to have an effect in inducing 
Yap activation, as reported in Fig. 4-16D.  
Finally, the expression of two YAP-responsive genes, CTGF and Birc5, were marked increased 
upon Dyrk1a silencing or harmine treatment, as shown in Fig. 4-16E and -16F. 
 
FIGURE 4-16. DYRK1 FAMILY AND YAP EFFECT ON CARDIOMYOCYTE PROLIFERATION 
A. Schematic representation of Dyrk family member structure. NSL= nuclear localization  sequence; DH: DYRK-
homology box; kinase catalytic domain; PEST: proline, glutamic acid, serine, and threonine rich domain; HIS: poly-
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histidine domain; S/T: region rich in serines/threonines; NAPA: N-terminal auto-phosphorylation accessory region. B. 
Quantification of EdU+ CMs (%). Data are mean ±SEM (n=3 independent experiments); *P<0.01; one-way ANOVA. C. 
Representative images showing CMs transfected with siRNAs against each member of the Dyrk family (Dyrk1a, 
Dyrk2,Dyrk3, Dyrk4). CMs were visualized with a-actinin staining (green); EdU staining (red) was used to identify 
proliferating cells. Nuclei are visualized with Hoechst 33342 (blue). D. CMs were treated with siRNAs against Dyrk1a, 
Dyrk2 and Dyrk4 and transfected with a TEAD luciferase reporter. Results were normalized to those obtained by a 
constitutively expressed Renilla luciferase plasmid and calculated as fold over control (non-coding siRNA). Data are 
mean ±SEM (n=4 independent experiments). E-F. Real-time RT-PCR quantification of YAP target genes, CTGF and 
Birc5, in CMs upon harmine treatment and Dyrk1a silencing. DMSO treatment and siRNA non-coding (nc) were used as 
controls. Data are mean ±SEM (n=3 independent experiments); *P<0.01; one-way ANOVA 
 
 
4.14 Cardiac specific Dyrk1a KO induces cardiac proliferation 
in adult mice 
To verify whether Dyrk1a silencing would also promote cardiac cell proliferation in vivo, an 
inducible mouse model of cardiomyocyte-specific Dyrk1a KO was created (MHC-
MerCreMer-Dyrk1a f/f) by crossing a Dyrk1a floxed mouse (obtained from Prof. John D. 
Crispino, Robert H Lurie Medical Research Centre, US) with an MHC-MerCreMer driver 
mouse. The induction of Dyrk1a KO specifically in cardiomyocytes was obtained by 5 
injections of 4-OH-tamoxifen, which was administrated intraperitoneally in two month-old 
mice (n=6) at the dosage of 40 mg/kg body weight (experimental scheme Fig. 4-17A).  
We verified the cardiac specific Dyrk1a ablation in the hearts of MHC-MerCreMer-Dyrk1a 
f/f mice and in the Dyrk1a f/f control group (n=6) using Real Time-qPCR Fig. 4-17B. Mice 
were monitored with echocardiography for functional cardiac parameters such as left 
ventricular ejection fraction (LVEF), left ventricular mass (LVmass) and left ventricular area 
of the wall in diastole, LVAWd, at different time points (week 0, 2, 4 and 8 weeks) (Fig. 4-
17D, -17E and -17F). We referred to week 0 as the time point just after the injections of 4-
OH-tamoxifen (week-1) and before the first EdU injection (week1). EdU was injected in mice 
from week 1 to the end of the follow-up period (2 months). As shown in Fig. 4-17D and -
17F, analysis of the left ventricular parameters of cardiomyocyte-specific Dyrk1a KO mice 
revealed a significant increase in LVAWd already at week 1 after the induction of the KO 
phenotype, which, in combination with an increase in LVmass, that becomes significant at 
week 2, was indicative of an increased thickness of the left ventricular wall without any 
correlation with an eventual increased in heart weight (Fig.4-17C).  
In order to assess whether the observed phenotype was due to hyperhrophic remodelling of 
CMs or to an increase in CM number, wheat germ agglutinin staining (WGA) was used to 
identify plasma membranes and measure cardiac cell surface (Fig 4-17G and -17H), while 
EdU incorporation in α-actinin positive cells was used as a marker of proliferating cells, as 
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shown in Fig. 4-17I. The results obtained indicated that cardiac proliferation was responsible 
for the thickness of the heart wall (Fig. 4-17F-17D), since CM size in the Dyrk1a KO mice 
was not different from that of the control group, as quantification in Fig. 4-17H shows. 
Collectively, these data show that the cardiomyocyte-specific Dyrk1a ablation leads to 
increased adult CM proliferation in vivo.  
 
 
FIGURE 4-17. DYRK1A CARDIAC SPECIFIC KO PROMOTES CARDIOMYOCYTE PROLIFERATION IN VIVO 
A. Schematic overview of the in vivo experiment. Three doses of 4-OH-tamoxifen were injected in MCM-CRE-f/f 
Dyrk1a mice to induce cardiac Dyrk1a knock out. Mice were monitored for a period of two months. B. Dyrk1a 
expression levels were evaluated in qRT-PCR in WT and Dyrk1a KO murine hearts. GAPDH was used as 
housekeeping gene. C. The weight of Dyrk1a WT and KO hearts were measured and normalized on tibia length. D-F. 
Left ventricular anterior wall thickness in diastolic phase was evaluated at at 0, 1, 2, 4 and 8 weeks. E. Left ventricle 
ejection fraction (LVEF) was evaluating at different time points to monitor heart functionality. F. Left ventricle mass, 
expressed in mg, was evaluated at 0, 1, 2, 4 and 8 weeks. G. Representative images of WGA staining showing CM 
area in WT and Dyrk1a KO hearts. H. Quantification of the relative cross-sectional area in WT and Dyrk1a KO mice. 
I. EdU staining (red) of tropomyosin positive cells (green) in paraffin sections of heart tissue of Dyrk1a KO or WT 




The scanty information so far available on the molecular mechanisms that regulate cardiomyocyte 
cell cycle progression and those that are involved in physiological regeneration during the 
embryonic, fetal and early neonatal life still hamper the development of novel therapeutic 
approaches for the vast number of patients suffering of post-myocardial infarction heart failure. In 
the present work, we investigated the mechanism of action of two distinct pro-proliferative stimuli 
able to promote cardiomyocyte cell cycle re-entry: a series of microRNAs, identified in our 
previous work for their ability to stimulate neonatal rodent CM proliferation, and the neuroactive 
compound harmine, which had emerged from a high throughput screening using a library of FDA-
registered drugs.  
 
Our results clearly indicate that signaling from all investigated, pro-proliferative miRNAs 
converges towards nuclear translocation of the YAP transcriptional co-activator. This final 
molecular outcome is achieved through the modulation of different pathways, among which the 
regulation of actin cytoskeleton dynamics plays an essential role. 
The Hippo-Yap signaling pathway is a master biochemical cascade in the control of organ size, as 
shown in YAP overexpression experiments	  (Camargo, Gokhale et al. 2007) or Hippo core 
component knock-down (Heallen, Morikawa et al. 2013). In particular, multiple evidence over the 
last few years has shown that this pathway is an essential regulator of physiological cell 
proliferation during normal heart development	 (Xiao, Leach et al. 2016). In adult hearts, YAP 
overexpression induces CM cell cycle re-entry	 (Lin, von Gise et al. 2014), while in the case of 
myocardial infarction, YAP activation drives heart tissue regeneration (Heallen, Morikawa et al. 
2013)	(Xin, Kim et al. 2013). 
Our results, showing that the downregulation of YAP expression by RNAi blunts the pro-
proliferative effect of all the 10 top effective miRNAs originally identified to stimulate CM 
proliferation, confirm that this pathway is also crucial for the exogenous stimulation of 
proliferation of post-natal CMs. This conclusion is reinforced by the observations that these pro-
proliferative miRNAs promote the activation of a TEAD-responsive promoter, increase YAP-
responsive gene expression and trigger nuclear import of active YAP. 
 
Given the above discussed link between pro-proliferative microRNAs and YAP signaling, we 
investigated the molecular targets of these miRNAs, the downregulation of which might be 
eventually responsible for YAP functional activation in cardiomyocytes. Transcriptomic analysis of 
CMs in response to miRNA transfection revealed that 6 of the investigated miRNAs act through 
distinct pathways to achieve YAP activation. Indeed, all 6 of them determined downregulation of at 
least one of the kinases known to inactivate YAP (STK38L, LATS1/2 and TAOK1). Our results 
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further confirm previous findings from the Morrisey laboratory, showing that the miR-302/367 
cluster - in our work, we analyzed miR-302c and miR-302d, belonging to this family - induces 
activation of the Hippo pathway in cardiac cells through the downregulation of MST1, MOB1b and 
LATS2	 (Tian, Liu et al. 2015) MiR-199a-3p instead directly targets the 3’UTR of TAOK1 and 
β−TrCP, the latter acting as the E3 ubiquitin ligase driving YAP degradation through the 
proteasome	(Zhao, Li et al. 2010) . Conversely, we found that the 3’UTR of STK38L is not directly 
bound by MiR-199a-3p: its downregulation upon miR-199a-3p, miR-302d and miR-373 
transfection suggests either an indirect effect or an effect mediated by miRNA binding outside the 
3’UTR region of the STK38L transcript. 
Of interest, individual downregulation of either TAOK1 or β−TrCP by RNAi was sufficient to 
stimulate CM proliferation, indicating that the effect of miR-199a is likely the combinatorial 
outcome of downregulation of these (and likely other) genes, possibly impacting on the same 
pathway. Finally, consistent with their positive effect on the Hippo pathway, all the tested miRNAs 
upregulated the levels of the transcriptional enhancer factor TEF-4, TEAD2. This transcription 
factor belongs to the TEAD family: this isoform is highly expressed in muscles and mediates YAP 
coactivation of genes involved in DNA replication and cell cycle progression	 (Kapoor, Yao et al. 
2014)	(Zhao, Caretti et al. 2006). 
 
Another molecular signature shared by most of the investigated miRNAs was the modulation of the 
actin cytoskeleton network. In particular, the levels of several factors preventing actin 
polymerization were significantly downregulated upon miRNA transfection in CMs: these included 
Cofilin2, Twinfilin1/2, Thymosin β4 and Profilin2. These regulatory proteins are important to 
maintain an active monomeric (G-actin) pool and prevent filamentous (F-actin) nucleation events 
(Xue and Robinson 2013). Few miRNAs dowregulated Csrp3, a Cofilin2-binding protein that 
enhances Cofilin2-dependent F-actin depolymerization	 (Papalouka, Arvanitis et al. 2009) and 
Mical3, known to destabilize F-actin, inhibiting local actin assembly	(Fremont, Romet-Lemonne et 
al. 2017). Downregulation of these factors shifts the balance between F- and G-actin towards the 
polymerized state, as we observed in the case of transfection of individual miRNA mimics in 
cardiac cells, in particular miR-199a-3p, miR-302d, miR-373 and miR-33b*. Consistent with this 
effect, cells treated with miR-199a-3p or miR-373 macroscopically showed a rounded shape and 
displayed formation of layers of cortical, polymerized actin in bundles close to the cytoplasm 
periphery. 
 
Interestingly, all the miRNAs we investigated, with the exception of miR-590-3p, were able to 
down-regulate the transcript of Cofilin2. This protein belongs to the muscle-specific ADF/Cofilin 
family, essential to modulate the equilibrium of actin assembly, thus being involved in all aspects 
of cell motility, locomotion and invasion	 (Bernstein and Bamburg 2010)	 (Bravo-Cordero, 
Magalhaes et al. 2013). In particular, Cofilin causes depolymerization of actin filaments, 
preventing their reassembly	 (Ghosh, Song et al. 2004). We found that four of the investigated 
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miRNAs (miR-199a-3p, miR-1825, miR-302d and miR-373) directly targeted the 3’UTR of 
Cofilin2 transcript. Even more notably, silencing of Cofilin2 by a specific siRNA was sufficient to 
stimulate CM proliferation and drive morphological changes in the treated cells, in terms of cortical 
actin accumulation and shape, which were superimposable to the phenotype triggered by miRNA 
transfection. We also found that the downregulation of Cofilin2 triggered YAP nuclear 
translocation with consequent activation of its transcriptional pathway, while inhibition of actin 
polymerization by cytochalasin D blocked this effect. Our results are perfectly consistent with 
previous findings showing that actin cytoskeleton dynamics is a strong activation signal for YAP in 
response to mechanical cues from the extracellular environment	(Dupont, Morsut et al. 2011). 
Keeping with the above experimental results and considerations, there is evidence that YAP 
activity is promoted and maintained by polymerized F-actin, essential for the maintenance of 
cellular homeostasis, resulting from a combination of extracellular hits affecting cell morphology 
and shape	(Dupont, Morsut et al. 2011). The interplay between YAP activation and the cytoskeletal 
arrangement of CMs has an additional layer of complexity, since recent work has shown that YAP 
directly regulates genes encoding for proteins that promote F-actin polymerization and link the 
actin cytoskeleton to the extracellular environment, including components of the dystrophin 
glycoprotein complex (Morikawa, Zhang et al. 2015). Recent data also demonstrate that a 
component of this complex, Dag1, directly binds YAP and inhibits its pro-proliferative function 
(Morikawa, Heallen et al. 2017). Since the dystrophin glycoprotein complex connects the 
extracellular matrix to the actin cytoskeleton, it is conceivable that perturbing integrity of this 
connection at different levels might lead to YAP activation. This possibility is consistent with our 
observation that the individual Cofilin2 knockdown, which promotes actin rearrangement, is 
sufficient to activate YAP. 
As far as miR-590 is concerned, although Cofilin2 was not a direct target of miR-590-3p, we 
cannot exclude that this miRNA interferes with cytoskeleton remodelling in exerting its pro-
proliferative effect. Indeed, from the TargetScan prediction, in line with our RNaseq data, miR-
590-3p downregulates the cysteine and glycine-rich protein 3 (Csrp3) mRNA levels, which 
encodes for the Muscle LIM Protein (MLP). As previously mentioned, this protein is involved in 
the maintenance of cytoarchitecture integrity of muscle cells and increases actin depolymerisation 
in a Cfl2-mediated manner (Papalouka, Arvanitis et al. 2009). We therefore can speculate that, 
although miR-590-3p is not directly affecting Cfl2 expression, it most likely acts on actin 
cytoskeleton remodeling through the silencing of Csrp3, in order to alter G-/F-actin balance to 
allow CM proliferation.  
Recently, the study of actin dynamics has also unveiled a role of nuclear actin in the regulation of 
cellular transcriptional activity. In this context, additional molecular mechanisms of CM cell cycle 
regulation could be revealed by exploring the role of nuclear actin upon miRNA treatment, as it 
would shed lights in the understanding whether it is able to directly affect CM transcriptional 
activity in the proliferative effect exerted by microRNAs.   
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Finally, the interconnection between cytoskeletal dynamics, CM replication and YAP activation is 
further corroborated by the observation that all the pro-proliferative microRNAs under examination 
activated expression of Aurora A kinase, a protein that regulates G2/M phase transition during the 
cell cycle	 (Nikonova, Astsaturov et al. 2013). On the one hand, this serine/threonine kinase 
phosphorylates Cofilin at multiple sites during early mitosis resulting in the inactivation of its actin 
depolymerizing function	(Ritchey and Chakrabarti 2014). On the other hand, recent work in cancer 
cells indicates that Aurora A kinase also acts as a direct, positive regulator to enhance YAP-
mediated transcription	(Chang, Yamaguchi et al. 2017). 
 
In this work we also aimed at identifying small molecule drugs able to boost CM proliferation and 
thus potentially rescue myocardial function after ischemic injury. A library of 780 FDA-registered 
compounds was chosen for our screening, which was assembled by the vendor (Enzo) in order to 
ensure maximum heterogeneity in the chemical and pharmacological spectrum among all the 
available compounds. Our high-throughput, small molecule screening identified the neuroactive 
alokaloid drug harmine, as the most potent inducer of CM proliferation.  
Harmine, is a small molecule historically isolated from P. harmala and B. Caapi and belonging to 
beta-carboline alkaloids family. Harmine was traditionally used in hallucinogen preparations in 
tribial cerimonies in the Central Asia, Middle East and South America. Besides its hallucinating 
properties of harmine, an interesting series of pharmacological effects have been attributed to this 
drug, including as anti-inflammatory, anti-microbial and anti-psychotic activities (reviewed in 
(Patel, Gadewar et al. 2012). 
In the more recent literature, several papers report that harmine functions as a potent anti-tumor 
compound. In particular, in Hep3b and HuH7 hepatic cancer cell lines, harmine interferes with the 
double-stranded DNA break repair mechanism of cancer cells, which naturally allow these cells to 
survive and rapidly divide. In this context, harmine negatively affects the homologous 
recombination pathway by inhibiting the recruitment of Rad51 and consequentially determines 
failure of DNA damage repair mechanisms, with cytotoxicity as the ultimate result	(Zhang, Zhang 
et al. 2015). Moreover, harmine was reported to inhibit tumor growth in head and neck squamous 
cell carcinoma (HNSCC) by inhibiting Dyrk1a-mediated Foxo3 phosphorylation, thereby 
promoting cell death (Radhakrishnan, Nanjappa et al. 2016).  
In light of the above reported, known effect of harmine, it was quite surprising to us to discover 
that the drug was a powerful inducer of CM proliferation, in combination with miR-199a-3p or 
miR-590-3p, but also by itself. Moreover, in vivo and in neonatal mice harmine induced CM 
proliferation already at a dosage of 10mg/kg body weight. In addition, we found that harmine 
treatment significantly improve cardiac function after the induction of a myocardial infarction in 
mice, showing its beneficial potential in the heart regenerative process. 
In considering the literature, however, one should mention that harmine was already reported to 
also stimulate proliferation of human neural progenitor cells in vitro	(Dakic, Maciel et al. 2016) as 
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well as that of pancreatic β-cells, both in in vitro and in vivo (Wang, Alvarez-Perez et al. 2015). In 
both cases, inhibition of the ubiquitous kinase Dyrk-1a was found to mediate the proliferative 
effect of the drug. In particular, in pancreatic β-cells, inhibition of Dyrk1a was shown to result in 
NFAT nuclear translocation, which in turn induced expression of genes that stimulate cell cycle 
progression, such as c-Myc.  
Our experimental data indicate that, among the alkaloid family members, harmine was the only 
tested compound able to promote CM proliferation, while the harmine analogues harmaline and 
harmane, which share a very similar biochemical structure with harmine, did not exert any 
significant effect.  
The Dyrk1a gene is located on human chromosome 21, in the Down syndrome critical 
region (Shindoh, Kudoh et al. 1996) and is highly expressed in different tissues, such as brain and 
heart. It is considered to be crucial during early development of the nervous system and a master 
regulator in brain growth	 (Guedj, Pereira et al. 2012).	Although, in neural cells, Dyrk1a has been 
described to regulate cell cycle progression and apoptosis, the detailed Dyrk1a downstream 
molecular mechanism still remains a topic of debate	 (Fernandez-Martinez, Zahonero et al. 2015). 
As for harmine, function of Dyrk1a seems to be dependent on the specific cell type and the cell 
proliferating status. 
The role of Dyrk1a in cardiac myocytes is under investigation in various laboratories. One study 
has described Dyrk1a as a regulator of cardiac hypertrophy	 (Kuhn, Frank et al. 2009). Dyrk1a 
inhibition, mediated by a recombinant adenovirus carrying synthetic miRNAs targeting the kinase 
mRNA, was shown to induce in vitro cardiomyocyte hypertrophy induced by a 24 hr-pulse of 
phenylephrine. In addition, overexpression of Dyrk1a (AdDyrk1a) was reported to completely 
rescue the hypertrophic phenotype in vitro, while an inactive mutant of Dyrk1a (AdK188R) was 
ineffective. These findings were explained by the correlation between a decrease in Dyrk1a activity 
and the increased level of nuclear NFAT, the downstream transducer of calcineurin signaling 
responsible for CM hypertrophy.  
There is an apparent contradiction between the above reported findings and those we obtained 
regarding the role of Dyrk1a as a negative regulator of CM proliferation. Indeed, we clearly 
observed that RNAi-mediated silencing of Dyrk1a stimulated CM proliferation without exerting 
obvious effects on either CM size or hypertrophic fetal gene expression. Differences in the 
experimental conditions and in timing of observation might explain these different results. In our 
experiments, Dyrk1a silencing was obtained by using a specific siRNA, which requires at least 72 
hr to be effective, while the inactive mutant of Dyrk1a used by Hille and colleagues was evaluated 
24 hr after transduction, which is a too short timeframe to appreciate any proliferative events in 
CMs. In addition, a recent line of though postulates that CM hypertrophy and proliferation are 
different sides of the same coin, which depends on the status of the cell that receives a given 
stimulation. In particular, CMs might require an increase in size (hypertrophic phase) before 
division; if adult CMs receive a pro-proliferative stimulus, they fail to proliferate and become 
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hypertrophic. Conversely, neonatal CMs are still capable to accomplish cell division therefore, 
once exposed to the same kind of stimulation, they overcome the “hypertrophic phase” and 
complete their mitosis.  
The finding that harmine activates CM proliferation by targeting Dyrk1a raises the obvious 
question of which is the molecular mechanism by which this kinase controls cell proliferation. In 
this respect, the observation that harmine treatment did not exert any addictive effect with that of 
miR-199a-3p is consistent with the possibility that both the drug and this miRNA act through 
similar molecular mechanisms. Consistent with this possibility, we indeed found that harmine 
treatment resulted in YAP activation and that YAP was essential to mediate the pro-proliferative 
effect of the drug, again highlighting the essential role of the Hippo/YAP pathway in the regulation 
of cell cycle progression in CMs. However, how does Dyrk1 inhibition end up in YAP activation 
still remains a very interesting matter for future investigations. One might speculate that the kinase 
directly phosphorylates YAP thus inhibiting its activity or that, alternatively, it activates other 
known upstream kinases in the Hippo pathway, which are known to exert a negative role on YAP. 
Both possibilities appear to be experimentally testable. 
The conclusion that Dyrk1a is an inhibitor of CM proliferation is fully consistent with the findings 
we observed in vivo in the Dyrk1a conditional knock-out mice. Full Dyrk1a knock-out is known to 
be embryonically lethal, while its overexpression during embryogenesis results in cardiovascular 
abnormalities	 (Fotaki, Dierssen et al. 2002). In our experiments, adult animals in which Dyrk1a 
was inactivated specifically in the heart, using tamoxifen-inducible Cre under the control of the 
MHC promoter, showed a significant increase in cardiomyocyte proliferation, with consequent 
hyperplastic increase in cardiac ventricle mass. These results might appear substantially different 
from those reported by the De Windt group in a haploinsufficient Dyrk1a mouse, in which 
pathologic hypertrophic growth after TAC was observed (da Costa Martins, Salic et al. 2010). 
However this discrepancy is only apparent, since the animal models used in the two studies are 
substantially different. Da Costa Martins and collaborators, to avoid embryonic lethality, took 
advantage of a haploinsufficient Dyrk1a mouse model, which is substantially different from the 
inducible cardiac specific knock-out used in our studies. Additionally, in the da Costa Martins 
study, analysis was performed at one week after transverse aortic constriction, while, in our case, 
mice were analysed in the absence of damage.  
The effect of Dyrk1a overexpression was also recently studied in the heart	 (Hille, Dierck et al. 
2016), showing that cardiac specific Dyrk1a transgenic mice developed dilated cardiomyopathy. In 
the same study, the hearts of neonatal transgenic mice, overexpressing Dyrk1a, presented decreased 
levels of CM proliferation, in agreement with our conclusions. At the molecular level, Hille et al. 
defined a new role for Dyrk1a as a negative regulator of Rb/E2F signalling mediated by cyclin-D 
and thus of cardiac myocyte proliferation. These conclusions appear to be fully consistent with our 
observation that Dyrk1a knock-out significantly increases CM proliferation. 
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Conclusions and translational perspectives 
The discovery that individual miRNAs regulate post-natal CM proliferation is of particular interest 
towards the potential utilization of these molecules to promote cardiac regeneration. The 
identification of the molecular targets of the pro-proliferative miRNA is obviously important in this 
context. The results presented in this Thesis indicate that the stimulation of CM proliferation by 
miRNAs is a process that requires downregulation of multiple targets, with likely additive 
functions. In this respect, the pleiotropic effect of miRNAs appears to be of significant advantage 
compared to the use of single genes or siRNA knockdowns, provided, obviously, that the potential 
deleterious effects are minimized. For example, miR-199a-3p, one of the most effective miRNAs 
both ex vivo and in vivo, targets directly the 3’UTRs of Cofilin2 (modulation of actin 
cytoskeleton), TAOK1 (activation of the YAP inhibitory kinases) and β−TrCP (reduction of YAP 
degradation), in addition to the 3’UTRs of Hopx1 (a suppressor of embryonic CM proliferation 
(Trivedi, Zhu et al. 2010) and Homer1 (involved in the regulation of calcium signaling in cardiac 
cells (Jardin, Lopez et al. 2013), as shown in our previous work	(Eulalio, Mano et al. 2012); other 
mRNAs are likely to be targeted as well. Despite these pleiotropic gene downregulation, however, 
it is of notice that all the proproliferative pathways appear to converge, and require, YAP 
activation. This conclusion is consistent with our previous observation, unexplained at the time, 
that combinatorial combinations of the four most effective miRNAs in our original HTS screen did 
not exert an effect that was superior to that of each individual miRNA when used at the same 
concentration of the combined molecules	(Eulalio, Mano et al. 2012).  
The pleiotropic function of miRNAs stimulating cardiac proliferation suggests that these molecules 
should be considered with caution in translational terms. While the permanent expression of miR-
199a and miR-590 pri-miRNAs using AAV9 vectors in the mouse did not result in apparent 
deleterious effects	 (Eulalio, Mano et al. 2012), permanent expression of the miR-302/367 cluster 
led transgenic animals to develop cardiac dysfunction due to CM hyperproliferation coupled with 
cell de-differentiation (Tian, Liu et al. 2015). This observation is consistent with the finding that 
miR-302/367 enhances the reprogramming efficiency of mouse embryonic fibroblasts into induced 
pluripotent stem cells (iPSCs)	(Judson, Babiarz et al. 2009)	(Li, Yang et al. 2011). The pleiotropic 
effect of miRNAs and these observations, however, do not rule out that appropriate dose and 
schedule for the delivery of synthetic miRNA mimics would be effective and well tolerated. 
Available evidence already shows that single dose, systemic injection of miR302b/c itself (Tian, 
Liu et al. 2015) or intracardiac injection of miR-199a-3p mimics	(Lesizza, Prosdocimo et al. 2017) 
determine significant beneficial effect in terms of recovery of myocardial tissue and function. 
These observations warrant further translation of these findings to large animals first and to the 
clinics later. 
As far harmine is concerned, the potential beneficial effects of this molecule in the clinics was 
considered for different therapeutic approaches	 (Patel, Gadewar et al. 2012, Moloudizargari, 
Mikaili et al. 2013). In this regard, it is important to emphasize that pro-proliferative compounds, in 
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general, have the potential to promote cell cycle progression in a non-specific way, which could 
stimulate tumor growth at off-target sides. Harmine, however, appears to be quite peculiar in this 
respect, since its pro-proliferative effects are exerted in tissues with low proliferative capacity, such 
brain, β-cells and heart in our study. While this would be reassuring in terms of safety, however, it 
still needs to be considered that harmine itself exerts neuroexcitatory effects, which would prevent 
its direct clinical use. Other alkaloid compounds derived form harmine, might instaed prove 
equally effective in the downregulation of Dyrk1a but devoid of effects on the central nervous 
system and thus be more apt for clinical use. Thus, there is a translational perspective for this 
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Table 1. Hippo-related genes. An update catalogue of genes known to have a role in the regulation of YAP-Hippo pathway are reported in the table. 
For each gene are reported its expression (RPKM) in  fold changes (log2) for each miRNA treatment and the bioinformatic prediction 
according to TargetScan software.
lipo mir.1825 mir.199 mir.302d mir.33b mir.373 mir.590 mir.67 mir.1825 mir.199 mir.302d mir.33b mir.373 mir.590 mir.1825 mir.199 mir.302d mir.33b mir.373 mir.590







Stk3 65189 ENSRNOG00000011278 serine/threonine	
kinase	3







Stk4 311622 ENSRNOG00000013529 serine/threonine	
kinase	4

















Lats1 308265 ENSRNOG00000014916 large	tumor	
suppressor	kinase	1






Lats2 305922 ENSRNOG00000056343 large	tumor	
suppressor	kinase	2






Mob1a 297387 ENSRNOG00000059474 MOB	kinase	activator	
1A




Mob1b 360920 ENSRNOG00000010996 MOB	kinase	activator	
1B




Mob2 499288 ENSRNOG00000020044 MOB	kinase	activator	
2
14,43 12,89 11,22 11,79 13,01 10,78 11,75 14,44 -0,16 -0,36 -0,29 -0,15 -0,42 -0,30 -0,24 0,00 0,00 0,00 0,00 0,00 Mediates	an	inhibitory	interaction	with	NDR1/2
PMID:	20624913	PMID:	
26728553
Yap1 363014 ENSRNOG00000005933 yes-associated	
protein	1


















Tead1 361630 ENSRNOG00000015488 TEA	domain	
transcription	factor	1






Tead2 308582 ENSRNOG00000020695 TEA	domain	
transcription	factor	2






Tead3 294299 ENSRNOG00000000506 TEA	domain	
transcription	factor	3


















0,40 0,36 0,30 0,47 0,44 0,49 0,45 0,35 0,04 -0,22 0,42 0,32 0,48 0,36 -0,25 -0,07 -0,12 -0,02 -0,12 -0,02 Phosphorylates	Yap1	thereby	inhibiting	transnucleationPMID:	26838548	PMID:	24362629
Akap8 116633 ENSRNOG00000006559 A-kinase	anchoring	
protein	8
4,38 4,09 3,86 5,37 4,73 5,19 4,31 4,50 -0,14 -0,22 0,25 0,07 0,20 -0,06 -0,04 0,00 0,00 0,00 0,00 -0,03 Phosphorylates	Yap1	thereby	inhibiting	transnucleationPMID:	24362629
Epha7 171287 ENSRNOG00000007030 Eph	receptor	A7 0,36 0,50 0,54 0,39 0,37 0,35 0,36 0,53 -0,11 0,00 -0,46 -0,54 -0,62 -0,58 0,00 0,00 -0,17 -0,07 -0,17 -0,09 Phosphorylates	Yap1	thereby	inhibiting	transnucleationPMID:	24362629
Gak 81659 ENSRNOG00000000048 cyclin	G	associated	
kinase
2,55 2,59 2,95 3,08 2,14 3,04 2,48 2,62 -0,01 0,17 0,23 -0,29 0,22 -0,08 0,00 0,00 0,00 0,00 0,00 0,00 Phosphorylates	Yap1	thereby	inhibiting	transnucleationPMID:	24362629
Ly6g5b 406867 ENSRNOG00000027516 lymphocyte	antigen	6	
complex,	locus	G5B






























9,26 8,86 10,50 10,29 6,20 8,04 7,73 8,09 0,13 0,38 0,35 -0,38 -0,01 -0,07 0,00 0,00 0,00 -0,01 0,00 -0,16 Phosphorylates	Yap1	thereby	inhibiting	transnucleationPMID:	24362629
Mylk2 117558 ENSRNOG00000008235 myosin	light	chain	
kinase	2
0,03 0,04 0,01 0,01 0,02 0,05 0,04 0,00 - - - - - - -0,15 0,00 -0,01 0,00 -0,01 0,00 Phosphorylates	Yap1	thereby	inhibiting	transnucleationPMID:	24362629





7,04 5,17 5,51 3,24 4,49 3,88 6,63 5,61 -0,12 -0,03 -0,79 -0,32 -0,53 0,24 0,00 0,00 0,00 0,00 0,00 0,00 Phosphorylates	Yap1	thereby	inhibiting	transnucleationPMID:	24362629
Sgk1 29517 ENSRNOG00000011815 serum/glucocorticoid	
regulated	kinase	1
1,08 1,61 1,21 0,63 1,11 0,75 1,35 1,45 0,15 -0,27 -1,21 -0,39 -0,96 -0,11 0,00 0,00 0,00 0,00 0,00 -0,02 Phosphorylates	Yap1	thereby	inhibiting	transnucleationPMID:	24362629
Stk10 29398 ENSRNOG00000004217 serine/threonine	
kinase	10
0,86 1,06 0,98 1,13 1,21 1,04 0,81 1,12 -0,08 -0,20 0,01 0,12 -0,11 -0,47 0,00 0,00 0,00 -0,01 0,00 0,00 Phosphorylates	Yap1	thereby	inhibiting	transnucleationPMID:	24362629
Stk11 314621 ENSRNOG00000014287 serine/threonine	
kinase	11
6,52 7,97 6,87 4,83 6,49 4,09 7,26 6,75 0,24 0,03 -0,48 -0,06 -0,73 0,10 0,00 0,00 0,00 0,00 0,00 0,00 Phosphorylates	Yap1	thereby	inhibiting	transnucleationPMID:	24362629
Stk33 690861 ENSRNOG00000014590 serine/threonine	
kinase	33
- - - - - - - - - - - - - - - - - - - - Phosphorylates	Yap1	thereby	inhibiting	transnucleationPMID:	24362629
Stk38l 691337 ENSRNOG00000001828 serine/threonine	
kinase	38	like
35,70 24,90 13,63 16,94 18,68 15,03 23,49 34,71 -0,48 -1,35 -1,04 -0,89 -1,21 -0,56 -0,25 -0,11 -0,14 0,00 -0,14 -0,15 Phosphorylates	Yap1	thereby	inhibiting	transnucleationPMID:	23985307
Tesk1 29460 ENSRNOG00000053729 testis-specific	kinase	1 3,65 3,79 2,75 2,79 2,55 2,94 3,72 3,42 0,15 -0,32 -0,29 -0,42 -0,22 0,12 0,00 0,00 -0,15 0,00 -0,15 0,00 Phosphorylates	Yap1	thereby	inhibiting	transnucleationPMID:	24362629
Traf3ip3 360900 ENSRNOG00000005565 TRAF3	interacting	
protein	3



































































Crb1 304825 ENSRNOG00000010903 crumbs	1,	cell	polarity	
complex	component




Crb2 366031 ENSRNOG00000025498 crumbs	2,	cell	polarity	
complex	component




Crb3 301112 ENSRNOG00000047322 crumbs	3,	cell	polarity	
complex	component




















































































Scrib 362938 ENSRNOG00000032574 scribbled	planar	cell	
polarity	protein







Dlg1 25252 ENSRNOG00000038597 discs	large	MAGUK	
scaffold	protein	1







Dlg2 64053 ENSRNOG00000022635 discs	large	MAGUK	
scaffold	protein	2







Dlg3 58948 ENSRNOG00000002767 discs	large	MAGUK	
scaffold	protein	3







Dlg4 29495 ENSRNOG00000018526 discs	large	MAGUK	
scaffold	protein	4







Dlg5 305645 ENSRNOG00000005783 discs	large	MAGUK	
scaffold	protein	5












































Pard3 81918 ENSRNOG00000032437 par-3	family	cell	
polarity	regulator


























































Frmd6 257646 ENSRNOG00000007329 FERM	domain	
containing	6














Wwc1 303039 ENSRNOG00000008065 WW	and	C2	domain	
containing	1











































Cdh1 83502 ENSRNOG00000020151 cadherin	1 0,55 0,53 0,57 0,36 0,29 0,50 0,48 0,77 -0,52 -0,43 -1,09 -1,41 -0,60 -0,67 0,00 0,00 0,00 0,00 0,00 0,00 Leads	to	Yap1	inactivation
PMID:	21730131	PMID:	
23431053
Ajuba 85265 ENSRNOG00000012791 ajuba	LIM	protein 22,69 16,64 19,14 21,07 17,85 19,68 23,18 19,57 -0,23 -0,03 0,11 -0,13 0,01 0,24 0,00 0,00 -0,23 0,00 -0,23 0,00 Leads	to	Yap1	inactivation
PMID:	20303269	PMID:	
23431053
Nphp4 313749 ENSRNOG00000011967 nephronophthisis	4 0,02 0,03 0,02 0,02 0,02 0,02 0,02 0,02 0,42 0,02 -0,29 -0,23 0,15 0,10 0,00 0,00 0,00 0,00 0,00 -0,21 Inhibits	LATS1 PMID:	21555462	PMID:	23431053
Tjp1 292994 ENSRNOG00000011077 tight	junction	protein	
1
1,35 1,82 1,54 1,15 1,56 1,24 1,39 1,05 0,80 0,56 0,14 0,58 0,25 0,41 0,00 0,00 0,00 0,00 0,00 0,00 Represses	Wwtr1		activation
PMID:	20850437	PMID:	
23431053
Tjp2 115769 ENSRNOG00000015030 tight	junction	protein	
2
1,19 1,17 1,40 1,03 0,92 1,07 1,32 1,37 -0,22 0,03 -0,41 -0,57 -0,36 -0,05 0,00 0,00 0,00 -0,11 0,00 0,00 Induce	Yap1	nuclear	localization
PMID:	20868367	PMID:	
23431053
Tjp3 314640 ENSRNOG00000020501 tight	junction	protein	
3
0,14 0,18 0,18 0,13 0,19 0,11 0,11 0,16 0,18 0,17 -0,23 0,26 -0,46 -0,53 0,00 0,00 0,00 0,00 0,00 0,00 Predicted	to	interact	with	Yap1 PMID:	19371381
Tjap1 316233 ENSRNOG00000018980 tight	junction	
associated	protein	1





12,96 13,47 15,34 15,92 10,70 14,11 12,48 13,67 -0,02 0,17 0,22 -0,35 0,05 -0,13 -0,01 0,00 -0,02 0,00 -0,02 0,00 Activates	Rhoa PMID:	22863277	PMID:	23431053
Gna12 81663 ENSRNOG00000001235 G	protein	subunit	
alpha	12
14,31 14,66 5,71 16,76 13,73 15,58 12,00 15,45 -0,08 -1,44 0,12 -0,17 0,01 -0,36 0,00 -1,47 0,00 0,00 0,00 0,00 Activates	Rhoa PMID:	22863277	PMID:	23431053
Gna13 303634 ENSRNOG00000036745 G	protein	subunit	
alpha	13
10,95 14,11 11,31 12,21 14,66 11,40 13,31 9,18 0,62 0,30 0,41 0,68 0,31 0,54 -0,18 0,00 0,00 0,00 0,00 -0,13 Activates	Rhoa PMID:	22863277	PMID:	23431053
Gna14 309242 ENSRNOG00000014840 G	protein	subunit	
alpha	14





0,10 0,11 0,04 0,04 0,05 0,05 0,07 0,18 -0,66 -2,26 -2,02 -2,00 -1,84 -1,30 0,00 0,00 0,00 0,00 0,00 0,00 Activates	Rhoa PMID:	22863277	PMID:	23431053
Gnaq 81666 ENSRNOG00000014183 G	protein	subunit	
alpha	q
17,29 21,81 21,32 19,58 13,64 19,53 18,80 16,14 0,43 0,40 0,28 -0,24 0,27 0,22 0,00 0,00 0,00 -0,11 0,00 -0,06 Activates	Rhoa PMID:	22863277	PMID:	23431053
Gnao1 50664 ENSRNOG00000019482 G	protein	subunit	
alpha	o1
2,10 2,80 1,39 2,20 3,01 2,08 1,56 2,57 0,12 -0,89 -0,22 0,23 -0,30 -0,72 -0,03 0,00 0,00 -0,11 0,00 -0,01 Activates	Rhoa PMID:	22863277	PMID:	23431053
Gnai1 25686 ENSRNOG00000057096 G	protein	subunit	
alpha	i1
7,49 6,27 5,15 4,68 4,72 4,36 7,73 6,26 0,00 -0,28 -0,42 -0,41 -0,52 0,30 0,00 0,00 0,00 -0,15 0,00 -0,12 Activates	Rhoa PMID:	22863277	PMID:	23431053
Gnai2 81664 ENSRNOG00000016592 G	protein	subunit	
alpha	i2
31,36 31,28 35,98 29,16 23,15 26,37 31,06 27,64 0,18 0,38 0,08 -0,26 -0,07 0,17 0,00 0,00 0,00 0,00 0,00 0,00 Activates	Rhoa PMID:	22863277	PMID:	23431053
Gnai3 25643 ENSRNOG00000019465 G	protein	subunit	
alpha	i3
27,45 40,80 36,91 43,64 37,38 42,68 29,56 29,00 0,49 0,35 0,59 0,37 0,56 0,03 -0,61 0,00 0,00 -0,38 0,00 -0,18 Activates	Rhoa PMID:	22863277	PMID:	23431053
Gnaz 25740 ENSRNOG00000001313 G	protein	subunit	
alpha	z
0,01 0,01 0,01 0,01 0,02 0,02 0,03 0,00 - - - - - - 0,00 0,00 0,00 0,00 0,00 0,00 Activates	Rhoa PMID:	22863277	PMID:	23431053
Gnal 24611 ENSRNOG00000010440 G	protein	subunit	
alpha	L
0,39 0,60 0,44 0,32 0,78 0,31 0,61 0,65 -0,12 -0,56 -1,03 0,26 -1,08 -0,11 0,00 -0,13 -0,07 0,00 -0,07 -0,01 Activates	Rhoa PMID:	22863277	PMID:	23431053
Gnas 24896 ENSRNOG00000025889 GNAS	complex	locus 7,87 9,86 7,29 7,85 11,38 7,92 8,53 7,68 0,36 -0,08 0,03 0,57 0,04 0,15 0,00 -0,11 0,00 0,00 0,00 -0,05 Inhibits	Rhoa PMID:	22863277	PMID:	23431053
Rhoa 117273 ENSRNOG00000050519 ras	homolog	family	
member	A
45,30 41,42 52,35 43,39 41,50 43,30 44,96 44,40 -0,10 0,24 -0,03 -0,10 -0,04 0,02 0,00 0,00 0,00 0,00 0,00 0,00 Inhibits	Lats1/2 PMID:	22863277	PMID:	23431053
Fat1 83720 ENSRNOG00000030954 FAT	atypical	cadherin	
1










Fat2 65048 ENSRNOG00000012575 FAT	atypical	cadherin	
2




Fat3 191571 ENSRNOG00000011585 FAT	atypical	cadherin	
3




Fat4 310341 ENSRNOG00000028335 FAT	atypical	cadherin	
4




Dchs1 308912 ENSRNOG00000031643 dachsous	cadherin-
related	1










Fjx1 366140 ENSRNOG00000005347 four	jointed	box	1 3,778 2,047 3,705 2,713 2,547 2,287 3,716 3,922 -0,938 -0,082 -0,532 -0,623 -0,778 -0,078 0,000 0,000 0,000 0,000 0,000 -0,050 Regulates	Hippo	pathway PMID:	22499807		PMID:	23592229
Zyx 114636 ENSRNOG00000017354 zyxin 6,373 5,771 5,338 4,212 3,569 3,818 5,000 5,486 0,073 -0,039 -0,381 -0,620 -0,523 -0,134 0,000 0,000 0,000 0,000 0,000 0,000 Regulates	Hippo	pathway PMID:	21666802	PMID:	27030211
Zdhhc1 291967 ENSRNOG00000017045 zinc	finger,	DHHC-
type	containing	1
0,378 0,286 0,375 0,156 0,284 0,223 0,359 0,416 -0,542 -0,149 -1,416 -0,552 -0,899 -0,211 0,000 0,000 0,000 0,000 0,000 0,000 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc2 246326 ENSRNOG00000022686 zinc	finger,	DHHC-
type	containing	2
26,180 25,532 13,609 26,045 20,109 30,728 22,837 18,432 0,470 -0,438 0,499 0,126 0,737 0,309 0,000 0,000 0,000 -0,092 0,000 -0,032 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc3 301081 ENSRNOG00000004344 zinc	finger,	DHHC-
type	containing	3
3,270 3,489 3,567 3,269 2,911 3,156 3,585 3,273 0,092 0,124 -0,002 -0,169 -0,053 0,131 -0,169 0,000 0,000 -0,080 0,000 -0,030 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc4 304291 ENSRNOG00000051699 zinc	finger,	DHHC-
type	containing	4
2,210 3,684 2,620 3,718 2,846 3,493 2,561 2,727 0,434 -0,058 0,447 0,062 0,357 -0,091 0,000 0,000 0,000 0,000 0,000 0,000 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc5 362156 ENSRNOG00000006832 zinc	finger,	DHHC-
type	containing	5
5,731 5,594 5,622 5,372 4,552 5,316 5,670 5,731 -0,035 -0,028 -0,093 -0,332 -0,109 -0,016 0,000 0,000 0,000 0,000 0,000 0,000 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc6 361771 ENSRNOG00000036576 zinc	finger,	DHHC-
type	containing	6
17,412 18,543 18,712 19,813 15,020 18,000 16,294 15,319 0,276 0,289 0,371 -0,028 0,233 0,089 0,000 0,000 -0,081 0,000 -0,081 0,000 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc7 170906 ENSRNOG00000017342 zinc	finger,	DHHC-
type	containing	7
6,574 6,099 4,824 5,570 4,265 5,707 7,213 6,327 -0,053 -0,391 -0,184 -0,569 -0,149 0,189 0,000 0,000 0,000 0,000 0,000 -0,030 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc8 303796 ENSRNOG00000021891 zinc	finger,	DHHC-
type	containing	8
0,927 0,848 1,113 0,946 1,075 0,692 1,032 0,798 0,087 0,480 0,245 0,430 -0,206 0,370 0,000 0,000 -0,170 0,000 -0,170 -0,020 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc9 302808 ENSRNOG00000004581 zinc	finger,	DHHC-
type	containing	9
2,060 2,326 2,075 1,194 1,991 1,802 1,671 1,452 0,680 0,516 -0,282 0,456 0,312 0,203 -0,122 -0,066 -0,203 -0,101 -0,203 0,000 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc11 499000 ENSRNOG00000039743 zinc	finger,	DHHC-
type	containing	11
- - - - - - - - - - - - - - - - - - - - Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc12 366014 ENSRNOG00000015791 zinc	finger,	DHHC-
type	containing	12
4,858 6,561 4,711 8,487 6,651 7,319 5,570 5,436 0,271 -0,206 0,643 0,291 0,429 0,035 0,000 0,000 0,000 0,000 0,000 0,000 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc13 365252 ENSRNOG00000014277 zinc	finger,	DHHC-
type	containing	13
4,495 3,729 5,713 4,577 4,939 4,501 5,211 4,375 -0,230 0,385 0,065 0,175 0,041 0,252 0,000 0,000 0,000 0,000 0,000 0,000 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc14 499014 ENSRNOG00000029049 zinc	finger,	DHHC-
type	containing	14
0,240 0,205 0,305 0,147 0,207 0,200 0,245 0,304 -0,574 0,004 -1,053 -0,556 -0,608 -0,314 0,000 0,000 -0,192 0,000 -0,192 0,000 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc15 317235 ENSRNOG00000002751 zinc	finger,	DHHC-
type	containing	15
0,326 0,369 0,529 0,712 0,513 0,671 0,403 0,576 -0,641 -0,122 0,307 -0,166 0,221 -0,515 0,000 0,000 -0,049 -0,034 -0,049 -0,100 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc16 654495 ENSRNOG00000046530 zinc	finger,	DHHC-
type	containing	16
2,897 2,545 2,637 2,927 2,115 2,854 2,812 2,968 -0,222 -0,171 -0,020 -0,489 -0,057 -0,078 -0,382 0,000 0,000 0,000 0,000 0,000 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc17 366889 ENSRNOG00000003803 zinc	finger,	DHHC-
type	containing	17
4,023 5,836 4,474 4,251 6,782 4,731 5,064 4,698 0,313 -0,070 -0,144 0,530 0,010 0,108 0,000 0,000 -0,111 -0,094 -0,111 0,000 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc18 362613 ENSRNOG00000058156 zinc	finger,	DHHC-
type	containing	18
2,005 2,563 2,307 2,352 2,093 1,929 2,313 1,717 0,578 0,426 0,454 0,286 0,168 0,430 -0,125 0,000 0,000 0,000 0,000 0,000 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc19 288045 ENSRNOG00000025055 zinc	finger,	DHHC-
type	containing	19
0,000 0,025 0,018 0,053 0,088 0,022 0,034 0,022 0,173 -0,255 1,271 2,003 -0,015 0,630 0,000 0,000 0,000 0,000 0,000 0,000 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc20 305923 ENSRNOG00000011024 zinc	finger,	DHHC-
type	containing	20
2,645 4,118 3,101 3,599 3,754 3,244 3,478 3,164 0,380 -0,029 0,186 0,247 0,036 0,136 0,000 0,000 0,000 -0,073 0,000 -0,020 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc21 298184 ENSRNOG00000010484 zinc	finger,	DHHC-
type	containing	21
1,975 1,962 2,029 1,677 2,115 1,827 1,798 2,200 -0,165 -0,117 -0,392 -0,057 -0,268 -0,291 0,000 -0,225 -0,109 -0,031 -0,109 -0,384 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc22 299211 ENSRNOG00000011285 zinc	finger,	DHHC-
type	containing	22
- - - - - - - - - - - - - - - - - - - - Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc23 363783 ENSRNOG00000060348 zinc	finger,	DHHC-
type	containing	23
0,079 0,042 0,034 0,152 0,046 0,118 0,080 0,039 0,132 -0,203 1,973 0,249 1,610 1,045 0,000 -0,090 -0,020 0,000 -0,020 -0,040 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc24 293665 ENSRNOG00000019825 zinc	finger,	DHHC-
type	containing	24
1,235 0,729 0,678 1,437 0,811 1,101 1,202 1,051 -0,528 -0,634 0,451 -0,375 0,066 0,193 0,000 0,000 0,000 0,000 0,000 0,000 Regulates	cell	polarity PMID:	22174083	PMID:	23592229
Zdhhc25 300323 ENSRNOG00000046044 zinc	finger,	DHHC-
type	containing	25

























































Tp53bp2 305025 ENSRNOG00000003237 tumor	protein	p53	
binding	protein,	2







































































0,39 0,36 0,33 0,68 0,45 0,56 0,37 0,42 -0,22 -0,37 0,69 0,11 0,42 -0,19 -0,12 -0,17 -0,07 -0,05 -0,07 -0,02 Facilitates	Yap1/Wwtr1	degradation
PMID:	20048001	PMID:	
20858893
Fbxw11 303024 ENSRNOG00000004395 F-box	and	WD	repeat	
domain	containing	11
1,36 1,17 0,90 1,11 1,03 1,19 1,57 1,38 -0,24 -0,62 -0,32 -0,42 -0,21 0,18 -0,23 -0,29 -0,04 0,00 -0,04 0,00 Regulates	Hippo	pathway PMID:	27124581
Wbp2 192645 ENSRNOG00000007971 WW	domain	binding	
protein	2





1,02 0,82 0,72 1,01 0,89 1,08 0,89 1,16 -0,49 -0,69 -0,20 -0,38 -0,10 -0,39 -0,01 0,00 0,00 -0,06 0,00 -0,04 Promotes	Yap1	Activity PMID:	20514025
Itch 311567 ENSRNOG00000059043 itchy	E3	ubiquitin	
protein	ligase





Smad1 25671 ENSRNOG00000018483 SMAD	family	member	
1







Smad2 29357 ENSRNOG00000018140 SMAD	family	member	
2





Smad3 25631 ENSRNOG00000008620 SMAD	family	member	
3





Smad7 81516 ENSRNOG00000018359 SMAD	family	member	
7





Runx1 50662 ENSRNOG00000001704 runt-related	
transcription	factor	1






Runx2 367218 ENSRNOG00000020193 runt-related	
transcription	factor	2
















Erbb4 59323 ENSRNOG00000014248 erb-b2	receptor	
tyrosine	kinase	4














Ccna1 295052 ENSRNOG00000014052 cyclin	A1 0,00 0,01 0,01 0,01 0,01 0,01 0,01 0,01 1,08 1,07 0,57 1,46 0,38 1,48 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Cdc25a 171102 ENSRNOG00000020737 cell	division	cycle	25A 2,54 3,25 3,04 2,44 2,74 2,45 2,77 3,08 0,08 -0,02 -0,34 -0,17 -0,33 -0,16 0,00 0,00 -0,05 -0,08 -0,05 0,00 PMID:	26258633
Cdc6 360621 ENSRNOG00000027787 cell	division	cycle	6 2,46 1,24 2,72 2,31 1,97 2,68 2,26 1,86 -0,59 0,55 0,31 0,08 0,53 0,28 0,00 -0,19 0,00 -0,09 0,00 0,00 PMID:	26258633
Cdca5 684771 ENSRNOG00000046635 cell	division	cycle	
associated	5
2,60 2,97 2,53 2,52 1,96 2,76 3,12 1,90 0,64 0,41 0,40 0,05 0,53 0,71 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Cdca8 500545 ENSRNOG00000031431 cell	division	cycle	
associated	8
6,94 15,09 9,71 7,39 6,96 8,09 9,82 4,74 1,67 1,03 0,64 0,55 0,77 1,05 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Cenpf 257649 ENSRNOG00000003388 centromere	protein	F 8,50 29,47 12,52 13,04 14,62 15,29 19,01 5,52 2,42 1,18 1,24 1,41 1,47 1,79 -0,14 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Cenpv 501702 centromere	protein	V 0,83 1,20 1,32 0,85 0,79 0,57 1,52 1,06 0,18 0,31 -0,32 -0,43 -0,90 0,52 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Edn1 24323 ENSRNOG00000014361 endothelin	1 6,90 5,85 4,52 8,38 4,23 8,57 6,83 11,03 -0,92 -1,29 -0,40 -1,38 -0,36 -0,69 0,00 0,00 0,00 -0,12 0,00 -0,03 PMID:	26258633
Ets1 24356 ENSRNOG00000008941 ETS	proto-oncogene	
1,	transcription	factor
1,74 1,20 1,70 1,71 1,31 1,58 1,46 1,97 -0,72 -0,22 -0,21 -0,59 -0,32 -0,43 -0,22 -0,07 0,00 -0,07 0,00 -0,08 PMID:	26258633
Ets2 304063 ENSRNOG00000001647 ETS	proto-oncogene	
2,	transcription	factor










6,21 7,97 5,47 4,01 5,02 3,75 5,71 6,17 0,37 -0,17 -0,62 -0,30 -0,72 -0,11 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Gins1 499914 ENSRNOG00000008091 GINS	complex	subunit	
1
8,52 8,15 8,59 5,94 7,31 8,37 9,37 7,21 0,17 0,25 -0,28 0,02 0,21 0,38 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Kif14 360849 ENSRNOG00000037211 kinesin	family	
member	14
2,08 4,26 2,80 1,81 2,26 2,41 3,51 1,30 1,71 1,10 0,47 0,79 0,89 1,43 0,00 0,00 -0,10 0,00 -0,10 -0,01 PMID:	26258633
Kif20b 309523 ENSRNOG00000018929 kinesin	family	
member	20B
1,33 3,46 1,72 1,48 1,70 1,84 2,58 0,84 2,04 1,03 0,81 1,01 1,13 1,61 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Kif23 315740 ENSRNOG00000014080 kinesin	family	
member	23
7,95 16,66 13,31 10,15 9,86 11,54 14,46 5,09 1,71 1,39 1,00 0,95 1,18 1,51 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Kntc1 304477 ENSRNOG00000033658 kinetochore	
associated	1















1,68 1,64 1,81 2,15 1,63 2,03 1,66 1,67 -0,03 0,11 0,36 -0,04 0,28 -0,01 0,00 0,00 -0,05 -0,09 -0,05 -0,04 PMID:	26258633
Mybl1 297783 ENSRNOG00000021669 myeloblastosis	
oncogene-like	1
2,31 2,14 1,46 0,56 1,11 0,76 1,83 2,08 0,04 -0,51 -1,89 -0,90 -1,45 -0,18 0,00 0,00 -0,28 0,00 -0,28 -0,03 PMID:	26258633
Myc 24577 ENSRNOG00000004500 myelocytomatosis	
oncogene










10,21 14,48 9,29 11,39 11,36 11,89 10,63 8,09 0,84 0,20 0,49 0,49 0,56 0,39 0,00 0,00 -0,53 0,00 -0,53 0,00 PMID:	26258633
Polh 316235 ENSRNOG00000019195 DNA	polymerase	eta 2,77 2,71 2,71 1,60 2,12 2,07 3,22 2,26 0,26 0,26 -0,50 -0,09 -0,13 0,51 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Psmc3ip 140938 ENSRNOG00000020022 PSMC3	interacting	
protein
4,00 4,90 4,91 3,79 3,51 3,91 3,88 3,75 0,39 0,39 0,01 -0,09 0,06 0,05 -0,64 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Psmg1 288236 ENSRNOG00000001643 proteasome	assembly	
chaperone	1
6,10 5,73 3,08 6,37 5,97 5,90 5,62 4,94 0,21 -0,68 0,37 0,27 0,26 0,19 0,00 0,00 0,00 0,00 0,00 -0,22 PMID:	26258633
Rad18 362412 ENSRNOG00000005907 RAD18	E3	ubiquitin	
protein	ligase





40,39 65,09 46,44 26,95 21,29 36,66 55,61 31,04 1,07 0,58 -0,20 -0,54 0,24 0,84 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Ruvbl2 292907 ENSRNOG00000020793 RuvB-like	AAA	ATPase	
2
9,24 9,99 11,37 11,14 9,21 11,38 10,37 9,22 0,11 0,30 0,27 0,00 0,30 0,17 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633










0,49 0,73 0,71 0,66 0,59 0,64 0,90 0,56 0,39 0,33 0,23 0,08 0,19 0,68 0,00 0,00 -0,23 0,00 -0,23 -0,10 PMID:	26258633
Timeless 83508 ENSRNOG00000031916 timeless	circadian	
clock
3,99 2,44 4,96 4,02 3,46 3,81 3,68 3,52 -0,53 0,50 0,19 -0,03 0,12 0,06 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Tk1 24834 ENSRNOG00000047314 thymidine	kinase	1 6,17 5,37 7,21 5,09 5,92 5,17 8,01 2,49 1,11 1,53 1,03 1,25 1,05 1,68 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
Top2a 360243 ENSRNOG00000053047 topoisomerase	(DNA)	
II	alpha
59,77 158,05 81,57 54,36 70,39 66,40 106,43 35,91 2,14 1,18 0,60 0,97 0,89 1,57 0,00 0,00 0,00 0,00 0,00 -0,01 PMID:	26258633
Zwilch 691493 ENSRNOG00000009303 zwilch	kinetochore	
protein
14,80 21,67 16,18 16,53 12,90 17,58 16,58 10,73 1,01 0,59 0,62 0,27 0,71 0,63 0,00 0,00 0,00 0,00 0,00 0,00 PMID:	26258633
TRANSCRIPTIONAL	TARGETS	OF	YAP/TEAD
Table 2. Actin-related genes. An update catalouge of genes known to be involved in the actin cytoskeleton remodeling is shown in the table below.
The fold changes (log2) of gene expression (RPKM) upon transfection of miR-1825, miR-199a, miR-302d, miR-373, miR-590 are reported here
 along with the bioinformatic predictions (TargetsScan software); cel-miR-67 was used as control.
lipo mir.1825 mir.199 mir.302d mir.33b mir.373 mir.590 mir.67 mir.1825 mir.199 mir.302d mir.33b mir.373 mir.590 mir.1825 mir.199 mir.302d mir.33b mir.373 mir.590
Acta1 29437 ENSRNOG00000017786 actin,	alpha	1,	
skeletal	muscle
383,41 583,65 463,90 783,20 626,88 747,34 487,18 558,62 0,06 -0,27 0,49 0,17 0,42 -0,20 0,00 0,00 0,00 0,00 0,00 0,00 actin	component	in	skeletal	
striated	muscle	tissue
Acta2 81633 ENSRNOG00000058039 actin,	alpha	2,	
smooth	muscle,	aorta
240,42 177,94 269,73 110,02 132,95 120,41 202,55 155,73 0,19 0,79 -0,50 -0,23 -0,37 0,38 0,00 0,00 0,00 -0,12 0,00 0,00 actin	component	in	smoot	
muscle	tissue
Actb 81822 ENSRNOG00000034254 actin,	beta 1210,69 1263,93 1044,71 1164,71 858,20 1046,15 971,76 1162,83 0,12 -0,15 0,00 -0,44 -0,15 -0,26 0,00 0,00 0,00 -0,15 0,00 0,00 codes	for	cytoskeleton
Actc1 29275 ENSRNOG00000008536 actin,	alpha,	cardiac	
muscle	1
7975,25 6725,44 5645,82 5365,51 6442,26 5446,97 6371,87 6745,00 0,00 -0,26 -0,33 -0,07 -0,31 -0,08 0,00 0,00 0,00 0,00 0,00 0,00 actin	component	in	cardiac	
muscles





21,76 11,17 22,38 12,57 9,34 12,36 14,45 23,07 -1,05 -0,04 -0,88 -1,31 -0,90 -0,67 0,00 0,00 0,00 0,00 0,00 0,00 actin	component	in	the	
intestinal	muscles
Actbl2 294732 ENSRNOG00000043292 actin,	beta-like	2 0,07 0,04 0,03 0,06 0,11 0,02 0,06 0,03 0,34 -0,26 0,98 1,81 -0,43 0,89 0,00 0,00 0,00 0,00 0,00 -0,10
Tmsb4x 81814 ENSRNOG00000047931 thymosin	beta	4,	X-
linked
695,76 553,95 322,24 575,05 671,76 562,40 725,25 673,02 -0,28 -1,06 -0,23 0,00 -0,26 0,11 0,00 -0,81 0,00 0,00 0,00 0,00 binds	and	sequesters	G-actin PMID:	15039431,	
8506348,	17947588
Tmsb10 50665 ENSRNOG00000042499 thymosin,	beta	10 118,40 70,49 140,13 137,56 87,80 143,61 99,55 99,62 -0,50 0,49 0,47 -0,18 0,53 0,00 0,00 0,00 0,00 0,00 0,00 -0,15 binds	and	sequesters	G-actin PMID:	6578703
Tmsbl1 286978 ENSRNOG00000037661 thymosin	beta-like	
protein	1
13,42 14,47 16,13 15,55 19,40 22,15 16,08 15,17 -0,07 0,09 0,04 0,35 0,55 0,08 0,00 0,00 0,00 0,00 0,00 0,00 binds	and	sequesters	G-actin (by	similarity)


















Pfn4 494222 ENSRNOG00000050386 profilin	family,	
member	4






Twf1 315265 ENSRNOG00000022507 twinfilin	actin-binding	
protein	1






Twf2 684352 ENSRNOG00000048915 twinfilin	actin-binding	
protein	2






Gsn 296654 ENSRNOG00000018991 gelsolin 9,94 12,85 19,62 8,54 10,67 10,01 13,49 7,96 0,69 1,30 0,10 0,42 0,33 0,76 0,00 0,00 0,00 0,00 0,00 0,00 severing	protein;	caps	the	actin	filament	
at	(+)	end
PMID:	3021782
Cfl1 29271 ENSRNOG00000020660 cofilin	1 337,07 340,04 235,34 423,38 313,58 389,25 310,88 319,65 0,09 -0,44 0,41 -0,03 0,28 -0,04 -0,10 0,00 0,00 0,00 0,00 0,00 severing	protein non-muscle	cofilin PMID:	9265645,	
9087445






513,24 529,62 561,02 468,28 512,72 458,89 550,29 451,99 0,23 0,31 0,05 0,18 0,02 0,28 0,00 0,00 0,00 -0,17 0,00 -0,07 severing	protein PMID:	9265645,	
9087445










9,52 7,80 10,52 9,71 10,04 9,74 8,99 9,40 -0,27 0,16 0,05 0,10 0,05 -0,06 0,00 0,00 0,00 -0,22 0,00 0,00 caps	the	actin	filament	at	(+)	end PMID:	9915586
Capg 297339 ENSRNOG00000013668 capping	actin	protein,	
gelsolin	like
2,34 1,75 1,56 1,40 1,63 1,84 1,76 1,81 -0,05 -0,21 -0,37 -0,15 0,02 -0,04 0,00 0,00 0,00 0,00 0,00 0,00 caps	the	actin	filament	at	(+)	end PMID:	2255912
Tmod1 25566 ENSRNOG00000009761 tropomodulin	1 28,32 18,29 23,07 26,66 22,87 28,13 25,07 29,92 -0,71 -0,38 -0,17 -0,39 -0,09 -0,25 0,00 -0,07 0,00 0,00 0,00 0,00 caps	the	actin	filament	at	(-)	end PMID:	7798317
Tmod2 58814 ENSRNOG00000010447 tropomodulin	2 0,04 0,05 0,02 0,24 0,21 0,17 0,03 0,05 0,02 -1,12 2,35 2,16 1,85 -0,62 -0,31 -0,19 -0,33 0,00 -0,33 -0,11 caps	the	actin	filament	at	(-)	end PMID:	7798317
Tmod3 300838 ENSRNOG00000032436 tropomodulin	3 15,53 17,90 15,99 19,02 16,63 19,70 17,43 15,49 0,21 0,05 0,30 0,10 0,35 0,17 0,00 0,00 0,00 0,00 0,00 -0,17 caps	the	actin	filament	at	(-)	end PMID:	7798317
Tmod4 295261 ENSRNOG00000021088 tropomodulin	4 0,05 0,03 0,06 0,11 0,06 0,04 0,04 0,04 -0,24 0,82 1,69 0,74 0,31 0,05 -0,54 0,00 0,00 0,00 0,00 0,00 caps	the	actin	filament	at	(-)	end PMID:	7798317
















0,03 0,03 0,02 0,12 0,06 0,07 0,03 0,03 -0,15 -0,46 1,77 0,89 1,09 -0,01 0,00 0,00 0,00 0,00 0,00 0,00 uncapping	protein PMID:	16054028










Fmnl1 287746 ENSRNOG00000003207 formin-like	1 0,02 0,01 0,01 0,01 0,01 0,01 0,01 0,02 -0,83 -0,26 -0,28 -1,26 -0,56 -0,37 0,00 0,00 0,00 0,00 0,00 0,00 (by	similarity)
Fmnl2 311033 formin-like	2 - - - - - - - - - - - - - - - - - - - - (by	similarity)
Fmnl3 300225 ENSRNOG00000056297 formin-like	3 0,68 0,68 0,76 0,66 0,64 0,73 0,58 0,74 -0,11 0,05 -0,16 -0,21 -0,01 -0,34 0,00 0,00 -0,12 0,00 -0,12 0,00 (by	similarity)
Diaph1 307483 ENSRNOG00000019688 diaphanous-related	
formin	1












Diaph3 290396 ENSRNOG00000008986 diaphanous-related	
formin	3























Actr2 289820 ENSRNOG00000004959 ARP2	actin	related	
protein	2	homolog





Actr3 81732 ENSRNOG00000003206 ARP3	actin	related	
protein	3	homolog




































































Was 317371 ENSRNOG00000031058 Wiskott-Aldrich	
syndrome
0,28 0,05 0,13 0,23 0,22 0,28 0,32 0,19 -1,83 -0,52 0,27 0,23 0,57 0,77 0,00 0,00 0,00 0,00 0,00 0,00 binds	and	activates	Arp2/3	complex PMID:	19625501
Wasf1 294568 ENSRNOG00000047476 WAS	protein	family,	
member	1
0,20 0,20 0,13 0,30 0,29 0,34 0,19 0,14 0,48 -0,15 1,09 1,06 1,26 0,44 0,00 0,00 0,00 -0,13 0,00 0,00 binds	and	activates	Arp2/3	complex contains	WASp	domains PMID:	19625501
Wasf2 313024 ENSRNOG00000009805 WAS	protein	family,	
member	2
1,39 2,02 1,68 1,83 1,76 1,51 1,36 1,29 0,65 0,39 0,50 0,45 0,23 0,08 0,00 0,00 0,00 -0,05 0,00 0,00 binds	and	activates	Arp2/3	complex contains	WASp	domains PMID:	19625501
Wasf3 682937 WAS	protein	family,	
member	3















Wash1 367328 ENSRNOG00000053306 WAS	protein	family	
homolog	1
6,14 6,09 5,86 6,53 6,29 6,82 6,28 6,69 -0,13 -0,19 -0,04 -0,09 0,03 -0,09 0,00 0,00 0,00 0,00 0,00 0,00 binds	and	activates	Arp2/3	complex contains	WASp	domains PMID:	19625501
Wasl 682507 ENSRNOG00000006975 Wiskott-Aldrich	
syndrome-like
2,41 3,51 2,79 2,15 3,13 2,56 2,23 3,15 0,16 -0,17 -0,55 -0,01 -0,30 -0,50 -0,30 0,00 0,00 0,00 0,00 -0,14 binds	and	activates	Arp2/3	complex contains	WASp	domains PMID:	19625501
Spire1 307348 ENSRNOG00000025324 spire-type	actin	
nucleation	factor	1





Spire2 307925 ENSRNOG00000016920 spire-type	actin	
nucleation	factor	2





Cobl 305497 ENSRNOG00000004281 cordon-bleu	WH2	
repeat	protein





Cobll1 311088 ENSRNOG00000027016 cordon-bleu	WH2	
repeat	protein-like	1





























Apc 24205 ENSRNOG00000020423 APC,	WNT	signaling	
pathway	regulator





Apc2 299611 ENSRNOG00000033791 APC2,	WNT	signaling	
pathway	regulator





Tpm1 24851 ENSRNOG00000018184 tropomyosin	1,	alpha 74,33 62,51 71,31 58,17 54,99 61,73 64,40 69,80 -0,16 0,03 -0,26 -0,34 -0,18 -0,12 0,00 0,00 0,00 0,00 0,00 0,00 inhibits	the	rate	of	actin	polymerization	by	
stabilization
PMID:	3242622
Tpm2 500450 ENSRNOG00000016731 tropomyosin	2,	beta 67,88 52,56 59,34 44,80 45,28 46,29 59,03 52,01 0,02 0,19 -0,22 -0,20 -0,17 0,18 -0,48 -0,05 -0,25 0,00 -0,25 0,00 inhibits	the	rate	of	actin	polymerization	by	
stabilization
PMID:	3242622
Tpm3 117557 ENSRNOG00000017441 tropomyosin	3 3,79 4,45 3,82 4,26 3,80 4,38 3,43 3,37 0,40 0,18 0,34 0,17 0,38 0,02 0,00 0,00 0,00 0,00 0,00 0,00 inhibits	the	rate	of	actin	polymerization	by	
stabilization
PMID:	3242622





















11,57 12,32 10,00 9,91 10,80 8,99 12,29 13,96 -0,18 -0,48 -0,49 -0,37 -0,63 -0,18 -0,22 0,00 -0,05 0,00 -0,05 -0,02 synergizes	with	Cfl2	to	depolymerize	F-
actin
PMID:	27454820
Micall1 362958 ENSRNOG00000026212 MICAL-like	1 1,63 1,54 1,47 2,26 1,79 2,18 1,63 1,66 -0,11 -0,17 0,44 0,11 0,39 -0,03 -0,12 0,00 -0,05 0,00 -0,05 0,00 (by	similarity)
Micall2 288515 ENSRNOG00000022533 MICAL-like	2 1,07 1,28 0,87 0,93 0,98 0,88 0,89 0,94 0,44 -0,11 -0,03 0,05 -0,10 -0,09 0,00 0,00 0,00 0,00 0,00 0,00 (by	similarity)
Csrp3 117505 ENSRNOG00000014327 cysteine	and	glycine	
rich	protein	3
353,87 247,12 142,86 231,14 196,24 221,96 222,90 330,86 -0,42 -1,21 -0,52 -0,75 -0,58 -0,57 0,00 0,00 0,00 0,00 0,00 -0,12 interacts	with	Cfl2	and	aids	in	F-actin	
depolymerization
contains	two	LIM	domains PMID:	19752190























Table 3. FDA-registered drug screening results. Each drug is characterized by the FDA-registration number and with the name of the compound.
 The z-score mean value obtained by the evaluation of EdU+CMs in fold changes over control (for column 1= miR-67, column 2= miR-199a-3p, column 3= miR-590-3p); 
 n=3 indipendent experiments.
cel-miR-67 z-score	mean hsa-miR-199a-3p z-score	mean hsa-miR-590-3p z-score	mean
442-51-3	-	Harmine,	[H04] 4,302209435 442-51-3	-	Harmine,	[H04] 4,835986201 442-51-3	-	Harmine,	[H04] 5,288410519
16320-04-0	-	Gestrinone,	[L15] 3,609728936 50-91-9	-	Floxuridine,	[J11] 2,523485819 1400-61-9	-	Nystatin,	[E06] 3,00315612
135046-48-9	-	Clopidogrel	sulfate,	[O21] 3,16249897 555-30-6	-	Methyldopa,	[A12] 2,357681895 1421-86-9	-	Strychnine	HCl,	[D03] 2,996807097
63-92-3	-	Phenoxybenzamine	HCl,	[I10] 3,0704343 102767-28-2	-	Levetiracetam,	[L20] 2,332820399 75847-73-3	-	Enalapril,	[F07] 2,923657741
127045-41-4	-	Pazufloxacin,	[G08] 2,970817217 59804-37-4	-	Tenoxicam,	[O20] 2,320392418 51-48-9	-	L-thyroxine	[(3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-l-alanine]	,	[P18]2,870190593
22494-42-4	-	Diflunisal,	[D15] 2,907878738 298-46-4	-	Carbamazepine,	[M07] 2,298257552 68475-42-3	-	Anagrelide,	[C22] 2,764688972
cel-67,	[L02] 2,823268192 34911-55-2	-	Amfebutamone,	[H13] 2,296888605 1744-22-5	-	Riluzole	HCl,	[O19] 2,695375756
64-47-1	-	Physostigmine	sulfate,	[M11] 2,796058859 81-24-3	-	Taurocholic	acid,	sodium	salt	hydrate,	[N18] 2,138529634 112964-99-5	-	Hydroxytacrine	maleate,	[E16]2,686969862
11018-89-6	-	Ouabain,	[I20] 2,521178645 93479-97-1	-	Glimepiride,	[L17] 2,128706656 115956-12-2	-	Dolasetron,	[N22] 2,678050227
139264-17-8	-	zolmitriptan,	[O13] 2,465211256 54-85-3	-	Isoniazid,	[J15] 1,961600176 93479-97-1	-	Glimepiride,	[L17] 2,656415576
56-53-1	-	Diethylstilbestrol,	[D13] 2,317817115 24729-96-2	-	Clindamycin	palmitate,	[N16] 1,955836289 70458-96-7	-	Norfloxacin,	[E04] 2,586417727
21535-47-7	-	Mianserin	hcl,	[B03] 2,254082464 73210-73-8	-	Xamoterol	hemifumarate,	[I13] 1,889477934 32828-81-2	-	Picotamide,	[L18] 2,580532569
68373-14-8	-	Sulbactam,	[E07] 2,249205068 134308-13-7	-	Tolcapone,	[L13] 1,860628704 104227-87-4	-	Famciclovir,	[H09] 2,551573735
53885-35-1	-	Ticlopidine	HCl,	[J17] 2,108451047 20537-88-6	-	Amifostine,	[I03] 1,806075822 68-35-9	-	Sulfadiazine,	[O10] 2,53878607
26807-65-8	-	Indapamide,	[N15] 2,097717673 645-05-6	-	Altretamine,	[G17] 1,749431883 41859-67-0	-	Bezafibrate,	[F04] 2,508372407
53-16-7	-	Estrone,	[F21] 2,071084733 19728-88-2	-	Methiothepin	maleate,	[O12] 1,719849363 54-42-2	-	Idoxuridine,	[N09] 2,435270078
124832-27-5	-	Valaciclovir,	[D20] 2,062832738 73590-58-6	-	Omeprazole,	[E12] 1,67329992 28721-07-5	-	Oxcarbazepine,	[E14] 2,431940378
5536-17-4	-	Vidarabine,	[F06] 2,053082531 93106-60-6	-	Enrofloxacin,	[F11] 1,667314975 53-43-0	-	Dehydroepiandrosterone,	[D03] 2,418653261
139481-59-7	-	Candesartan,	[N21] 2,02530921 1501-84-4	-	Rimantadine	HCl,	[K20] 1,664883143 68550-75-4	-	Cilostamide,	[J06] 2,384203156
581-88-4	-	Debrisoquin	sulfate,	[O10] 2,022893494 74011-58-8	-	Enoxacin,	[F09] 1,663026965 19387-91-8	-	Tinidazole,	[B14] 2,375552942
93479-97-1	-	Glimepiride,	[L17] 1,978782304 5536-17-4	-	Vidarabine,	[F06] 1,657320145 115344-47-3	-	Siguazodan,	[J18] 2,354910367
124750-99-8	-	Losartan	potassium,	[P21] 1,958478025 36330-85-5	-	Fenbufen,	[H13] 1,547951178 2963-78-2	-	Butyrylcholine	Cl,	[J09] 2,322087608
69004-03-1	-	Toltrazuril,	[D08] 1,924130818 95635-56-6	-	Ranolazine	2HCl,	[K10] 1,531358122 13710-19-5	-	Tolfenamic	acid,	[D04] 2,309798117
16676-29-2	-	Naltrexone	HCl,	[O11] 1,913104378 50-12-4	-	Mephenytoin,	[J22] 1,509375397 81110-73-8	-	Racecadotril,	[K08] 2,246864088
35208-55-0	-	Clindamycin	PO4,	[A07] 1,882864461 135046-48-9	-	Clopidogrel	sulfate,	[O21] 1,501867801 161814-49-9	-	Amprenavir,	[N10] 2,203855566
73590-58-6	-	Omeprazole,	[E12] 1,865262026 149-64-4	-	Scopolamine	n-butylbromide,	[M12] 1,472369974 2078-54-8	-	Propofol,	[O21] 2,159406811
18046-21-4	-	Fentiazac,	[J20] 1,853208683 13710-19-5	-	Tolfenamic	acid,	[D04] 1,451384181 73590-58-6	-	Omeprazole,	[E12] 2,156869554
590-63-6	-	Carbamyl-beta-methylcholine	Cl,	[J07] 1,835542093 1405-41-0	-	Gentamycin	sulfate,	[L11] 1,450249533 124832-27-5	-	Valaciclovir,	[D20] 2,150171963
10118-90-8	-	Minocycline	HCl,	[C04] 1,800908069 51-48-9	-	L-thyroxine	[(3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-l-alanine]	,	[P18]1,447595474 20537-88-6	-	Amifostine,	[I03] 2,130884137
33386-08-2	-	Buspirone	HCl,	[K19] 1,760548193 1405-10-3	-	Neomycin	sulfate,	[O16] 1,441692529 114-49-8	-	Scopolamine	HBr,	[M14] 2,126549725
65141-46-0	-	Nicorandil,	[L12] 1,744530781 84-16-2	-	Hexestrol,	[L21] 1,41109735 298-46-4	-	Carbamazepine,	[M07] 2,125258686
74764-40-2	-	Bepridil,	[C05] 1,741441615 590-63-6	-	Carbamyl-beta-methylcholine	Cl,	[J07] 1,410595833 57-94-3	-	Tubocurarine	Cl		(+),	[D05] 2,112398868
139755-83-2	-	Sildenafil,	[N11] 1,723146024 93793-83-0	-	Roxatidine	acetate	HCl,	[M04] 1,367488738 62893-19-0	-	Cefoperazone	acid,	[M09] 2,092274112
84625-61-6	-	Itraconazole,	[N19] 1,673956842 70458-96-7	-	Norfloxacin,	[E04] 1,349538816 139755-83-2	-	Sildenafil,	[N11] 2,078878959
151615	-	Oxymetazoline	HCl,	[G03] 1,654779029 87333-19-5	-	Ramipril,	[K12] 1,339677251 82009-34-5	-	Cilastatin,	[L14] 2,06733222
115344-47-3	-	Siguazodan,	[J18] 1,574371767 53902-12-8	-	Tranilast,	[K08] 1,323318125 85622-93-1	-	Temozolomide,	[B08] 2,050923472
78415-72-2	-	Milrinone,	[J14] 1,573719823 28721-07-5	-	Oxcarbazepine,	[E14] 1,300927606 5104-49-4	-	Flurbiprofen,	[J05] 2,047711567
59729-33-8	-	Citalopram,	[O09] 1,5693853 93-14-1	-	Guaifenesin,	[L19] 1,273895036 91161-71-6	-	Terbinafine	HCl,	[B20] 2,039370819
64490-92-2	-	Tolmetin	Na,	[D06] 1,567525952 7177-48-2	-	Ampicillin	trihydrate,	[I11] 1,262699711 57381-26-7	-	Irsogladine	maleate,	[J12] 1,998735769
72599-27-0	-	Miglustat,	[N20] 1,566005107 14838-15-4	-	Phenylpropanolamine,	[P12] 1,25525547 24390-14-5	-	Doxycycline	HCl,	[F05] 1,963278781
61-68-7	-	Mefenamic	acid,	[A08] 1,565476017 59277-89-3	-	Acycloguanosine,	[G09] 1,248197706 60-54-8	-	Tetracycline,	[B04] 1,961661186
37321-09-8	-	Apramycin,	[I15] 1,565155129 25812-30-0	-	Gemfibrozil,	[L13] 1,247801943 42924-53-8	-	Nabumetone,	[C14] 1,935502307
72558-82-8	-	Ceftazidime,	[M13] 1,562765435 112811-59-3	-	Gatifloxacin,	[L09] 1,236435388 19453	-	Galanthamine	HBr,	[G04] 1,924470557
121268-17-5	-	Alendronate,	[G15] 1,538515787 39809-25-1	-	Penciclovir,	[G12] 1,229936063 16676-29-2	-	Naltrexone	HCl,	[O11] 1,917644454
88040-23-7	-	Cefepime,	[N17] 1,536867208 84625-61-6	-	Itraconazole,	[N19] 1,226440176 125-69-9	-	Dextromethorphan	HBr,	[D07] 1,917140012
154-21-2	-	Lincomycin,	[A13] 1,524107521 99-66-1	-	Valproic	acid,	[J06] 1,213510926 17360-35-9	-	Oxotremorine	sesquifumarate,	[E18]1 907510325
55528-07-9	-	Butaclamol	(+),	[D07] 1,523213485 32828-81-2	-	Picotamide,	[L18] 1,202980261 112811-59-3	-	Gatifloxacin,	[L09] 1,899607247
158966-92-8	-	Montelukast,	[C08] 1,50960949 33386-08-2	-	Buspirone	HCl,	[K19] 1,198812035 132539-06-1	-	Olanzapine,	[N03] 1,879075245
50-12-4	-	Mephenytoin,	[J22] 1,497887931 82419-36-1	-	Ofloxacin,	[E08] 1,184132874 111406-87-2	-	Zileuton,	[J12] 1,861088482
106017-08-7	-	Rufloxacin,	[M08] 1,477293324 78613-35-1	-	Amorolfine,	[J19] 1,180603079 21187-98-4	-	Gliclazide,	[L15] 1,843666802
68550-75-4	-	Cilostamide,	[J06] 1,47420242 2068-78-2	-	Vincristine	sulfate,	[E19] 1,178240007 636-54-4	-	Clopamide,	[I22] 1,837922345
75330-75-5	-	Lovastatin,	[N05] 1,441221105 106463-17-6	-	Tamsulosin	HCl,	[O16] 1,170182394 7481-89-2	-	2',3'	-	dideoxycytidine,	[D11] 1,823923639
81103-11-9	-	Clarithromycin,	[O11] 1,42150393 1677687	-	Pentoxifylline,	[G14] 1,148647879 84371-65-3	-	Mifepristone,	[L22] 1,820252447
21462-39-5	-	Clindamycin	HCl,	[A05] 1,418945496 hsa-199,	[E02] 1,136056592 26807-65-8	-	Indapamide,	[N15] 1,817605171
52-01-7	-	Spironolactone,	[M22] 1,414420153 152459-95-5	-	Imatinib,	[C04] 1,134293347 29094-61-9	-	Glipizide,	[C21] 1,817470104
99-66-1	-	Valproic	acid,	[J06] 1,407698829 1156-19-0	-	Tolazamide,	[L10] 1,122233376 84-16-2	-	Hexestrol,	[L21] 1,817314922
15826-37-6	-	Disodium	cromoglycate,	[M10] 1,407477365 517-	89-	5	-	Shikonin,	[K10] 1,109332549 15291-75-5	-	Ginkgolide	a,	[P12] 1,81550645
59277-89-3	-	Acycloguanosine,	[G09] 1,403199289 82586-55-8	-	Quinapril	HCl,	[K06] 1,108982995 24729-96-2	-	Clindamycin	palmitate,	[N16]1,790195563
50-28-2	-	Estradiol,	[F17] 1,398190836 19453	-	Galanthamine	HBr,	[G04] 1,086217684 95635-56-6	-	Ranolazine	2HCl,	[K10] 1,788113213
73-31-4	-	Melatonin,	[E10] 1,368199081 7240-38-2	-	Oxacillin	sodium	monohydrate,	[E18] 1,077839461 113712-98-4	-	Tenatoprazole,	[B06] 1,784939517
111406-87-2	-	Zileuton,	[J12] 1,364271841 67227-56-9	-	Fenoldopam	mesylate,	[H15] 1,051288339 72432-10-1	-	Aniracetam,	[O17] 1,784153004
114-80-7	-	Neostigmine	Br,	[B21] 1,361510968 hsa-199,	[F02] 1,047284422 379-79-3	-	Ergotamine	D-tartrate,	[H22] 1,776432922
2393-92-2	-	Thiamphenicol	glycinate,	[E09] 1,33181623 110871-86-8	-	Sparfloxacin,	[M20] 1,046940315 113806-05-6	-	Olopatadine,	[L09] 1,774067668
63527-52-6	-	Cefotaxime	acid,	[M11] 1,319063163 4394-00-7	-	Niflumic	acid,	[C20] 1,039837802 58066-85-6	-	Miltefosine,	[I16] 1,751725036
146-48-5	-	Yohimbine	HCl,	[G19] 1,309818249 64490-92-2	-	Tolmetin	Na,	[D06] 1,027566562 50700-72-6	-	Vecuronium	Br,	[D22] 1,723252074
7414-83-7	-	Etidronate	2Na,	[H03] 1,306350327 13523-86-9	-	Pindolol,	[I21] 1,0100818 110871-86-8	-	Sparfloxacin,	[M20] 1,71724195
91161-71-6	-	Terbinafine	HCl,	[B20] 1,295125687 69004-03-1	-	Toltrazuril,	[D08] 0,990396527 50-28-2	-	Estradiol,	[F17] 1,712217142
56392-17-7	-	Metoprolol	tartrate,	[A16] 1,25196 436349	-	Doxifluridine,	[D21] 0,988077038 60142-96-3	-	Gabapentin,	[I04] 1,707550068
112529-15-4	-	Pioglitazone,	[H14] 1,247203105 26921-17-5	-	Timolol	maleate	(s),	[I11] 0,985642784 17230-88-5	-	Danazol,	[B21] 1,703013798
115956-12-2	-	Dolasetron,	[N22] 1,240556994 105956-99-8	-	Clinafloxacin	HCl,	[O15] 0,982894364 53885-35-1	-	Ticlopidine	HCl,	[J17] 1,700206297
20537-88-6	-	Amifostine,	[I03] 1,236009569 147-24-0	-	Diphenhydramine	HCl,	[F05] 0,976100002 146-48-5	-	Yohimbine	HCl,	[G19] 1,694836442
64221-86-9	-	Imipenem,	[A15] 1,216067973 54029-12-8	-	Ricobendazole,	[E05] 0,971376289 69655-05-6	-	Didanosine,	[N20] 1,693844678
74863-84-6	-	Argatroban,	[L12] 1,202209182 50-28-2	-	Estradiol,	[F17] 0,96480993 59052-16-3	-	Nalbuphine	HCl,	[J03] 1,683896332
33069-62-4	-	Taxol,	[C08] 1,196361838 78415-72-2	-	Milrinone,	[J14] 0,957420018 1156-19-0	-	Tolazamide,	[L10] 1,683773093
114084-78-5	-	Ibandronate,	[A13] 1,19585598 59052-16-3	-	Nalbuphine	HCl,	[J03] 0,938337477 hsa-590,	[J23] 1,672104129
50-91-9	-	Floxuridine,	[J11] 1,191840065 2971-90-6	-	Clopidol,	[O19] 0,931223698 73210-73-8	-	Xamoterol	hemifumarate,	[I13]1,667142487
79794-75-5	-	Loratadine,	[P17] 1,190805403 130929-57-6	-	Entacapone,	[P15] 0,928687704 84057-84-1	-	Lamotrigine,	[N07] 1,663204784
65-49-6	-	4-aminosalicylic	acid,	[I07] 1,182762521 82009-34-5	-	Cilastatin,	[L14] 0,928687704 41570-61-0	-	Tulobuterol,	[E11] 1,660271787
57381-26-7	-	Irsogladine	maleate,	[J12] 1,181805021 23672-07-3	-	Sulpiride	s	(-),	[F03] 0,92330011 51037-30-0	-	Acipimox,	[G05] 1,655978064
60-54-8	-	Tetracycline,	[B04] 1,176890199 158966-92-8	-	Montelukast,	[C08] 0,919235402 57773-63-4	-	Triptorelin,	[C17] 1,638686475
16595-80-5	-	Levamisole	HCl,	[P03] 1,176396055 hsa-199,	[F23] 0,917012546 69975-86-6	-	Doxofylline,	[F03] 1,634282474
51037-30-0	-	Acipimox,	[G05] 1,157225515 21498-08-8	-	Lofexidine,	[C03] 0,916745395 83150-76-9	-	Octreotide,	[C09] 1,634169714
70458-96-7	-	Norfloxacin,	[E04] 1,12955987 22204-53-1	-	Naproxen,	[M22] 0,915752438 65-49-6	-	4-aminosalicylic	acid,	[I07] 1,630874358
379-79-3	-	Ergotamine	D-tartrate,	[H22] 1,1233296 22494-42-4	-	Diflunisal,	[D15] 0,912656338 590-63-6	-	Carbamyl-beta-methylcholine	Cl,	[J07]1,630674451
2078-54-8	-	Propofol,	[O21] 1,114332806 62929-91-3	-	Procaterol	hcl,	[I17] 0,902218674 93793-83-0	-	Roxatidine	acetate	HCl,	[M04]1,629492602
125-84-8	-	Dl-aminoglutethimide,	[I05] 1,104507527 357-08-4	-	Naloxone	HCl,	[F20] 0,900460899 49562-28-9	-	Fenofibrate,	[H19] 1,623342138
6673-35-4	-	Practolol,	[I09] 1,10094875 66357-59-3	-	Ranitidine	HCl,	[F09] 0,899658684 103628-48-4	-	Sumatriptan	Succinate,	[G21]1,612660942
88671-89-0	-	Myclobutanil,	[C10] 1,093038589 38776-75-9	-	Rifampicin,	[F12] 0,897492534 124750-99-8	-	Losartan	potassium,	[P21] 1,593233861
28395-03-1	-	Bumetanide,	[O14] 1,090138976 56-75-7	-	Chloramphenicol,	[M15] 0,884810487 106463-17-6	-	Tamsulosin	HCl,	[O16] 1,580235484
50-78-2	-	Acetylsalicylic	acid,	[G03] 1,090021821 143491-57-0	-	Emtricitabine,	[I05] 0,88092172 85721-33-1	-	Ciprofloxacin,	[O07] 1,579256869
53716-50-0	-	Oxfendazole,	[E20] 1,088523277 154598-52-4	-	Efavirenz,	[N16] 0,866590367 41575-94-4	-	Carboplatin,	[M05] 1,568916888
50-33-9	-	Phenylbutazone,	[G18] 1,080678852 58-33-3	-	Promethazine	HCl,	[F07] 0,824782079 56-75-7	-	Chloramphenicol,	[M15] 1,543239689
69975-86-6	-	Doxofylline,	[F03] 1,051012405 16320-04-0	-	Gestrinone,	[L15] 0,824326263 7240-38-2	-	Oxacillin	sodium	monohydrate,	[E18]1,52 228131
603-50-9	-	Bisacodyl,	[K15] 1,048143875 315-30-0	-	Allopurinol,	[G13] 0,819012388 78110-38-0	-	Aztreonam,	[K09] 1,514534445
198904-31-3	-	Atazanavir,	[P22] 1,043678886 144701-48-4	-	Telmisartan,	[O18] 0,811518202 149676-40-4	-	Pefloxacine	mesylate,	[G10]1,510789429
92623-83-1	-	Pravadoline,	[K06] 1,037830676 106017-08-7	-	Rufloxacin,	[M08] 0,800264943 13523-86-9	-	Pindolol,	[I21] 1,468820601
66357-59-3	-	Ranitidine	HCl,	[F09] 1,037377356 60-81-1	-	Phloridzin,	[P10] 0,79801603 165800-03-3	-	Linezolid,	[L05] 1,445159302
224785-90-4	-	Vardenafil,	[L03] 1,030400848 40600-13-3	-	Cirazoline	HCl,	[E21] 0,771540684 105462-24-6	-	Risedronic	acid,	[C21] 1,435013485
54029-12-8	-	Ricobendazole,	[E05] 1,022866319 147416-96-4	-	Telenzepine	2HCl,	[M03] 0,762904865 65-29-2	-	Gallamine	triethiodide,	[E22] 1,426970333
357-08-4	-	Naloxone	HCl,	[F20] 1,003221121 75847-73-3	-	Enalapril,	[F07] 0,758203737 25717-80-0	-	Molsidomine,	[K04] 1,421699287
306-40-1	-	Succinylcholine,	[P14] 0,996368955 130636-43-0	-	Nifekalant	HCl,	[C07] 0,754789037 78613-35-1	-	Amorolfine,	[J19] 1,406873967
95734-82-0	-	Nedaplatin,	[P16] 0,988138985 28395-03-1	-	Bumetanide,	[O14] 0,749253708 497-30-3	-	Ergothioneine,	[D04] 1,396829759
120092-68-4	-	Manidipine,	[L11] 0,975304037 15307-79-6	-	Diclofenac,	Na,	[D09] 0,748275993 147416-96-4	-	Telenzepine	2HCl,	[M03] 1,396029774
2971-90-6	-	Clopidol,	[O19] 0,974618602 37321-09-8	-	Apramycin,	[I15] 0,745118539 357-08-4	-	Naloxone	HCl,	[F20] 1,394066285
29520-14-7	-	Guanfacine	HCl,	[P21] 0,961041079 hsa-199,	[E23] 0,744554143 106017-08-7	-	Rufloxacin,	[M08] 1,385447683
305-03-3	-	Chlorambucil,	[M19] 0,959611859 51803-78-2	-	Nimesulide,	[B14] 0,742115412 568-72-9	-	Tanshinone	iia,	[H08] 1,37511341
97964-56-2	-	Lorglumide,	[P19] 0,945462256 50-27-1	-	Estriol,	[F19] 0,736639182 69004-03-1	-	Toltrazuril,	[D08] 1,373259585
2216-88-5	-	Ketoprofen	(s),	[N21] 0,942132005 151615	-	Oxymetazoline	HCl,	[G03] 0,736639043 738-70-5	-	Trimethoprim,	[D14] 1,371767444
57754-86-6	-	Nisoxetine	HCl,	[K13] 0,929474101 7232-21-5	-	Metoclopramide	HCl,	[H15] 0,707442693 25812-30-0	-	Gemfibrozil,	[L13] 1,365600915
cel-67,	[D23] 0,923868998 14222-60-7	-	Prothionamide,	[I12] 0,701234128 57-41-0	-	Phenytoin,	[E11] 1,363991543
1421-86-9	-	Strychnine	HCl,	[D03] 0,908763393 41859-67-0	-	Bezafibrate,	[F04] 0,696389453 81732-65-2	-	Bambuterol,	[J18] 1,35395249
61413-54-5	-	Rolipram,	[J16] 0,906831192 6055-19-2	-	Cyclophosphamide	monohydrate,	[B11] 0,691376583 hsa-590,	[M23] 1,347986866
32828-81-2	-	Picotamide,	[L18] 0,906404757 113806-05-6	-	Olopatadine,	[L09] 0,683894381 154598-52-4	-	Efavirenz,	[N16] 1,347884577
366-70-1	-	Procarbazine	HCl,	[I10] 0,90615979 65-49-6	-	4-aminosalicylic	acid,	[I07] 0,673190928 50-91-9	-	Floxuridine,	[J11] 1,347612226
3778-73-2	-	Ifosfamide,	[N11] 0,90150199 29122-68-7	-	Atenolol,	[I19] 0,671407671 1791337	-	Carbadox,	[M03] 1,340698907
98079-52-8	-	Lomefloxacin	HCl,	[P15] 0,897356694 27203-92-5	-	Tramadol	HCl,	[D10] 0,658983126 50-63-5	-	Chloroquine	phosphate,	[O03] 1,336237305
83150-76-9	-	Octreotide,	[C09] 0,89693375 3366-95-8	-	Secnidazole,	[M16] 0,653478966 14838-15-4	-	Phenylpropanolamine,	[P12] 1,332951789
14222-60-7	-	Prothionamide,	[I12] 0,896754444 68291-97-4	-	Zonisamide,	[O07] 0,645482977 530-78-9	-	Flufenamic	acid,	[E07] 1,322528308
98-92-0	-	Medroxyprogesterone	17-acetate,	[A06] 0,896453174 28822-58-4	-	Isobutylmethylxanthine,	[J10] 0,640769917 78415-72-2	-	Milrinone,	[J14] 1,319262741
89197-32-0	-	Efaroxan,	[C16] 0,892363245 36322-90-4	-	Piroxicam,	[B06] 0,636552388 40391-99-9	-	Pamidronic	acid,	[C13] 1,300034848
58066-85-6	-	Miltefosine,	[I16] 0,886452929 41575-94-4	-	Carboplatin,	[M05] 0,631283562 56-53-1	-	Diethylstilbestrol,	[D13] 1,289879637
68291-97-4	-	Zonisamide,	[O07] 0,885932268 54-71-7	-	Pilocarpine	HCl,	[K17] 0,625160293 64490-92-2	-	Tolmetin	Na,	[D06] 1,288032153
53-86-1	-	Indomethacin,	[M20] 0,883574251 119141-88-7	-	Esomeprazole	potassium,	[F15] 0,624905813 61413-54-5	-	Rolipram,	[J16] 1,279885511
10238-21-8	-	Glyburide,	[L06] 0,88227408 79855-88-2	-	Trequinsin,	[J20] 0,617637118 15307-79-6	-	Diclofenac,	Na,	[D09] 1,273911988
73210-73-8	-	Xamoterol	hemifumarate,	[I13] 0,880296416 57381-26-7	-	Irsogladine	maleate,	[J12] 0,601994842 63590-64-7	-	Terazosin	HCl,	[O22] 1,266875441
34580-14-8	-	Ketotifen	fumarate,	[F16] 0,874159085 89-57-6	-	5-aminosalicylic	acid,	[I09] 0,598415986 614-39-1	-	Procainamide,	[E13] 1,263586235
54-85-3	-	Isoniazid,	[J15] 0,871633233 603-50-9	-	Bisacodyl,	[K15] 0,584410014 15687-27-1	-	Ibuprofen,	[O06] 1,2606048
81409-90-7	-	Cabergoline,	[A09] 0,862010261 hsa-199,	[F01] 0,576067669 68291-97-4	-	Zonisamide,	[O07] 1,242416271
98048-97-6	-	Fosinopril,	[P08] 0,856870257 84057-84-1	-	Lamotrigine,	[N07] 0,570817197 99464-64-9	-	Ampiroxicam,	[I13] 1,240736983
cel-67,	[D23] 0,853002779 54-31-9	-	Furosemide,	[L05] 0,55138641 50-27-1	-	Estriol,	[F19] 1,240049295
3160-91-6	-	Moroxydine	HCl,	[A03] 0,841900605 60-54-8	-	Tetracycline,	[B04] 0,543420348 122892-31-3	-	Itopride	HCl,	[N17] 1,228444817
1716-12-7	-	Sodium	phenylbutyrate,	[B22] 0,831205686 73-31-4	-	Melatonin,	[E10] 0,536999633 39809-25-1	-	Penciclovir,	[G12] 1,226998603
99300-78-4	-	Venlafaxine	HCl,	[F04] 0,828364081 891986	-	Dacarbazine,	[B19] 0,536915663 566-48-3	-	Formestane,	[J21] 1,224119188
16170-76-6	-	Bromebric	acid,	[L16] 0,824704208 1791337	-	Carbadox,	[M03] 0,53499909 427-51-0	-	Cyproterone	acetate,	[B13] 1,212247691
10596-23-3	-	Clodronate	disodium,	[N14] 0,822464968 50-35-1	-	Thalidomide,	[O05] 0,531177194 2216-88-5	-	Ketoprofen	(s),	[N21] 1,198994467
122-11-2	-	Sulfadimethoxine,	[O12] 0,820785653 15826-37-6	-	Disodium	cromoglycate,	[M10] 0,51669484 91296-87-6	-	Sarafloxacin	HCl,	[M10] 1,179761989
1400-61-9	-	Nystatin,	[E06] 0,819166048 122892-31-3	-	Itopride	HCl,	[N17] 0,513373315 98079-52-8	-	Lomefloxacin	HCl,	[P15] 1,174889225
cel-67,	[L23] 0,815384798 2216-88-5	-	Ketoprofen	(s),	[N21] 0,512513908 73-31-4	-	Melatonin,	[E10] 1,174818477
107753-78-6	-	Zafirlukast,	[J10] 0,812888164 hsa-199,	[F02] 0,495100531 69014-14-8	-	Tiotidine,	[O05] 1,173331172
5786-21-0	-	Clozapine,	[K14] 0,798728287 81110-73-8	-	Racecadotril,	[K08] 0,482706257 81-24-3	-	Taurocholic	acid,	sodium	salt	hydrate,	[N18]1,17324 397
54-31-9	-	Furosemide,	[L05] 0,794359047 24390-14-5	-	Doxycycline	HCl,	[F05] 0,464497843 364-98-7	-	Diazoxide,	[L04] 1,172566545
322-35-0	-	Benserazide	HCl,	[O08] 0,794032195 104632-26-0	-	Pramipexole,	[C15] 0,463555221 19728-88-2	-	Methiothepin	maleate,	[O12]1,166105766
104632-26-0	-	Pramipexole,	[C15] 0,791512524 162011-90-7	-	Rofecoxib,	[H20] 0,460729659 125-84-8	-	Dl-aminoglutethimide,	[I05] 1,163890529
530-78-9	-	Flufenamic	acid,	[E07] 0,787438249 657-24-9	-	Metformin,	[C20] 0,45746628 7361-61-7	-	Xylazine	HCl,	[F19] 1,161117253
125494-59-9	-	Sibutramine	HCl,	[M18] 0,782633751 10118-90-8	-	Minocycline	HCl,	[C04] 0,45739471 59277-89-3	-	Acycloguanosine,	[G09] 1,149699543
15307-79-6	-	Diclofenac,	Na,	[D09] 0,767395477 79547-78-7	-	Levocabastine	HCl,	[F18] 0,445506723 434-03-7	-	Ethisterone,	[F13] 1,143218252
90357-06-5	-	Bicalutamide,	[N12] 0,763293879 3810-74-0	-	Streptomycin	sulfate,	[O06] 0,433723976 6673-35-4	-	Practolol,	[I09] 1,137604216
cel-67,	[K23] 0,761386409 153559-49-0	-	Bexarotene,	[L14] 0,426873788 54-92-2	-	Iproniazid,	[F08] 1,135933935
22204-24-6	-	Pyrantel	pamoate,	[I22] 0,758986674 80288-49-9	-	Furafylline,	[B07] 0,423704648 99011-02-6	-	Imiquimod,	[N13] 1,133325044
95233-18-4	-	Atovaquone,	[N13] 0,752977831 99464-64-9	-	Ampiroxicam,	[I13] 0,418086926 1508-75-4	-	Tropicamide,	[M05] 1,13057883
106463-17-6	-	Tamsulosin	HCl,	[O16] 0,743387795 132539-06-1	-	Olanzapine,	[N03] 0,416722536 1405-54-5	-	Tylosin	tartrate,	[D18] 1,128343581
54-71-7	-	Pilocarpine	HCl,	[K17] 0,716956573 51-12-7	-	Nialamide,	[M13] 0,415283786 17902-23-7	-	Ftorafur,	[L03] 1,109844
22071-15-4	-	Ketoprofen,	[B16] 0,716390049 53-86-1	-	Indomethacin,	[M20] 0,414870794 90098-04-7	-	Rebamipide,	[K14] 1,107501404
99011-02-6	-	Imiquimod,	[N13] 0,71582756 611-75-6	-	Bromhexine	HCl,	[K17] 0,413724668 976-71-6	-	Canrenone,	[K21] 1,1043615
74011-58-8	-	Enoxacin,	[F09] 0,714920613 74863-84-6	-	Argatroban,	[L12] 0,411402443 hsa-590,	[J24] 1,101762669
105956-99-8	-	Clinafloxacin	HCl,	[O15] 0,707031412 80214-83-1	-	Roxithromycin,	[M06] 0,405624343 hsa-590,	[I24] 1,098823168
cel-67,	[K24] 0,704521222 541-22-0	-	Decamethonium	2Br,	[B17] 0,402306457 15500-66-0	-	Pancuronium	Br,	[M07] 1,072675718
1649-18-9	-	Azaperone,	[K03] 0,70275246 568-72-9	-	Tanshinone	iia,	[H08] 0,400296854 73-05-2	-	PhentolamineHCl,	[E03] 1,072467691
555-30-6	-	Methyldopa,	[A12] 0,700827552 2078-54-8	-	Propofol,	[O21] 0,38244441 132-98-9	-	Pencillin	v	potassium,	[G16] 1,060236127
89796-99-6	-	Aceclofenac,	[G07] 0,698428216 81732-65-2	-	Bambuterol,	[J18] 0,372986132 60-81-1	-	Phloridzin,	[P10] 1,052524505
4205-91-8	-	Clonidine	HCl,	[G11] 0,687981017 133040-01-4	-	Eprosartan,	[P09] 0,356871172 90-05-1	-	Guaiacol,	[D18] 1,049813903
71-82-9	-	Levallorphan	tartrate,	[H21] 0,681319723 101975-10-4	-	Zardaverine,	[L06] 0,35072254 53902-12-8	-	Tranilast,	[K08] 1,046612913
26921-17-5	-	Timolol	maleate	(s),	[I11] 0,677765731 25717-80-0	-	Molsidomine,	[K04] 0,350171004 82419-36-1	-	Ofloxacin,	[E08] 1,030238653
14611-51-9	-	Selegiline,	[C10] 0,675141514 14252-80-3	-	Bupivacaine	HCl,	[F12] 0,341166052 123948-87-8	-	Topotecan,	[B20] 1,024528621
105826-92-4	-	Tropisetron	HCl,	[D16] 0,671439979 88040-23-7	-	Cefepime,	[N17] 0,34076535 3366-95-8	-	Secnidazole,	[M16] 1,023472138
105816-04-4	-	nateglinide,	[B09] 0,670970871 51-02-5	-	Pronethalol	HCl,	[K07] 0,340200472 65141-46-0	-	Nicorandil,	[L12] 1,022443355
6119-47-7	-	Quinine,	[E05] 0,667927479 599-79-1	-	Sulfasalazine,	[O14] 0,338037457 145-13-1	-	Pregnenolone,	[I16] 1,02187646
80288-49-9	-	Furafylline,	[B07] 0,666075091 72558-82-8	-	Ceftazidime,	[M13] 0,337720468 99-66-1	-	Valproic	acid,	[J06] 1,020382364
56-75-7	-	Chloramphenicol,	[M15] 0,666049965 4205-91-8	-	Clonidine	HCl,	[G11] 0,336955103 1405-10-3	-	Neomycin	sulfate,	[O16] 1,019322235
404-86-4	-	Capsaicin,	[M12] 0,66572771 63-92-3	-	Phenoxybenzamine	HCl,	[I10] 0,335901993 99300-78-4	-	Venlafaxine	HCl,	[F04] 1,0038296
315-30-0	-	Allopurinol,	[G13] 0,648310146 145-13-1	-	Pregnenolone,	[I16] 0,332213748 97964-56-2	-	Lorglumide,	[P19] 1,002910897
26786-84-5	-	Lomofungin,	[A15] 0,645018868 83150-76-9	-	Octreotide,	[C09] 0,331842024 81147-92-4	-	Esmolol,	[P06] 1,000321676
5104-49-4	-	Flurbiprofen,	[J05] 0,643970348 637-07-0	-	Clofibrate,	[O04] 0,32747031 54029-12-8	-	Ricobendazole,	[E05] 0,999747685
99464-64-9	-	Ampiroxicam,	[I13] 0,642783653 49745-95-1	-	Dobutamine	HCl,	[K05] 0,319356283 7232-21-5	-	Metoclopramide	HCl,	[H15] 0,982566538
32986-56-4	-	Tobramycin	(free	base),	[B16] 0,639943394 10238-21-8	-	Glyburide,	[L06] 0,313892855 637-07-0	-	Clofibrate,	[O04] 0,977425694
133-67-5	-	Trichloromethiazide,	[H07] 0,62969035 139481-59-7	-	Candesartan,	[N21] 0,308173654 119302-91-9	-	Rocuronium	bromide,	[E03]0,973933541
57-94-3	-	Tubocurarine	Cl		(+),	[D05] 0,626224704 40391-99-9	-	Pamidronic	acid,	[C13] 0,305018783 86386-73-4	-	Fluconazole,	[J19] 0,973406978
cel-67,	[D01] 0,612211022 120511-73-1	-	Anastrozole,	[N10] 0,296560342 101975-10-4	-	Zardaverine,	[L06] 0,969591361
34911-55-2	-	Amfebutamone,	[H13] 0,611877592 122-11-2	-	Sulfadimethoxine,	[O12] 0,296275316 2393-92-2	-	Thiamphenicol	glycinate,	[E09]0,969573561
53-03-2	-	Prednisone,	[I14] 0,61178274 21187-98-4	-	Gliclazide,	[L15] 0,290278392 144701-48-4	-	Telmisartan,	[O18] 0,964809604
364-98-7	-	Diazoxide,	[L04] 0,604700999 64795-35-3	-	Mesulergine	HCl,	[H11] 0,288260075 1716-12-7	-	Sodium	phenylbutyrate,	[B22]0,964751102
13311-84-7	-	Flutamide,	[J17] 0,587118165 129-46-4	-	Suramin	sodium,	[D14] 0,286103386 1476-53-5	-	Novobiocin	Na,	[A19] 0,961978394
89-57-6	-	5-aminosalicylic	acid,	[I09] 0,582378556 18046-21-4	-	Fentiazac,	[J20] 0,284755834 366-70-1	-	Procarbazine	HCl,	[I10] 0,956186643
59804-37-4	-	Tenoxicam,	[O20] 0,570228988 103177-37-3	-	Pranlukast,	[H16] 0,281894832 38776-75-9	-	Rifampicin,	[F12] 0,951320494
202409-33-4	-	Etoricoxib,	[A05] 0,570194823 81103-11-9	-	Clarithromycin,	[O11] 0,279077346 29520-14-7	-	Guanfacine	HCl,	[P21] 0,943657653
111469-81-9	-	Naltrindole	HCl,	[F11] 0,56555021 113-92-8	-	Chlorpheniramine	maleate,	[M21] 0,271097784 27203-92-5	-	Tramadol	HCl,	[D10] 0,940780431
97322-87-7	-	Troglitazone,	[D22] 0,565344894 69014-14-8	-	Tiotidine,	[O05] 0,267433883 143491-57-0	-	Emtricitabine,	[I05] 0,939691318
657-24-9	-	Metformin,	[C20] 0,564851855 76824-35-6	-	Famotidine,	[J11] 0,264472813 133040-01-4	-	Eprosartan,	[P09] 0,935605481
24729-96-2	-	Clindamycin	palmitate,	[N16] 0,558820477 7361-61-7	-	Xylazine	HCl,	[F19] 0,253702394 22204-53-1	-	Naproxen,	[M22] 0,934519374
58-33-3	-	Promethazine	HCl,	[F07] 0,554610863 11018-89-6	-	Ouabain,	[I20] 0,250934959 hsa-590,	[I23] 0,930815152
50700-72-6	-	Vecuronium	Br,	[D22] 0,554399209 10418-03-8	-	Stanozolol,	[O04] 0,249669871 76824-35-6	-	Famotidine,	[J11] 0,920118681
79660-72-3	-	Fleroxacin,	[J07] 0,552291432 hsa-199,	[E01] 0,243025396 51-12-7	-	Nialamide,	[M13] 0,918517133
1476-53-5	-	Novobiocin	Na,	[A19] 0,551644327 50-40-1	-	Norepinephrine-(+)-tartrate	l	(-),	[F21] 0,236889232 436349	-	Doxifluridine,	[D21] 0,91685391
80809-81-0	-	Docebenone,	[O22] 0,549422632 65141-46-0	-	Nicorandil,	[L12] 0,235794191 61-68-7	-	Mefenamic	acid,	[A08] 0,914011462
65277-42-1	-	Ketoconazole,	[M06] 0,547146831 114-49-8	-	Scopolamine	HBr,	[M14] 0,229533008 22254-24-6	-	Ipratropium	Br,	[K19] 0,9015711
3810-74-0	-	Streptomycin	sulfate,	[O06] 0,516697179 125-84-8	-	Dl-aminoglutethimide,	[I05] 0,213127063 53-16-7	-	Estrone,	[F21] 0,899140788
93793-83-0	-	Roxatidine	acetate	HCl,	[M04] 0,514165133 2393-92-2	-	Thiamphenicol	glycinate,	[E09] 0,208124293 22204-24-6	-	Pyrantel	pamoate,	[I22] 0,897148562
41575-94-4	-	Carboplatin,	[M05] 0,505147026 16676-29-2	-	Naltrexone	HCl,	[O11] 0,202812544 159989-64-7	-	Nelfinavir	Mesylate,	[K18] 0,895761063
78613-35-1	-	Amorolfine,	[J19] 0,505109588 483-63-6	-	Crotamiton,	[B09] 0,20019634 54-71-7	-	Pilocarpine	HCl,	[K17] 0,893245889
124858-35-1	-	Nadifloxacin,	[C12] 0,500929796 1649-18-9	-	Azaperone,	[K03] 0,197621776 514-78-3	-	Canthaxanthin,	[K15] 0,885922284
17230-88-5	-	Danazol,	[B21] 0,481012981 19982-08-2	-	Memantine	HCl,	[O15] 0,193814697 517-	89-	5	-	Shikonin,	[K10] 0,880486855
cel-67,	[D24] 0,474822463 50-07-7	-	Mitomycin	c,	[F16] 0,193743031 24730-10-7	-	Dihydroergocristine	mesylate,	[H10]0,880395213
cel-67,	[D01] 0,472700995 68475-42-3	-	Anagrelide,	[C22] 0,185390626 50-33-9	-	Phenylbutazone,	[G18] 0,874324303
96036-03-2	-	Meropenem,	[C05] 0,467992558 57773-63-4	-	Triptorelin,	[C17] 0,168049539 105816-04-4	-	nateglinide,	[B09] 0,87332771
28721-07-5	-	Oxcarbazepine,	[E14] 0,467983406 55268-74-1	-	Praziquantel,	[I20] 0,167642035 34580-14-8	-	Ketotifen	fumarate,	[F16] 0,869135976
53-43-0	-	Dehydroepiandrosterone,	[D03] 0,466703655 99300-78-4	-	Venlafaxine	HCl,	[F04] 0,146980396 891986	-	Dacarbazine,	[B19] 0,846116548
82419-36-1	-	Ofloxacin,	[E08] 0,465078147 49562-28-9	-	Fenofibrate,	[H19] 0,129294809 96036-03-2	-	Meropenem,	[C05] 0,8460852
78755-81-4	-	Flumazenil,	[A16] 0,462680979 56-53-1	-	Diethylstilbestrol,	[D13] 0,127112776 149-64-4	-	Scopolamine	n-butylbromide,	[M12]0,844786333
132-98-9	-	Pencillin	v	potassium,	[G16] 0,46098356 129-03-3	-	Cyproheptadine,	[P20] 0,126820209 119141-88-7	-	Esomeprazole	potassium,	[F15]0,833820162
103745-39-7	-	Fasudil,	[E14] 0,458436371 976-71-6	-	Canrenone,	[K21] 0,120984684 100643-71-8	-	Desloratadine,	[D05] 0,83049229
58-54-8	-	Ethacrynic	acid,	[M18] 0,458186915 84225-95-6	-	Raclopride	l-tartrate	s(-),	[D19] 0,120359652 64-47-1	-	Physostigmine	sulfate,	[M11] 0,825317144
75706-12-6	-	Leflunomide,	[P11] 0,457670729 315-80-0	-	Dibenzepine	HCl,	[H08] 0,10650889 28822-58-4	-	Isobutylmethylxanthine,	[J10]0,823453824
93-14-1	-	Guaifenesin,	[L19] 0,453672652 41570-61-0	-	Tulobuterol,	[E11] 0,105240152 hsa-590,	[J02] 0,822474391
87333-19-5	-	Ramipril,	[K12] 0,452727624 37762-06-4	-	Zaprinast,	[L04] 0,10198785 1166-34-3	-	Cinanserin,	[H06] 0,819230968
50-07-7	-	Mitomycin	c,	[F16] 0,45140219 113712-98-4	-	Tenatoprazole,	[B06] 0,095852016 79-83-4	-	Pantothenic	acid,	[P08] 0,818939309
78919-13-8	-	Iloprost,	[A19] 0,445135934 364-98-7	-	Diazoxide,	[L04] 0,091841 603-50-9	-	Bisacodyl,	[K15] 0,817094243
90098-04-7	-	Rebamipide,	[K14] 0,443978185 68-35-9	-	Sulfadiazine,	[O10] 0,091492851 28797-61-7	-	Pirenzepine	2HCl,	[K21] 0,816215955
69655-05-6	-	Didanosine,	[N20] 0,440846041 hsa-199,	[E24] 0,091369429 6108-05-0	-	Lidocaine,	[E15] 0,814883178
95635-56-6	-	Ranolazine	2HCl,	[K10] 0,438115094 1716-12-7	-	Sodium	phenylbutyrate,	[B22] 0,084652523 hsa-590,	[I23] 0,813116526
51803-78-2	-	Nimesulide,	[B14] 0,437749094 85622-93-1	-	Temozolomide,	[B08] 0,077623946 145781-92-6	-	Goserelin	acetate,	[D16] 0,799014505
102625-70-7	-	Pantoprazole,	[G04] 0,433241611 2038-35-9	-	Phenamil,	[E19] 0,072534705 315-80-0	-	Dibenzepine	HCl,	[H08] 0,785489777
2447-57-6	-	Sulfadoxine,	[O08] 0,431829513 22254-24-6	-	Ipratropium	Br,	[K19] 0,066967199 4205-91-8	-	Clonidine	HCl,	[G11] 0,779969393
361-37-5	-	Methysergide,	[P04] 0,431379622 119-36-8	-	Methyl	salicylate,	[H12] 0,061314812 68373-14-8	-	Sulbactam,	[E07] 0,77648438
497-30-3	-	Ergothioneine,	[D04] 0,418834592 95233-18-4	-	Atovaquone,	[N13] 0,054079969 89-57-6	-	5-aminosalicylic	acid,	[I09] 0,776432745
18683-91-5	-	Ambroxol,	[D06] 0,413581713 83915-83-7	-	Lisinopril,	[P13] 0,050759382 hsa-590,	[N23] 0,756747583
33286-22-5	-	Diltiazem,	[G10] 0,401923714 614-39-1	-	Procainamide,	[E13] 0,046609546 3810-74-0	-	Streptomycin	sulfate,	[O06] 0,75342654
14252-80-3	-	Bupivacaine	HCl,	[F12] 0,379005232 111406-87-2	-	Zileuton,	[J12] 0,031850641 37148-27-9	-	Clenbuterol,	[I15] 0,749391654
82586-55-8	-	Quinapril	HCl,	[K06] 0,375030477 29094-61-9	-	Glipizide,	[C21] 0,021408919 hsa-590,	[N01] 0,743948203
1166-34-3	-	Cinanserin,	[H06] 0,369200107 434-03-7	-	Ethisterone,	[F13] 0,020894615 93-14-1	-	Guaifenesin,	[L19] 0,739297603
27203-92-5	-	Tramadol	HCl,	[D10] 0,35591877 124832-27-5	-	Valaciclovir,	[D20] 0,011316357 53716-50-0	-	Oxfendazole,	[E20] 0,738678548
7232-21-5	-	Metoclopramide	HCl,	[H15] 0,35057556 21736-83-4	-	Spectinomycin,	[C03] 0,008533744 54-31-9	-	Furosemide,	[L05] 0,73457836
15687-27-1	-	Ibuprofen,	[O06] 0,342426721 26807-65-8	-	Indapamide,	[N15] 0,005406089 10596-23-3	-	Clodronate	disodium,	[N14] 0,726106533
25717-80-0	-	Molsidomine,	[K04] 0,342039789 161814-49-9	-	Amprenavir,	[N10] 0,004127709 826-39-1	-	Mecamylamine	HCl,	[B19] 0,716972837
147-24-0	-	Diphenhydramine	HCl,	[F05] 0,338403859 53885-35-1	-	Ticlopidine	HCl,	[J17] 0,001115637 1405-41-0	-	Gentamycin	sulfate,	[L11] 0,705341058
147536-97-8	-	Bosentan,	[N14] 0,337557345 61413-54-5	-	Rolipram,	[J16] -0,008743516 67121-76-0	-	Fluperlapine,	[H12] 0,697341306
24390-14-5	-	Doxycycline	HCl,	[F05] 0,329211502 54-92-2	-	Iproniazid,	[F08] -0,013266137 22494-42-4	-	Diflunisal,	[D15] 0,694040265
38194-50-2	-	Sulindac,	[J04] 0,327660753 835-31-4	-	Naphazoline	HCl,	[C16] -0,014152012 53-86-1	-	Indomethacin,	[M20] 0,688696005
64-77-7	-	Tolbutamide,	[C17] 0,32253609 366-70-1	-	Procarbazine	HCl,	[I10] -0,015517897 139481-59-7	-	Candesartan,	[N21] 0,68595205
50-63-5	-	Chloroquine	phosphate,	[O03] 0,310281594 50-33-9	-	Phenylbutazone,	[G18] -0,019476722 93106-60-6	-	Enrofloxacin,	[F11] 0,676617159
93106-60-6	-	Enrofloxacin,	[F11] 0,304670956 53-16-7	-	Estrone,	[F21] -0,020424665 114-80-7	-	Neostigmine	Br,	[B21] 0,676255856
28822-58-4	-	Isobutylmethylxanthine,	[J10] 0,30433401 75706-12-6	-	Leflunomide,	[P11] -0,021145462 7414-83-7	-	Etidronate	2Na,	[H03] 0,668061184
1501-84-4	-	Rimantadine	HCl,	[K20] 0,303092154 1986-47-6	-	Tranylcypromine,	[B04] -0,023759977 317-34-0	-	Aminophylline,	[B05] 0,666526732
113-52-0	-	Imipramine	HCl,	[H07] 0,302889185 115344-47-3	-	Siguazodan,	[J18] -0,031585334 88040-23-7	-	Cefepime,	[N17] 0,665847355
144701-48-4	-	Telmisartan,	[O18] 0,298042851 53716-50-0	-	Oxfendazole,	[E20] -0,041575958 118072-93-8	-	Zoledronic	acid,	[O09] 0,665684158
cel-67,	[C01] 0,294721734 85371-64-8	-	Pinacidil,	[C19] -0,04482604 80214-83-1	-	Roxithromycin,	[M06] 0,66308971
112811-59-3	-	Gatifloxacin,	[L09] 0,294640199 144689-63-4	-	Olmesartan,	[L17] -0,045857042 224785-90-4	-	Vardenafil,	[L03] 0,661482135
81147-92-4	-	Esmolol,	[P06] 0,293711557 73220-03-8	-	Remoxipride,	[K20] -0,059299997 306-40-1	-	Succinylcholine,	[P14] 0,660289942
315-80-0	-	Dibenzepine	HCl,	[H08] 0,288628346 88150-42-9	-	Amlodipine,	[G08] -0,062180308 82586-55-8	-	Quinapril	HCl,	[K06] 0,65683106
64795-35-3	-	Mesulergine	HCl,	[H11] 0,28849575 105826-92-4	-	Tropisetron	HCl,	[D16] -0,070462083 52549-17-4	-	Pranoprofen,	[I04] 0,654053356
170729-80-3	-	Aprepitant,	[N12] 0,288028279 hsa-199,	[E24] -0,070582585 305-03-3	-	Chlorambucil,	[M19] 0,638001834
114-70-5	-	Sodium	phenylacetate,	[P11] 0,287295134 51481-61-9	-	Cimetidine,	[O03] -0,083944006 hsa-590,	[J23] 0,633202528
196618-13-0	-	Oseltamivir,	[C11] 0,278012087 19216-56-9	-	Prazosin	HCl,	[G09] -0,084918397 147536-97-8	-	Bosentan,	[N14] 0,630212658
37762-06-4	-	Zaprinast,	[L04] 0,277528115 85721-33-1	-	Ciprofloxacin,	[O07] -0,090765431 14222-60-7	-	Prothionamide,	[I12] 0,624915459
3521-84-4	-	Meglumine,	[A06] 0,27192163 17360-35-9	-	Oxotremorine	sesquifumarate,	[E18] -0,09664317 74863-84-6	-	Argatroban,	[L12] 0,609530729
90-05-1	-	Guaiacol,	[D18] 0,268401894 68-22-4	-	Norethindrone,	[C22] -0,098436727 53164-05-9	-	Acemetacin,	[E21] 0,596055157
123441-03-2	-	Rivastigmine,	[H18] 0,26645581 77883-43-3	-	Doxazosin	mesylate,	[D19] -0,104121567 14252-80-3	-	Bupivacaine	HCl,	[F12] 0,594705898
1684-40-8	-	Tacrine	HCl,	[E20] 0,256218109 63527-52-6	-	Cefotaxime	acid,	[M11] -0,116528606 50-78-2	-	Acetylsalicylic	acid,	[G03] 0,594540342
62929-91-3	-	Procaterol	hcl,	[I17] 0,255362339 119302-91-9	-	Rocuronium	bromide,	[E03] -0,120680785 85371-64-8	-	Pinacidil,	[C19] 0,590690052
82410-32-0	-	Ganciclovir,	[L07] 0,25282087 125-69-9	-	Dextromethorphan	HBr,	[D07] -0,121671539 16170-76-6	-	Bromebric	acid,	[L16] 0,578178456
19728-88-2	-	Methiothepin	maleate,	[O12] 0,251569589 59-92-7	-	Levodopa,	[P07] -0,133434015 135046-48-9	-	Clopidogrel	sulfate,	[O21] 0,574814752
60-81-1	-	Phloridzin,	[P10] 0,244732565 68550-75-4	-	Cilostamide,	[J06] -0,13571606 90357-06-5	-	Bicalutamide,	[N12] 0,573281813
31879-05-7	-	Fenoprofen,	[H17] 0,234829104 224785-90-4	-	Vardenafil,	[L03] -0,137897751 50-35-1	-	Thalidomide,	[O05] 0,554813825
13710-19-5	-	Tolfenamic	acid,	[D04] 0,234559433 5104-49-4	-	Flurbiprofen,	[J05] -0,140141131 22071-15-4	-	Ketoprofen,	[B16] 0,545074881
57808-65-8	-	Closantel,	[B05] 0,234504881 62893-19-0	-	Cefoperazone	acid,	[M09] -0,145805339 74011-58-8	-	Enoxacin,	[F09] 0,541881646
81732-65-2	-	Bambuterol,	[J18] 0,233504609 379-79-3	-	Ergotamine	D-tartrate,	[H22] -0,149816419 89796-99-6	-	Aceclofenac,	[G07] 0,539676484
28860-95-9	-	Carbidopa,	[B12] 0,2289996 514-78-3	-	Canthaxanthin,	[K15] -0,152608921 81103-11-9	-	Clarithromycin,	[O11] 0,525026039
110871-86-8	-	Sparfloxacin,	[M20] 0,227920856 42924-53-8	-	Nabumetone,	[C14] -0,1550297 103745-39-7	-	Fasudil,	[E14] 0,523286272
105462-24-6	-	Risedronic	acid,	[C21] 0,226305389 113-52-0	-	Imipramine	HCl,	[H07] -0,156948577 1501-84-4	-	Rimantadine	HCl,	[K20] 0,518987516
112809-51-5	-	Letrozole,	[L22] 0,220645624 738-70-5	-	Trimethoprim,	[D14] -0,157834447 hsa-590,	[N01] 0,518305316
13707-88-5	-	Alprenolol	HCl,	[H05] 0,21809245 65-29-2	-	Gallamine	triethiodide,	[E22] -0,166463216 104-46-1	-	Anethole,	trans-,	[P20] 0,515284802
79547-78-7	-	Levocabastine	HCl,	[F18] 0,217508215 305-03-3	-	Chlorambucil,	[M19] -0,17687322 72599-27-0	-	Miglustat,	[N20] 0,508663376
50-35-1	-	Thalidomide,	[O05] 0,216250756 636-54-4	-	Clopamide,	[I22] -0,180284673 541-22-0	-	Decamethonium	2Br,	[B17] 0,505878782
32672-69-8	-	Mesoridazine	besylate,	[H22] 0,209479459 104227-87-4	-	Famciclovir,	[H09] -0,186403157 139264-17-8	-	zolmitriptan,	[O13] 0,500304337
29122-68-7	-	Atenolol,	[I19] 0,209110376 50700-72-6	-	Vecuronium	Br,	[D22] -0,202974498 16595-80-5	-	Levamisole	HCl,	[P03] 0,492573346
738-70-5	-	Trimethoprim,	[D14] 0,200464778 54187-04-1	-	Rilmenidine	hemifumarate,	[G15] -0,204386186 4394-00-7	-	Niflumic	acid,	[C20] 0,4886123
143491-57-0	-	Emtricitabine,	[I05] 0,197031583 57-41-0	-	Phenytoin,	[E11] -0,212642301 51-83-2	-	Carbamylcholine	Cl,	[J05] 0,486793682
134308-13-7	-	Tolcapone,	[L13] 0,188861699 17230-88-5	-	Danazol,	[B21] -0,21500352 57808-65-8	-	Closantel,	[B05] 0,475852405
152459-95-5	-	Imatinib,	[C04] 0,188400038 15687-27-1	-	Ibuprofen,	[O06] -0,225195226 1649-18-9	-	Azaperone,	[K03] 0,468920915
cel-67,	[L24] 0,180813033 hsa-199,	[F24] -0,227577533 89365-50-4	-	Salmeterol,	[E17] 0,468314194
147221-93-0	-	Delavirdine	mesylate,	[F20] 0,175657474 31879-05-7	-	Fenoprofen,	[H17] -0,260408642 144689-63-4	-	Olmesartan,	[L17] 0,466790174
cel-67,	[L01] 0,166004945 114-70-5	-	Sodium	phenylacetate,	[P11] -0,276864955 645-05-6	-	Altretamine,	[G17] 0,462811164
84-16-2	-	Hexestrol,	[L21] 0,163983668 497-30-3	-	Ergothioneine,	[D04] -0,27739855 28395-03-1	-	Bumetanide,	[O14] 0,456330807
55-48-1	-	Atropine	sulfate,	[B15] 0,163610499 55-48-1	-	Atropine	sulfate,	[B15] -0,288111506 55268-74-1	-	Praziquantel,	[I20] 0,452332123
749-13-3	-	Trifluperidol	2HCl,	[P16] 0,162862068 551-11-1	-	Dinoprost,	[E12] -0,294642837 38304-91-5	-	Minoxidil,	[L08] 0,44872727
66085-59-4	-	Nimodipine,	[G14] 0,159342225 107753-78-6	-	Zafirlukast,	[J10] -0,296469942 121268-17-5	-	Alendronate,	[G15] 0,448269441
81110-73-8	-	Racecadotril,	[K08] 0,152795223 96036-03-2	-	Meropenem,	[C05] -0,303395807 133-67-5	-	Trichloromethiazide,	[H07] 0,444347587
69-09-0	-	Chlorpromazine	HCl,	[D11] 0,145142467 24730-10-7	-	Dihydroergocristine	mesylate,	[H10] -0,306426533 59804-37-4	-	Tenoxicam,	[O20] 0,442146512
cel-67,	[L01] 0,14094485 154-21-2	-	Lincomycin,	[A13] -0,309154155 33286-22-5	-	Diltiazem,	[G10] 0,440456702
60142-96-3	-	Gabapentin,	[I04] 0,140302398 34580-14-8	-	Ketotifen	fumarate,	[F16] -0,318764753 51803-78-2	-	Nimesulide,	[B14] 0,432125487
52549-17-4	-	Pranoprofen,	[I04] 0,137620389 2447-57-6	-	Sulfadoxine,	[O08] -0,31986199 88671-89-0	-	Myclobutanil,	[C10] 0,427375337
85721-33-1	-	Ciprofloxacin,	[O07] 0,134611636 54-42-2	-	Idoxuridine,	[N09] -0,32102834 657-24-9	-	Metformin,	[C20] 0,425894548
7361-61-7	-	Xylazine	HCl,	[F19] 0,133647346 10596-23-3	-	Clodronate	disodium,	[N14] -0,330134024 1986-47-6	-	Tranylcypromine,	[B04] 0,422340539
cel-67,	[C23] 0,11683242 hsa-199,	[E02] -0,333188826 2971-90-6	-	Clopidol,	[O19] 0,419179683
51022-70-9	-	Salbutamol	sulfate,	[I19] 0,11586686 97964-56-2	-	Lorglumide,	[P19] -0,341065195 82410-32-0	-	Ganciclovir,	[L07] 0,39412333
976-71-6	-	Canrenone,	[K21] 0,111687029 63659-19-8	-	Betaxolol	HCl,	[I07] -0,35013368 79660-72-3	-	Fleroxacin,	[J07] 0,392628319
130929-57-6	-	Entacapone,	[P15] 0,110277734 566-48-3	-	Formestane,	[J21] -0,360656017 53-03-2	-	Prednisone,	[I14] 0,384335819
1405-41-0	-	Gentamycin	sulfate,	[L11] 0,103777857 124750-99-8	-	Losartan	potassium,	[P21] -0,372897639 hsa-590,	[M01] 0,375542208
42924-53-8	-	Nabumetone,	[C14] 0,102608998 1400-61-9	-	Nystatin,	[E06] -0,373888014 581-88-4	-	Debrisoquin	sulfate,	[O10] 0,372067967
20559-55-1	-	Oxibendazole,	[E22] 0,09520962 112809-51-5	-	Letrozole,	[L22] -0,381782329 68-22-4	-	Norethindrone,	[C22] 0,369763564
103177-37-3	-	Pranlukast,	[H16] 0,090108291 121268-17-5	-	Alendronate,	[G15] -0,406090776 3778-73-2	-	Ifosfamide,	[N11] 0,368876935
74050-98-9	-	Ketanserin	tartrate,	[H18] 0,084848557 51-83-2	-	Carbamylcholine	Cl,	[J05] -0,411127504 18683-91-5	-	Ambroxol,	[D06] 0,364273864
3366-95-8	-	Secnidazole,	[M16] 0,081496637 hsa-199,	[E01] -0,417281921 107753-78-6	-	Zafirlukast,	[J10] 0,359247277
38776-75-9	-	Rifampicin,	[F12] 0,079890249 57-94-3	-	Tubocurarine	Cl		(+),	[D05] -0,428324267 114-70-5	-	Sodium	phenylacetate,	[P11] 0,357757116
10418-03-8	-	Stanozolol,	[O04] 0,078519346 53-43-0	-	Dehydroepiandrosterone,	[D03] -0,44331458 79547-78-7	-	Levocabastine	HCl,	[F18] 0,351282693
443-48-1	-	Metronidazole,	[A20] 0,074461639 58186-27-9	-	Idebenone,	[D08] -0,451331808 54-85-3	-	Isoniazid,	[J15] 0,350561629
599-79-1	-	Sulfasalazine,	[O14] 0,074404856 118072-93-8	-	Zoledronic	acid,	[O09] -0,451770743 10118-90-8	-	Minocycline	HCl,	[C04] 0,350320805
122892-31-3	-	Itopride	HCl,	[N17] 0,07111076 78110-38-0	-	Aztreonam,	[K09] -0,480088586 23672-07-3	-	Sulpiride	s	(-),	[F03] 0,333853837
23672-07-3	-	Sulpiride	s	(-),	[F03] 0,070182169 11032-41-0	-	Dihydroergotamine	mesylate,	[G21] -0,491436499 104632-26-0	-	Pramipexole,	[C15] 0,331739956
101828-21-1	-	Butenafine,	[P03] 0,060020937 3778-73-2	-	Ifosfamide,	[N11] -0,491756203 32672-69-8	-	Mesoridazine	besylate,	[H22]0,326750234
43210-67-9	-	Fenbendazole,	[H11] 0,056698719 55528-07-9	-	Butaclamol	(+),	[D07] -0,504549686 98-92-0	-	Medroxyprogesterone	17-acetate,	[A06]0,326170329
13523-86-9	-	Pindolol,	[I21] 0,054903314 125494-59-9	-	Sibutramine	HCl,	[M18] -0,506015826 21736-83-4	-	Spectinomycin,	[C03] 0,298182436
54-92-2	-	Iproniazid,	[F08] 0,053804696 hsa-199,	[F23] -0,508908801 120279-95-0	-	Dorzolamide,	[P05] 0,297194227
149676-40-4	-	Pefloxacine	mesylate,	[G10] 0,050507116 145781-92-6	-	Goserelin	acetate,	[D16] -0,509153387 60-31-1	-	Acetylcholine	Cl,	[B13] 0,290661668
50-27-1	-	Estriol,	[F19] 0,049606982 7481-89-2	-	2',3'	-	dideoxycytidine,	[D11] -0,513143925 hsa-590,	[M24] 0,28915566
1156-19-0	-	Tolazamide,	[L10] 0,049093588 6108-05-0	-	Lidocaine,	[E15] -0,514276821 55528-07-9	-	Butaclamol	(+),	[D07] 0,284616379
104-46-1	-	Anethole,	trans-,	[P20] 0,028810133 29520-14-7	-	Guanfacine	HCl,	[P21] -0,519672933 51-30-9	-	Isoproterenol	HCl	(rac),	[B11] 0,277837419
79-83-4	-	Pantothenic	acid,	[P08] 0,02750672 7414-83-7	-	Etidronate	2Na,	[H03] -0,523187098 54239-37-1	-	Cimaterol,	[K03] 0,266931882
118072-93-8	-	Zoledronic	acid,	[O09] 0,026488809 58066-85-6	-	Miltefosine,	[I16] -0,523540459 361-37-5	-	Methysergide,	[P04] 0,266781161
568-72-9	-	Tanshinone	iia,	[H08] 0,026301653 82571-53-7	-	Ozagrel,	[P13] -0,524072693 hsa-590,	[N02] 0,246671994
149-64-4	-	Scopolamine	n-butylbromide,	[M12] 0,026024137 68373-14-8	-	Sulbactam,	[E07] -0,526634466 87333-19-5	-	Ramipril,	[K12] 0,241214176
68-35-9	-	Sulfadiazine,	[O10] 0,023994775 3521-84-4	-	Meglumine,	[A06] -0,527288395 202409-33-4	-	Etoricoxib,	[A05] 0,240236223
80214-83-1	-	Roxithromycin,	[M06] 0,021163651 89197-32-0	-	Efaroxan,	[C16] -0,528248557 66357-59-3	-	Ranitidine	HCl,	[F09] 0,228665223
51-02-5	-	Pronethalol	HCl,	[K07] 0,015517442 69975-86-6	-	Doxofylline,	[F03] -0,544435369 3506-09-0	-	Propranolol,	[K22] 0,225299508
427-51-0	-	Cyproterone	acetate,	[B13] 0,01463297 88671-89-0	-	Myclobutanil,	[C10] -0,547174052 26921-17-5	-	Timolol	maleate	(s),	[I11] 0,225011634
30484-77-6	-	Flunarizine-2HCl,	[G22] 0,014008533 58-54-8	-	Ethacrynic	acid,	[M18] -0,548740348 101828-21-1	-	Butenafine,	[P03] 0,224412984
19453	-	Galanthamine	HBr,	[G04] 0,012356217 59729-33-8	-	Citalopram,	[O09] -0,558440733 105956-99-8	-	Clinafloxacin	HCl,	[O15] 0,216138241
69014-14-8	-	Tiotidine,	[O05] 0,012000553 79660-72-3	-	Fleroxacin,	[J07] -0,559936574 31431-39-7	-	Mebendazol,	[A04] 0,186876579
120511-73-1	-	Anastrozole,	[N10] 0,008951278 133-67-5	-	Trichloromethiazide,	[H07] -0,560844341 102767-28-2	-	Levetiracetam,	[L20] 0,173187671
19216-56-9	-	Prazosin	HCl,	[G09] 0,0066543 82410-32-0	-	Ganciclovir,	[L07] -0,562016377 51022-77-6	-	Etazolate,	[J08] 0,158899097
84371-65-3	-	Mifepristone,	[L22] 0,005916612 123441-03-2	-	Rivastigmine,	[H18] -0,56572917 85760-74-3	-	Quinpirole	HCl	(-)-,	[K18] 0,136524693
1677687	-	Pentoxifylline,	[G14] 0,005440114 21535-47-7	-	Mianserin	hcl,	[B03] -0,573209132 99614-01-4	-	Ondansetron,	[H16] 0,122283916
835-31-4	-	Naphazoline	HCl,	[C16] -0,00132272 16595-80-5	-	Levamisole	HCl,	[P03] -0,584923679 6055-19-2	-	Cyclophosphamide	monohydrate,	[B11]0,122281968
15291-75-5	-	Ginkgolide	a,	[P12] -0,012034754 65277-42-1	-	Ketoconazole,	[M06] -0,58588149 2447-57-6	-	Sulfadoxine,	[O08] 0,116590669
91296-87-6	-	Sarafloxacin	HCl,	[M10] -0,012103648 72599-27-0	-	Miglustat,	[N20] -0,5890872 42971-09-5	-	Vinpocetine,	[J22] 0,111681183
78110-38-0	-	Aztreonam,	[K09] -0,020488986 57808-65-8	-	Closantel,	[B05] -0,593423458 97322-87-7	-	Troglitazone,	[D22] 0,103005765
113-92-8	-	Chlorpheniramine	maleate,	[M21] -0,021062482 103745-39-7	-	Fasudil,	[E14] -0,598360581 196618-13-0	-	Oseltamivir,	[C11] 0,102876398
100-33-4	-	Pentamidine,	[J14] -0,023992084 139264-17-8	-	zolmitriptan,	[O13] -0,599968188 6119-47-7	-	Quinine,	[E05] 0,09471332
483-63-6	-	Crotamiton,	[B09] -0,024718794 530-78-9	-	Flufenamic	acid,	[E07] -0,601071802 315-30-0	-	Allopurinol,	[G13] 0,090970808
59052-16-3	-	Nalbuphine	HCl,	[J03] -0,029398627 90-05-1	-	Guaiacol,	[D18] -0,607560649 36330-85-5	-	Fenbufen,	[H13] 0,086750342
11032-41-0	-	Dihydroergotamine	mesylate,	[G21] -0,031489055 103628-48-4	-	Sumatriptan	Succinate,	[G21] -0,610451293 83905-01-5	-	Azithromycin,	[K07] 0,079605223
81-24-3	-	Taurocholic	acid,	sodium	salt	hydrate,	[N18]-0,038931011 212141-54-3	-	Vatalanib,	[C12] -0,611512753 10418-03-8	-	Stanozolol,	[O04] 0,074936541
97825-25-7	-	Ractopamine,	[N09] -0,040047532 22204-24-6	-	Pyrantel	pamoate,	[I22] -0,612863836 151615	-	Oxymetazoline	HCl,	[G03] 0,072894926
cel-67,	[L02] -0,049940331 32986-56-4	-	Tobramycin	(free	base),	[B16] -0,62215839 21462-39-5	-	Clindamycin	HCl,	[A05] 0,06824526
1791337	-	Carbadox,	[M03] -0,050325489 60-31-1	-	Acetylcholine	Cl,	[B13] -0,627600909 170729-80-3	-	Aprepitant,	[N12] 0,060959865
23210-56-2	-	Ifenprodil,	[G05] -0,051346974 69655-05-6	-	Didanosine,	[N20] -0,644257403 hsa-590,	[M02] 0,056322265
51-48-9	-	L-thyroxine	[(3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-l-alanine]	,	[P18]-0,060407206 97322-87-7	-	Troglitazone,	[D22] -0,657966358 11032-41-0	-	Dihydroergotamine	mesylate,	[G21]0,051849583
29094-61-9	-	Glipizide,	[C21] -0,071944773 51-30-9	-	Isoproterenol	HCl	(rac),	[B11] -0,670785271 88150-42-9	-	Amlodipine,	[G08] 0,047616509
184475-35-2	-	Gefitinib,	[A20] -0,074677374 64-47-1	-	Physostigmine	sulfate,	[M11] -0,672343485 84225-95-6	-	Raclopride	l-tartrate	s(-),	[D19]0,045067519
82571-53-7	-	Ozagrel,	[P13] -0,075264491 51322-75-9	-	Tizanidine	HCl,	[A04] -0,675038027 hsa-590,	[N23] 0,038374191
19982-08-2	-	Memantine	HCl,	[O15] -0,07540171 146-48-5	-	Yohimbine	HCl,	[G19] -0,677932247 51022-70-9	-	Salbutamol	sulfate,	[I19] 0,035448705
17902-23-7	-	Ftorafur,	[L03] -0,076960517 98079-52-8	-	Lomefloxacin	HCl,	[P15] -0,692524312 147221-93-0	-	Delavirdine	mesylate,	[F20] 0,031252743
51-83-2	-	Carbamylcholine	Cl,	[J05] -0,081029074 hsa-199,	[E23] -0,702867497 124858-35-1	-	Nadifloxacin,	[C12] 0,028958464
113806-05-6	-	Olopatadine,	[L09] -0,081105517 22071-15-4	-	Ketoprofen,	[B16] -0,70751917 611-75-6	-	Bromhexine	HCl,	[K17] 0,016792772
cel-67,	[C01] -0,084904974 13707-88-5	-	Alprenolol	HCl,	[H05] -0,707560924 64-77-7	-	Tolbutamide,	[C17] 0,006835664
62893-19-0	-	Cefoperazone	acid,	[M09] -0,08677488 84371-65-3	-	Mifepristone,	[L22] -0,70933524 51-02-5	-	Pronethalol	HCl,	[K07] -0,001153498
298-46-4	-	Carbamazepine,	[M07] -0,088463239 959-24-0	-	Sotalol	HCl,	[K09] -0,713839303 29122-68-7	-	Atenolol,	[I19] -0,00233951
145-13-1	-	Pregnenolone,	[I16] -0,089193093 90098-04-7	-	Rebamipide,	[K14] -0,725634053 599-79-1	-	Sulfasalazine,	[O14] -0,007528215
73-05-2	-	PhentolamineHCl,	[E03] -0,097285724 99011-02-6	-	Imiquimod,	[N13] -0,736507525 835-31-4	-	Naphazoline	HCl,	[C16] -0,016024473
68475-42-3	-	Anagrelide,	[C22] -0,102917286 33286-22-5	-	Diltiazem,	[G10] -0,745498294 95233-18-4	-	Atovaquone,	[N13] -0,017341099
125-69-9	-	Dextromethorphan	HBr,	[D07] -0,106208915 51022-70-9	-	Salbutamol	sulfate,	[I19] -0,750858038 hsa-590,	[M02] -0,021753695
54143-56-5	-	Flecainide,	[E17] -0,11175307 99614-01-4	-	Ondansetron,	[H16] -0,765147524 32986-56-4	-	Tobramycin	(free	base),	[B16]-0,023234437
642-72-8	-	Benzydamine,	[P22] -0,112052447 91161-71-6	-	Terbinafine	HCl,	[B20] -0,766450783 55-48-1	-	Atropine	sulfate,	[B15] -0,027607609
112964-99-5	-	Hydroxytacrine	maleate,	[E16] -0,115652495 143-67-9	-	Vinblastine	sulfate,	[K05] -0,776577294 84625-61-6	-	Itraconazole,	[N19] -0,036259406
53164-05-9	-	Acemetacin,	[E21] -0,117648753 136310-93-5	-	Tiotropium	Br,	[H20] -0,777185879 hsa-590,	[J02] -0,068043698
595-33-5	-	Megestrol	acetate,	[N04] -0,123384236 114-80-7	-	Neostigmine	Br,	[B21] -0,781648771 hsa-590,	[M23] -0,068070651
130636-43-0	-	Nifekalant	HCl,	[C07] -0,123740822 165800-03-3	-	Linezolid,	[L05] -0,784764623 hsa-590,	[M24] -0,08188818
49562-28-9	-	Fenofibrate,	[H19] -0,124095361 85760-74-3	-	Quinpirole	HCl	(-)-,	[K18] -0,785093388 hsa-590,	[I01] -0,09271933
cel-67,	[D02] -0,130108265 147221-93-0	-	Delavirdine	mesylate,	[F20] -0,795394913 hsa-590,	[J01] -0,095872649
79855-88-2	-	Trequinsin,	[J20] -0,134600169 38083-17-9	-	Climbazole,	[O13] -0,802451457 2898-76-2	-	Benzamil,	[F10] -0,110358276
cel-67,	[C24] -0,137344385 91296-87-6	-	Sarafloxacin	HCl,	[M10] -0,808775378 36322-90-4	-	Piroxicam,	[B06] -0,113652306
144689-63-4	-	Olmesartan,	[L17] -0,142566166 61-68-7	-	Mefenamic	acid,	[A08] -0,809375206 95734-82-0	-	Nedaplatin,	[P16] -0,128531384
63590-64-7	-	Terazosin	HCl,	[O22] -0,150704686 54965-21-8	-	Albendazole,	[G19] -0,819722068 21535-47-7	-	Mianserin	hcl,	[B03] -0,12933726
83905-01-5	-	Azithromycin,	[K07] -0,155876223 361-37-5	-	Methysergide,	[P04] -0,823362334 13707-88-5	-	Alprenolol	HCl,	[H05] -0,134565207
636-54-4	-	Clopamide,	[I22] -0,160119661 63-45-6	-	Primaquine	phosphate,	[I18] -0,830410781 hsa-590,	[I02] -0,146848507
76420-72-9	-	Enalaprilat,	[P04] -0,161454754 53164-05-9	-	Acemetacin,	[E21] -0,83668514 80288-49-9	-	Furafylline,	[B07] -0,152101331
132539-06-1	-	Olanzapine,	[N03] -0,162158647 63590-64-7	-	Terazosin	HCl,	[O22] -0,84003 113-92-8	-	Chlorpheniramine	maleate,	[M21]-0,15481155
25812-30-0	-	Gemfibrozil,	[L13] -0,163321896 1508-75-4	-	Tropicamide,	[M05] -0,841272619 83915-83-7	-	Lisinopril,	[P13] -0,17142516
85622-93-1	-	Temozolomide,	[B08] -0,17644662 36791-04-5	-	Ribavirin,	[K16] -0,844593638 37321-09-8	-	Apramycin,	[I15] -0,173339139
317-34-0	-	Aminophylline,	[B05] -0,187426532 132203-70-4	-	Cilnidipine,	[I08] -0,850022436 14611-51-9	-	Selegiline,	[C10] -0,176750791
73220-03-8	-	Remoxipride,	[K20] -0,189184507 52-01-7	-	Spironolactone,	[M22] -0,855770831 122-11-2	-	Sulfadimethoxine,	[O12] -0,178436599
119141-88-7	-	Esomeprazole	potassium,	[F15] -0,192786106 100490-36-6	-	Tosufloxacin,	[B18] -0,861442725 7177-48-2	-	Ampicillin	trihydrate,	[I11] -0,190826236
cel-67,	[D24] -0,192952657 15291-75-5	-	Ginkgolide	a,	[P12] -0,86190389 125494-59-9	-	Sibutramine	HCl,	[M18] -0,196507798
36330-85-5	-	Fenbufen,	[H13] -0,195019926 15500-66-0	-	Pancuronium	Br,	[M07] -0,876212441 62929-91-3	-	Procaterol	hcl,	[I17] -0,198344266
38304-91-5	-	Minoxidil,	[L08] -0,195443277 28797-61-7	-	Pirenzepine	2HCl,	[K21] -0,882041405 57076-71-8	-	Denbufylline,	[I14] -0,234022994
cel-67,	[K01] -0,201566758 38304-91-5	-	Minoxidil,	[L08] -0,883510551 119-36-8	-	Methyl	salicylate,	[H12] -0,241879713
39562-70-4	-	Nitrendipine,	[G16] -0,202115818 64-77-7	-	Tolbutamide,	[C17] -0,884962231 hsa-590,	[I01] -0,245490304
514-78-3	-	Canthaxanthin,	[K15] -0,206438943 79-83-4	-	Pantothenic	acid,	[P08] -0,886114404 797-63-7	-	Levonorgestrel,	[P05] -0,246177145
64490-92-2	-	Tolmetin	Na,	[D06] -0,213573042 60-56-0	-	Methimazole,	[A18] -0,89094017 18046-21-4	-	Fentiazac,	[J20] -0,248182942
21187-98-4	-	Gliclazide,	[L15] -0,217411329 98048-97-6	-	Fosinopril,	[P08] -0,895635428 443-48-1	-	Metronidazole,	[A20] -0,255441713
cel-67,	[K02] -0,220413672 149676-40-4	-	Pefloxacine	mesylate,	[G10] -0,911513144 64795-35-3	-	Mesulergine	HCl,	[H11] -0,255510458
311074	-	Troleandomycin,	[B10] -0,221976562 86386-73-4	-	Fluconazole,	[J19] -0,916021627 130929-57-6	-	Entacapone,	[P15] -0,256660455
cel-67,	[C02] -0,223655815 16170-76-6	-	Bromebric	acid,	[L16] -0,92366332 40600-13-3	-	Cirazoline	HCl,	[E21] -0,260849067
40600-13-3	-	Cirazoline	HCl,	[E21] -0,224298504 595-33-5	-	Megestrol	acetate,	[N04] -0,926294756 71125-38-7	-	Meloxicam,	[B18] -0,265688892
57-41-0	-	Phenytoin,	[E11] -0,229632061 5051-62-7	-	Guanabenz	acetate,	[G13] -0,93447803 78919-13-8	-	Iloprost,	[A19] -0,275204741
7240-38-2	-	Oxacillin	sodium	monohydrate,	[E18] -0,231512217 306-40-1	-	Succinylcholine,	[P14] -0,937621523 82571-53-7	-	Ozagrel,	[P13] -0,278271483
cel-67,	[C02] -0,236077837 1744-22-5	-	Riluzole	HCl,	[O19] -0,938379812 80809-81-0	-	Docebenone,	[O22] -0,278670897
23313-68-0	-	Verapamil,	[G18] -0,240250237 3506-09-0	-	Propranolol,	[K22] -0,960359158 63527-52-6	-	Cefotaxime	acid,	[M11] -0,30665489
6108-05-0	-	Lidocaine,	[E15] -0,251050494 745-65-3	-	Alprostadil,	[L08] -0,960489548 123441-03-2	-	Rivastigmine,	[H18] -0,327388459
41859-67-0	-	Bezafibrate,	[F04] -0,256409047 21462-39-5	-	Clindamycin	HCl,	[A05] -0,960809108 67227-56-9	-	Fenoldopam	mesylate,	[H15]-0,347932439
13010-47-4	-	Lomustine,	[A17] -0,257674321 52549-17-4	-	Pranoprofen,	[I04] -1,035034449 103177-37-3	-	Pranlukast,	[H16] -0,354019495
51481-61-9	-	Cimetidine,	[O03] -0,258227638 317-34-0	-	Aminophylline,	[B05] -1,040413045 14611-52-0	-	Deprenyl	HCl	r	(-),	[B08] -0,370527609
797-63-7	-	Levonorgestrel,	[P05] -0,272792767 30484-77-6	-	Flunarizine-2HCl,	[G22] -1,041281485 959-24-0	-	Sotalol	HCl,	[K09] -0,379334131
436349	-	Doxifluridine,	[D21] -0,275898497 581-88-4	-	Debrisoquin	sulfate,	[O10] -1,056625706 127045-41-4	-	Pazufloxacin,	[G08] -0,388350268
51-12-7	-	Nialamide,	[M13] -0,276668982 18683-91-5	-	Ambroxol,	[D06] -1,083626307 98048-97-6	-	Fosinopril,	[P08] -0,388839342
75847-73-3	-	Enalapril,	[F07] -0,278515509 19387-91-8	-	Tinidazole,	[B14] -1,086201817 595-33-5	-	Megestrol	acetate,	[N04] -0,393836926
53902-12-8	-	Tranilast,	[K08] -0,293802316 53643-48-4	-	Vindesine,	[E15] -1,09226914 hsa-590,	[I02] -0,42211626
cel-67,	[C23] -0,294205076 32672-69-8	-	Mesoridazine	besylate,	[H22] -1,101380063 72558-82-8	-	Ceftazidime,	[M13] -0,449488114
161814-49-9	-	Amprenavir,	[N10] -0,301588332 443-48-1	-	Metronidazole,	[A20] -1,110344108 56296-78-7	-	Fluoxetine	HCl,	[H14] -0,455471603
99614-01-4	-	Ondansetron,	[H16] -0,309170362 60142-96-3	-	Gabapentin,	[I04] -1,134776175 58186-27-9	-	Idebenone,	[D08] -0,455888783
120279-95-0	-	Dorzolamide,	[P05] -0,314167466 98319-26-7	-	Finasteride,	[H21] -1,138215345 50-07-7	-	Mitomycin	c,	[F16] -0,460435245
6055-19-2	-	Cyclophosphamide	monohydrate,	[B11] -0,327530719 112529-15-4	-	Pioglitazone,	[H14] -1,138774803 73231-34-2	-	Florfenicol,	[J09] -0,463018668
15500-66-0	-	Pancuronium	Br,	[M07] -0,329886464 13311-84-7	-	Flutamide,	[J17] -1,144640159 NA	-	Pravastatin	lactone,	[G22] -0,47295972
84225-95-6	-	Raclopride	l-tartrate	s(-),	[D19] -0,332780175 123948-87-8	-	Topotecan,	[B20] -1,15963749 1677687	-	Pentoxifylline,	[G14] -0,490047842
1986-47-6	-	Tranylcypromine,	[B04] -0,334099985 42971-09-5	-	Vinpocetine,	[J22] -1,16889753 114084-78-5	-	Ibandronate,	[A13] -0,49881485
637-07-0	-	Clofibrate,	[O04] -0,3356481 28860-95-9	-	Carbidopa,	[B12] -1,174519375 129-46-4	-	Suramin	sodium,	[D14] -0,499958374
60607-34-3	-	Oxatomide,	[M08] -0,341745518 1405-54-5	-	Tylosin	tartrate,	[D18] -1,185060347 15826-37-6	-	Disodium	cromoglycate,	[M10]- ,500818948
22204-53-1	-	Naproxen,	[M22] -0,344590429 196618-13-0	-	Oseltamivir,	[C11] -1,203522933 75706-12-6	-	Leflunomide,	[P11] -0,512370189
6998-60-3	-	Rifamycin	sv,	[C19] -0,35219622 61477-96-1	-	Piperacillin,	[G20] -1,204427196 79855-88-2	-	Trequinsin,	[J20] -0,534048075
59-92-7	-	Levodopa,	[P07] -0,369646985 6119-47-7	-	Quinine,	[E05] -1,220863147 63-92-3	-	Phenoxybenzamine	HCl,	[I10] -0,541574066
54063-53-5	-	Propafenone,	[E09] -0,370979721 2963-78-2	-	Butyrylcholine	Cl,	[J09] -1,221848311 28860-95-9	-	Carbidopa,	[B12] -0,54374821
109889-09-0	-	Granisetron,	[P14] -0,379954078 139755-83-2	-	Sildenafil,	[N11] -1,223199999 38083-17-9	-	Climbazole,	[O13] -0,551440338
21736-83-4	-	Spectinomycin,	[C03] -0,380467194 95734-82-0	-	Nedaplatin,	[P16] -1,224670795 162011-90-7	-	Rofecoxib,	[H20] -0,552662148
133040-01-4	-	Eprosartan,	[P09] -0,38659441 112964-99-5	-	Hydroxytacrine	maleate,	[E16] -1,225616785 73220-03-8	-	Remoxipride,	[K20] -0,553957529
79944-56-2	-	Idazoxan,	[F13] -0,391273085 71125-38-7	-	Meloxicam,	[B18] -1,232756061 120511-73-1	-	Anastrozole,	[N10] -0,557409038
40391-99-9	-	Pamidronic	acid,	[C13] -0,399324231 64221-86-9	-	Imipenem,	[A15] -1,25379485 65277-42-1	-	Ketoconazole,	[M06] -0,563728919
119302-91-9	-	Rocuronium	bromide,	[E03] -0,424803994 132-98-9	-	Pencillin	v	potassium,	[G16] -1,255494996 50-40-1	-	Norepinephrine-(+)-tartrate	l	(-),	[F21]-0,581358009
103628-48-4	-	Sumatriptan	Succinate,	[G21] -0,434981629 749-13-3	-	Trifluperidol	2HCl,	[P16] -1,257183003 198904-31-3	-	Atazanavir,	[P22] -0,599449971
cel-67,	[K02] -0,437809336 124858-35-1	-	Nadifloxacin,	[C12] -1,25834064 136310-93-5	-	Tiotropium	Br,	[H20] -0,605480858
88150-42-9	-	Amlodipine,	[G08] -0,446936376 101477-55-8	-	Lomerizine	HCl,	[A21] -1,261545763 134308-13-7	-	Tolcapone,	[L13] -0,607535929
119-36-8	-	Methyl	salicylate,	[H12] -0,448984639 826-39-1	-	Mecamylamine	HCl,	[B19] -1,261704604 37762-06-4	-	Zaprinast,	[L04] -0,612305786
37148-27-9	-	Clenbuterol,	[I15] -0,453561805 62658-64-4	-	Bopindolol	malonate,	[P19] -1,26353201 31879-05-7	-	Fenoprofen,	[H17] -0,639815733
90-69-7	-	Lobeline,	[E08] -0,467339262 81147-92-4	-	Esmolol,	[P06] -1,266040922 31430-15-6	-	Flubendazole,	[J15] -0,662665877
60-31-1	-	Acetylcholine	Cl,	[B13] -0,468952086 hsa-199,	[F01] -1,270962252 212141-54-3	-	Vatalanib,	[C12] -0,662791431
31431-39-7	-	Mebendazol,	[A04] -0,484262689 17902-23-7	-	Ftorafur,	[L03] -1,286695555 749-13-3	-	Trifluperidol	2HCl,	[P16] -0,669513898
112965-21-6	-	Calcipotriene,	[J08] -0,486324241 57076-71-8	-	Denbufylline,	[I14] -1,288193404 147-24-0	-	Diphenhydramine	HCl,	[F05] -0,669738934
183321-74-6	-	Erlotinib,	[E06] -0,486976046 115956-12-2	-	Dolasetron,	[N22] -1,300456305 hsa-590,	[I24] -0,67299733
611-75-6	-	Bromhexine	HCl,	[K17] -0,493432127 31430-15-6	-	Flubendazole,	[J15] -1,30247477 311074	-	Troleandomycin,	[B10] -0,708050606
04199-10-4	-	Propranolol	HCl	s(-),	[A08] -0,503062216 100986-85-4	-	Levofloxacin	HCl,	[P09] -1,302677415 hsa-590,	[M01] -0,716870373
14611-52-0	-	Deprenyl	HCl	r	(-),	[B08] -0,505599711 1951-25-3	-	Amiodarone,	[C07] -1,325156323 158966-92-8	-	Montelukast,	[C08] -0,728338128
106266-06-2	-	Risperidone,	[D21] -0,520540719 80809-81-0	-	Docebenone,	[O22] -1,357386141 154-21-2	-	Lincomycin,	[A13] -0,729413771
165800-03-3	-	Linezolid,	[L05] -0,528863899 92623-83-1	-	Pravadoline,	[K06] -1,379853661 16320-04-0	-	Gestrinone,	[L15] -0,744625315
54965-21-8	-	Albendazole,	[G19] -0,532780846 hsa-199,	[F24] -1,38395237 555-30-6	-	Methyldopa,	[A12] -0,762136485
28797-61-7	-	Pirenzepine	2HCl,	[K21] -0,533077761 5786-21-0	-	Clozapine,	[K14] -1,392476705 63659-19-8	-	Betaxolol	HCl,	[I07] -0,780914978
113712-98-4	-	Tenatoprazole,	[B06] -0,533967404 6673-35-4	-	Practolol,	[I09] -1,393070009 59-92-7	-	Levodopa,	[P07] -0,782230458
891986	-	Dacarbazine,	[B19] -0,535239734 105816-04-4	-	nateglinide,	[B09] -1,411916296 36791-04-5	-	Ribavirin,	[K16] -0,788946307
154598-52-4	-	Efavirenz,	[N16] -0,550248761 198904-31-3	-	Atazanavir,	[P22] -1,415167689 111469-81-9	-	Naltrindole	HCl,	[F11] -0,793651934
434-03-7	-	Ethisterone,	[F13] -0,556741248 83366-66-9	-	Nefazodone,	[C18] -1,417567442 83366-66-9	-	Nefazodone,	[C18] -0,802636812
959-24-0	-	Sotalol	HCl,	[K09] -0,566697416 100643-71-8	-	Desloratadine,	[D05] -1,418495261 112809-51-5	-	Letrozole,	[L22] -0,822837946
cel-67,	[D02] -0,568527097 50-63-5	-	Chloroquine	phosphate,	[O03] -1,432058995 34911-55-2	-	Amfebutamone,	[H13] -0,839694225
1405-10-3	-	Neomycin	sulfate,	[O16] -0,570278376 50-41-9	-	Clomiphene	citrate,	[O17] -1,441835054 51481-61-9	-	Cimetidine,	[O03] -0,846714802
2963-78-2	-	Butyrylcholine	Cl,	[J09] -0,57134726 59122-46-2	-	Misoprostol,	[L10] -1,452170601 49745-95-1	-	Dobutamine	HCl,	[K05] -0,85961058
100986-85-4	-	Levofloxacin	HCl,	[P09] -0,579564068 38194-50-2	-	Sulindac,	[J04] -1,454873498 100986-85-4	-	Levofloxacin	HCl,	[P09] -0,877983481
24730-10-7	-	Dihydroergocristine	mesylate,	[H10] -0,581811963 311074	-	Troleandomycin,	[B10] -1,463718285 58-33-3	-	Promethazine	HCl,	[F07] -0,881993356
72432-10-1	-	Aniracetam,	[O17] -0,584614227 66104-23-2	-	Pergolide	mesylate,	[D17] -1,46500608 30484-77-6	-	Flunarizine-2HCl,	[G22] -0,911073825
57773-63-4	-	Triptorelin,	[C17] -0,584880847 183321-74-6	-	Erlotinib,	[E06] -1,476457881 60-56-0	-	Methimazole,	[A18] -0,919903827
cel-67,	[K01] -0,598924171 50-78-2	-	Acetylsalicylic	acid,	[G03] -1,483828438 6998-60-3	-	Rifamycin	sv,	[C19] -0,924677865
83915-83-7	-	Lisinopril,	[P13] -0,599594552 NA	-	Pravastatin	lactone,	[G22] -1,498193703 101477-55-8	-	Lomerizine	HCl,	[A21] -0,93458154
1405-54-5	-	Tylosin	tartrate,	[D18] -0,599735541 57754-86-6	-	Nisoxetine	HCl,	[K13] -1,503093003 100-33-4	-	Pentamidine,	[J14] -0,939989012
114977-28-5	-	Docetaxil,	[L07] -0,602192209 97825-25-7	-	Ractopamine,	[N09] -1,503119877 5536-17-4	-	Vidarabine,	[F06] -0,947133612
302-22-7	-	Chlormadinone	acetate,	[M17] -0,607319564 114084-78-5	-	Ibandronate,	[A13] -1,539283885 13311-84-7	-	Flutamide,	[J17] -0,957814004
93957-54-1	-	Fluvastatin	Na,	[P06] -0,614154087 105462-24-6	-	Risedronic	acid,	[C21] -1,554322941 2016-88-8	-	Amiloride,	[G06] -0,973227024
614-39-1	-	Procainamide,	[E13] -0,617517568 72432-10-1	-	Aniracetam,	[O17] -1,563642373 98319-26-7	-	Finasteride,	[H21] -0,97831354
101975-10-4	-	Zardaverine,	[L06] -0,617698075 322-35-0	-	Benserazide	HCl,	[O08] -1,575733623 hsa-590,	[N24] -0,979997541
67121-76-0	-	Fluperlapine,	[H12] -0,629754486 73-05-2	-	PhentolamineHCl,	[E03] -1,582528642 51322-75-9	-	Tizanidine	HCl,	[A04] -0,989058606
76824-35-6	-	Famotidine,	[J11] -0,630156127 1166-34-3	-	Cinanserin,	[H06] -1,583609012 113-52-0	-	Imipramine	HCl,	[H07] -1,016590645
85371-64-8	-	Pinacidil,	[C19] -0,632789715 109889-09-0	-	Granisetron,	[P14] -1,585116635 483-63-6	-	Crotamiton,	[B09] -1,017850262
143-67-9	-	Vinblastine	sulfate,	[K05] -0,633328025 76420-72-9	-	Enalaprilat,	[P04] -1,601952696 97825-25-7	-	Ractopamine,	[N09] -1,023578168
54-42-2	-	Idoxuridine,	[N09] -0,638773301 56296-78-7	-	Fluoxetine	HCl,	[H14] -1,645272062 5051-62-7	-	Guanabenz	acetate,	[G13] -1,029815006
114-49-8	-	Scopolamine	HBr,	[M14] -0,650309754 2016-88-8	-	Amiloride,	[G06] -1,648614792 109889-09-0	-	Granisetron,	[P14] -1,03613347
38083-17-9	-	Climbazole,	[O13] -0,656393624 73231-34-2	-	Florfenicol,	[J09] -1,666252266 21498-08-8	-	Lofexidine,	[C03] -1,044167622
83366-66-9	-	Nefazodone,	[C18] -0,666548125 6998-60-3	-	Rifamycin	sv,	[C19] -1,674714134 hsa-590,	[J24] -1,054713283
2016-88-8	-	Amiloride,	[G06] -0,666669358 1421-86-9	-	Strychnine	HCl,	[D03] -1,678137245 hsa-590,	[N02] -1,062754296
39809-25-1	-	Penciclovir,	[G12] -0,672093815 127045-41-4	-	Pazufloxacin,	[G08] -1,683305415 71-82-9	-	Levallorphan	tartrate,	[H21] -1,078257288
86386-73-4	-	Fluconazole,	[J19] -0,674102666 78755-81-4	-	Flumazenil,	[A16] -1,690959102 79944-56-2	-	Idazoxan,	[F13] -1,086629011
826-39-1	-	Mecamylamine	HCl,	[B19] -0,684680357 71-82-9	-	Levallorphan	tartrate,	[H21] -1,714973342 110429-49-8	-	Paroxetine	HCl,	[G06] -1,089806882
102767-28-2	-	Levetiracetam,	[L20] -0,688801711 98-92-0	-	Medroxyprogesterone	17-acetate,	[A06] -1,741997839 77883-43-3	-	Doxazosin	mesylate,	[D19] -1,098933579
100490-36-6	-	Tosufloxacin,	[B18] -0,69314901 14611-52-0	-	Deprenyl	HCl	r	(-),	[B08] -1,749569803 50-12-4	-	Mephenytoin,	[J22] -1,142884208
36791-04-5	-	Ribavirin,	[K16] -0,697234576 90357-06-5	-	Bicalutamide,	[N12] -1,769176353 90-69-7	-	Lobeline,	[E08] -1,157912651
41570-61-0	-	Tulobuterol,	[E11] -0,706828959 83905-01-5	-	Azithromycin,	[K07] -1,778254325 61477-96-1	-	Piperacillin,	[G20] -1,165454768
54239-37-1	-	Cimaterol,	[K03] -0,712215772 130209-82-4	-	Latanoprost,	[I18] -1,779775843 89197-32-0	-	Efaroxan,	[C16] -1,173074861
169590-42-5	-	Celecoxib,	[L18] -0,722442093 89796-99-6	-	Aceclofenac,	[G07] -1,795680615 23210-56-2	-	Ifenprodil,	[G05] -1,18952063
145781-92-6	-	Goserelin	acetate,	[D16] -0,722588132 120279-95-0	-	Dorzolamide,	[P05] -1,815190129 33386-08-2	-	Buspirone	HCl,	[K19] -1,223120398
cel-67,	[K24] -0,723649422 79944-56-2	-	Idazoxan,	[F13] -1,856661813 11018-89-6	-	Ouabain,	[I20] -1,262421655
14028-44-5	-	Amoxapine,	[H09] -0,739356134 14611-51-9	-	Selegiline,	[C10] -1,866395216 52-01-7	-	Spironolactone,	[M22] -1,265993601
63-45-6	-	Primaquine	phosphate,	[I18] -0,75016066 1476-53-5	-	Novobiocin	Na,	[A19] -1,870570406 35208-55-0	-	Clindamycin	PO4,	[A07] -1,28486691
6138-79-0	-	Trans-triprolidine	HCl,	[M21] -0,751282498 81409-90-7	-	Cabergoline,	[A09] -1,906878094 551-11-1	-	Dinoprost,	[E12] -1,295078568
57808-66-9	-	Domperidone,	[D13] -0,754385523 57149-07-2	-	Naftopidil	2HCl,	[G07] -1,939671555 2038-35-9	-	Phenamil,	[E19] -1,302746748
NA	-	Pravastatin	lactone,	[G22] -0,766208084 202409-33-4	-	Etoricoxib,	[A05] -1,968293625 54143-56-5	-	Flecainide,	[E17] -1,329556492
17360-35-9	-	Oxotremorine	sesquifumarate,	[E18] -0,772369186 302-22-7	-	Chlormadinone	acetate,	[M17] -1,98079901 10238-21-8	-	Glyburide,	[L06] -1,357688701
55268-74-1	-	Praziquantel,	[I20] -0,783404738 797-63-7	-	Levonorgestrel,	[P05] -1,984362478 64221-86-9	-	Imipenem,	[A15] -1,362001169
101477-55-8	-	Lomerizine	HCl,	[A21] -0,796105873 170729-80-3	-	Aprepitant,	[N12] -1,999656425 59-33-6	-	Mepyramine	maleate,	[M19] -1,421407571
566-48-3	-	Formestane,	[J21] -0,810531026 31431-39-7	-	Mebendazol,	[A04] -2,009480338 3521-84-4	-	Meglumine,	[A06] -1,426254449
147416-96-4	-	Telenzepine	2HCl,	[M03] -0,811662777 79794-75-5	-	Loratadine,	[P17] -2,020568205 04199-10-4	-	Propranolol	HCl	s(-),	[A08] -1,43461035
cel-67,	[C24] -0,813816167 90-69-7	-	Lobeline,	[E08] -2,131981149 115256-11-6	-	Dofetilide,	[E04] -1,45972104
73231-34-2	-	Florfenicol,	[J09] -0,814072265 115256-11-6	-	Dofetilide,	[E04] -2,138750805 130636-43-0	-	Nifekalant	HCl,	[C07] -1,474615843
49745-95-1	-	Dobutamine	HCl,	[K05] -0,815238512 10347-81-6	-	Maprotiline	HCl,	[K11] -2,209739089 30516-87-1	-	3'-azido-3'-deoxythymidine,	[G11]-1,477110815
22254-24-6	-	Ipratropium	Br,	[K19] -0,817314997 51-40-1	-	Epinephrine-(+)-tartrate	l	(-),	[F17] -2,246889065 129-03-3	-	Cyproheptadine,	[P20] -1,498809598
51-21-8	-	5-fluorouracil,	[J03] -0,829799693 427-51-0	-	Cyproterone	acetate,	[B13] -2,271608412 100490-36-6	-	Tosufloxacin,	[B18] -1,507801847
21498-08-8	-	Lofexidine,	[C03] -0,838711802 89778-26-7	-	Toremifene,	[B22] -2,283126642 19982-08-2	-	Memantine	HCl,	[O15] -1,540496108
1508-75-4	-	Tropicamide,	[M05] -0,84652753 101828-21-1	-	Butenafine,	[P03] -2,331358931 38194-50-2	-	Sulindac,	[J04] -1,591787763
58186-27-9	-	Idebenone,	[D08] -0,848398024 184475-35-2	-	Gefitinib,	[A20] -2,373120238 112529-15-4	-	Pioglitazone,	[H14] -1,616708692
cel-67,	[L23] -0,855115688 104-46-1	-	Anethole,	trans-,	[P20] -2,383558138 302-22-7	-	Chlormadinone	acetate,	[M17]-1,637449587
4394-00-7	-	Niflumic	acid,	[C20] -0,857204735 74050-98-9	-	Ketanserin	tartrate,	[H18] -2,38879806 1054-88-2	-	Spiroxatrine,	[G17] -1,665680424
59865-13-3	-	Cyclosporin	a,	[A09] -0,858032594 100-33-4	-	Pentamidine,	[J14] -2,412628085 hsa-590,	[J01] -1,665836394
3506-09-0	-	Propranolol,	[K22] -0,85855482 749-02-0	-	Spiperone,	[F15] -2,436538178 642-72-8	-	Benzydamine,	[P22] -1,709894199
22260-51-1	-	Bromocriptine	mesylate,	[K12] -0,864034657 67121-76-0	-	Fluperlapine,	[H12] -2,460628089 54350-48-0	-	Etretinate,	[H05] -1,746097802
68-96-2	-	17-	hydroxyprogesterone,	[N07] -0,864679195 51022-77-6	-	Etazolate,	[J08] -2,463830637 153559-49-0	-	Bexarotene,	[L14] -1,787866005
103890-78-4	-	Lacidipine,	[L21] -0,869600228 363-24-6	-	Dinoprostone,	[C18] -2,476824035 105826-92-4	-	Tropisetron	HCl,	[D16] -1,804342404
27848-84-6	-	Nicergoline,	[I03] -0,875258394 111469-81-9	-	Naltrindole	HCl,	[F11] -2,489457037 26786-84-5	-	Lomofungin,	[A15] -1,812080389
2068-78-2	-	Vincristine	sulfate,	[E19] -0,885667477 13010-47-4	-	Lomustine,	[A17] -2,54993727 184475-35-2	-	Gefitinib,	[A20] -1,816591498
71125-38-7	-	Meloxicam,	[B18] -0,921364871 120092-68-4	-	Manidipine,	[L11] -2,550663851 43210-67-9	-	Fenbendazole,	[H11] -1,898295264
67227-56-9	-	Fenoldopam	mesylate,	[H15] -0,927783402 54239-37-1	-	Cimaterol,	[K03] -2,562222457 56392-17-7	-	Metoprolol	tartrate,	[A16] -1,902626603
153559-49-0	-	Bexarotene,	[L14] -0,935406248 59-33-6	-	Mepyramine	maleate,	[M19] -2,587093809 128196-01-0	-	Escitalopram,	[P07] -1,917032925
66104-23-2	-	Pergolide	mesylate,	[D17] -0,947062621 2919-66-6	-	Melengestrol	acetate,	[N06] -2,594598727 749-02-0	-	Spiperone,	[F15] -2,024325568
54350-48-0	-	Etretinate,	[H05] -0,952829386 147536-97-8	-	Bosentan,	[N14] -2,601439988 50-41-9	-	Clomiphene	citrate,	[O17] -2,12579507
50-40-1	-	Norepinephrine-(+)-tartrate	l	(-),	[F21] -0,953547919 26786-84-5	-	Lomofungin,	[A15] -2,606871141 106266-06-2	-	Risperidone,	[D21] -2,133518701
314-19-2	-	Apomorphine	r	(-),	[D09] -0,977192411 54143-56-5	-	Flecainide,	[E17] -2,622420361 78755-81-4	-	Flumazenil,	[A16] -2,149517138
123948-87-8	-	Topotecan,	[B20] -0,990979967 103890-78-4	-	Lacidipine,	[L21] -2,65149149 hsa-590,	[N24] -2,162857949
5051-62-7	-	Guanabenz	acetate,	[G13] -0,994451276 35208-55-0	-	Clindamycin	PO4,	[A07] -2,66065464 111555-58-9	-	Naltriben	mesylate,	[H17] -2,223640301
77883-43-3	-	Doxazosin	mesylate,	[D19] -1,022179258 169590-42-5	-	Celecoxib,	[L18] -2,672098898 1684-40-8	-	Tacrine	HCl,	[E20] -2,232752482
cel-67,	[L24] -1,023577353 51037-30-0	-	Acipimox,	[G05] -2,789680891 92623-83-1	-	Pravadoline,	[K06] -2,260238205
10347-81-6	-	Maprotiline	HCl,	[K11] -1,027217886 2898-76-2	-	Benzamil,	[F10] -2,805641671 6138-79-0	-	Trans-triprolidine	HCl,	[M21] -2,274732956
73573-88-3	-	Mevastatin,	[D10] -1,027217886 04199-10-4	-	Propranolol	HCl	s(-),	[A08] -2,806418239 102625-70-7	-	Pantoprazole,	[G04] -2,276655126
115256-11-6	-	Dofetilide,	[E04] -1,035700525 23210-56-2	-	Ifenprodil,	[G05] -2,82127001 148-82-3	-	Melphalan,	[A10] -2,277761115
65-29-2	-	Gallamine	triethiodide,	[E22] -1,040520287 71486-22-1	-	Vinorelbine,	[E13] -2,8251249 57754-86-6	-	Nisoxetine	HCl,	[K13] -2,280047479
84057-84-1	-	Lamotrigine,	[N07] -1,047898552 37148-27-9	-	Clenbuterol,	[I15] -2,833813194 50847-11-5	-	Ibudilast,	[A22] -2,332484429
cel-67,	[K23] -1,054079897 62571-86-2	-	Captopril,	[O20] -2,838303491 81409-90-7	-	Cabergoline,	[A09] -2,380815837
129-46-4	-	Suramin	sodium,	[D14] -1,069543081 89365-50-4	-	Salmeterol,	[E17] -2,884195419 59122-46-2	-	Misoprostol,	[L10] -2,402881382
82009-34-5	-	Cilastatin,	[L14] -1,074002476 54350-48-0	-	Etretinate,	[H05] -2,914658277 130-61-0	-	Thioridazine	HCl,	[J04] -2,414101818
59-33-6	-	Mepyramine	maleate,	[M19] -1,074916624 3160-91-6	-	Moroxydine	HCl,	[A03] -2,965613551 76420-72-9	-	Enalaprilat,	[P04] -2,431565975
51022-77-6	-	Etazolate,	[J08] -1,08894672 65899-73-2	-	Tioconazole,	[B12] -2,970048554 89778-26-7	-	Toremifene,	[B22] -2,597731643
98319-26-7	-	Finasteride,	[H21] -1,095426461 39562-70-4	-	Nitrendipine,	[G16] -2,971233754 62658-64-4	-	Bopindolol	malonate,	[P19] -2,611758606
551-11-1	-	Dinoprost,	[E12] -1,09617521 23313-68-0	-	Verapamil,	[G18] -2,974028042 66085-59-4	-	Nimodipine,	[G14] -2,620744011
51-40-1	-	Epinephrine-(+)-tartrate	l	(-),	[F17] -1,106558134 51-21-8	-	5-fluorouracil,	[J03] -2,982927387 59729-33-8	-	Citalopram,	[O09] -2,657951477
54527-84-3	-	Nicardipine,	[C09] -1,116519874 66085-59-4	-	Nimodipine,	[G14] -3,002838527 57149-07-2	-	Naftopidil	2HCl,	[G07] -2,663215036
14838-15-4	-	Phenylpropanolamine,	[P12] -1,148296945 78919-13-8	-	Iloprost,	[A19] -3,032603953 5786-21-0	-	Clozapine,	[K14] -2,66960054
50847-11-5	-	Ibudilast,	[A22] -1,148756185 1684-40-8	-	Tacrine	HCl,	[E20] -3,044986375 75330-75-5	-	Lovastatin,	[N05] -2,809163071
440-17-5	-	Trifluoperazine,	[I12] -1,173378168 14028-44-5	-	Amoxapine,	[H09] -3,108226496 13010-47-4	-	Lomustine,	[A17] -2,870360074
31430-15-6	-	Flubendazole,	[J15] -1,173749841 68-26-8	-	Vitamin	a	(acetate),	[H19] -3,157729971 152459-95-5	-	Imatinib,	[C04] -2,890810847
57-83-0	-	Progesterone,	[I08] -1,189538872 54063-53-5	-	Propafenone,	[E09] -3,158585744 73573-88-3	-	Mevastatin,	[D10] -2,929328729
100643-71-8	-	Desloratadine,	[D05] -1,212810843 74764-40-2	-	Bepridil,	[C05] -3,193818168 63-45-6	-	Primaquine	phosphate,	[I18] -2,951019093
23110-15-8	-	Fumagillone,	[C14] -1,214283429 64228-81-5	-	Atracurium	besylate,	[I21] -3,207120814 114977-28-5	-	Docetaxil,	[L07] -3,002668994
517-	89-	5	-	Shikonin,	[K10] -1,224012698 129453-61-8	-	Fulvestrant,	[N22] -3,231023549 79794-75-5	-	Loratadine,	[P17] -3,006670087
129453-61-8	-	Fulvestrant,	[N22] -1,231789035 111555-58-9	-	Naltriben	mesylate,	[H17] -3,269513893 39562-70-4	-	Nitrendipine,	[G16] -3,051419207
57076-71-8	-	Denbufylline,	[I14] -1,233008902 302-79-4	-	Retinoic	acid,	[D20] -3,36237223 2068-78-2	-	Vincristine	sulfate,	[E19] -3,100434686
51322-75-9	-	Tizanidine	HCl,	[A04] -1,23379549 50847-11-5	-	Ibudilast,	[A22] -3,38043317 57-83-0	-	Progesterone,	[I08] -3,19974392
54187-04-1	-	Rilmenidine	hemifumarate,	[G15] -1,267511088 53-03-2	-	Prednisone,	[I14] -3,399520597 74050-98-9	-	Ketanserin	tartrate,	[H18] -3,231846084
541-22-0	-	Decamethonium	2Br,	[B17] -1,269304293 60607-34-3	-	Oxatomide,	[M08] -3,402773897 93957-54-1	-	Fluvastatin	Na,	[P06] -3,250168009
51-30-9	-	Isoproterenol	HCl	(rac),	[B11] -1,270867867 129722-12-9	-	Aripiprazole,	[N19] -3,416495483 3160-91-6	-	Moroxydine	HCl,	[A03] -3,280695306
645-05-6	-	Altretamine,	[G17] -1,293072107 130-61-0	-	Thioridazine	HCl,	[J04] -3,429824789 20559-55-1	-	Oxibendazole,	[E22] -3,293489262
30516-87-1	-	3'-azido-3'-deoxythymidine,	[G11] -1,302520579 106266-06-2	-	Risperidone,	[D21] -3,482148219 78213-63-5	-	Piribedil	HCl,	[M17] -3,327089703
130209-82-4	-	Latanoprost,	[I18] -1,323116231 114977-28-5	-	Docetaxil,	[L07] -3,495714142 71486-22-1	-	Vinorelbine,	[E13] -3,32867328
72656-09-3	-	Carvedilol,	[A10] -1,346272005 57-83-0	-	Progesterone,	[I08] -3,517228452 130209-82-4	-	Latanoprost,	[I18] -3,397512212
60-56-0	-	Methimazole,	[A18] -1,36119697 78213-63-5	-	Piribedil	HCl,	[M17] -3,540246393 74764-40-2	-	Bepridil,	[C05] -3,412328291
85760-74-3	-	Quinpirole	HCl	(-)-,	[K18] -1,361676351 404-86-4	-	Capsaicin,	[M12] -3,569897527 132203-70-4	-	Cilnidipine,	[I08] -3,44522634
61825-94-3	-	Oxaliplatin,	[P18] -1,369481951 1054-88-2	-	Spiroxatrine,	[G17] -3,607429169 23313-68-0	-	Verapamil,	[G18] -3,477658618
128196-01-0	-	Escitalopram,	[P07] -1,390020368 63968-64-9	-	Artemisinin,	[I17] -3,612426618 54187-04-1	-	Rilmenidine	hemifumarate,	[G15]-3,488602789
104227-87-4	-	Famciclovir,	[H09] -1,401334444 33069-62-4	-	Taxol,	[C08] -3,641439376 58-54-8	-	Ethacrynic	acid,	[M18] -3,50720529
148-82-3	-	Melphalan,	[A10] -1,434669569 22260-51-1	-	Bromocriptine	mesylate,	[K12] -3,649239777 745-65-3	-	Alprostadil,	[L08] -3,527813806
68-22-4	-	Norethindrone,	[C22] -1,479028802 110429-49-8	-	Paroxetine	HCl,	[G06] -3,688151221 129453-61-8	-	Fulvestrant,	[N22] -3,572332423
63659-19-8	-	Betaxolol	HCl,	[I07] -1,484841191 5630-53-5	-	Tibolone,	[B10] -3,692517542 63968-64-9	-	Artemisinin,	[I17] -3,577053412
61477-96-1	-	Piperacillin,	[G20] -1,494001563 314-19-2	-	Apomorphine	r	(-),	[D09] -3,702036341 65899-73-2	-	Tioconazole,	[B12] -3,583471247
2898-76-2	-	Benzamil,	[F10] -1,507490748 54527-84-3	-	Nicardipine,	[C09] -3,732284197 54527-84-3	-	Nicardipine,	[C09] -3,595213852
53643-48-4	-	Vindesine,	[E15] -1,527753385 60628-96-8	-	Bifonazole,	[K13] -3,73572177 35898-87-4	-	Dilazep,	[A11] -3,610930012
36322-90-4	-	Piroxicam,	[B06] -1,557661207 30516-87-1	-	3'-azido-3'-deoxythymidine,	[G11] -3,744140752 68-96-2	-	17-	hydroxyprogesterone,	[N07]-3,759522452
50-41-9	-	Clomiphene	citrate,	[O17] -1,598549584 20559-55-1	-	Oxibendazole,	[E22] -3,769248473 64228-81-5	-	Atracurium	besylate,	[I21] -3,848950855
111555-58-9	-	Naltriben	mesylate,	[H17] -1,601638462 2058-52-8	-	Clothiapine,	[K16] -3,893406321 145599-86-6	-	Cerivastatin,	[A12] -3,934405994
78213-63-5	-	Piribedil	HCl,	[M17] -1,605014731 642-72-8	-	Benzydamine,	[P22] -3,983170647 51-40-1	-	Epinephrine-(+)-tartrate	l	(-),	[F17]-3,954042984
50-03-3	-	Hydrocortisone	21-acetate,	[N05] -1,616856632 57808-66-9	-	Domperidone,	[D13] -4,033548444 27848-84-6	-	Nicergoline,	[I03] -4,107041131
749-02-0	-	Spiperone,	[F15] -1,617659483 14976-57-9	-	Clemastine	fumarate,	[J21] -4,107423202 53643-48-4	-	Vindesine,	[E15] -4,119350389
363-24-6	-	Dinoprostone,	[C18] -1,618652502 159989-64-7	-	Nelfinavir	Mesylate,	[K18] -4,117923473 54965-21-8	-	Albendazole,	[G19] -4,124625903
1841-19-6	-	Fluspirilene,	[C15] -1,627247654 43210-67-9	-	Fenbendazole,	[H11] -4,136788133 54063-53-5	-	Propafenone,	[E09] -4,136317486
62571-86-2	-	Captopril,	[O20] -1,651796505 69-09-0	-	Chlorpromazine	HCl,	[D11] -4,170424074 14028-44-5	-	Amoxapine,	[H09] -4,242079216
42971-09-5	-	Vinpocetine,	[J22] -1,65259001 6138-79-0	-	Trans-triprolidine	HCl,	[M21] -4,311911165 10347-81-6	-	Maprotiline	HCl,	[K11] -4,341882724
132203-70-4	-	Cilnidipine,	[I08] -1,658298533 128196-01-0	-	Escitalopram,	[P07] -4,348691255 66104-23-2	-	Pergolide	mesylate,	[D17] -4,480513077
146-56-5	-	Fluphenazine	2HCl,	[D15] -1,673872996 148-82-3	-	Melphalan,	[A10] -4,380946082 33069-62-4	-	Taxol,	[C08] -4,704647158
57149-07-2	-	Naftopidil	2HCl,	[G07] -1,688655921 73573-88-3	-	Mevastatin,	[D10] -4,542685462 183321-74-6	-	Erlotinib,	[E06] -4,812956684
65646-68-6	-	Fenretinide,	[A18] -1,707587451 56392-17-7	-	Metoprolol	tartrate,	[A16] -4,586154805 2058-52-8	-	Clothiapine,	[K16] -4,952503331
162011-90-7	-	Rofecoxib,	[H20] -1,722307582 65646-68-6	-	Fenretinide,	[A18] -4,636644728 2919-66-6	-	Melengestrol	acetate,	[N06] -4,955795643
145599-86-6	-	Cerivastatin,	[A12] -1,737889194 68-96-2	-	17-	hydroxyprogesterone,	[N07] -4,640666328 404-86-4	-	Capsaicin,	[M12] -4,984239699
2058-52-8	-	Clothiapine,	[K16] -1,76132158 54965-24-1	-	Tamoxifen	citrate,	[N08] -4,667778388 19216-56-9	-	Prazosin	HCl,	[G09] -5,085367045
10212-25-6	-	Cyclocytidine	HCl,	[B15] -1,763994066 102625-70-7	-	Pantoprazole,	[G04] -4,831092524 50-03-3	-	Hydrocortisone	21-acetate,	[N05]-5,179393518
53123-88-9	-	Rapamycin,	[A21] -1,798103788 27848-84-6	-	Nicergoline,	[I03] -5,166670497 111974-72-2	-	Quetiapine	fumarate,	[H03]-5,211860437
56296-78-7	-	Fluoxetine	HCl,	[H14] -1,829977383 61825-94-3	-	Oxaliplatin,	[P18] -5,380333123 143-67-9	-	Vinblastine	sulfate,	[K05] -5,35146573
62658-64-4	-	Bopindolol	malonate,	[P19] -1,860056957 64211-46-7	-	Oxiconazole	nitrate,	[E16] -5,446745621 129722-12-9	-	Aripiprazole,	[N19] -5,383766434
159989-64-7	-	Nelfinavir	Mesylate,	[K18] -1,872025792 146-56-5	-	Fluphenazine	2HCl,	[D15] -5,45372414 72656-09-3	-	Carvedilol,	[A10] -5,406870987
7177-48-2	-	Ampicillin	trihydrate,	[I11] -1,943022361 440-17-5	-	Trifluoperazine,	[I12] -5,509163736 60607-34-3	-	Oxatomide,	[M08] -5,416973688
7481-89-2	-	2',3'	-	dideoxycytidine,	[D11] -1,946314285 59865-13-3	-	Cyclosporin	a,	[A09] -5,56828918 51-21-8	-	5-fluorouracil,	[J03] -5,462890658
2062-78-4	-	Pimozide,	[C11] -1,950252778 72656-09-3	-	Carvedilol,	[A10] -5,840993834 302-79-4	-	Retinoic	acid,	[D20] -5,560910033
1951-25-3	-	Amiodarone,	[C07] -1,963008713 23110-15-8	-	Fumagillone,	[C14] -5,893168356 22260-51-1	-	Bromocriptine	mesylate,	[K12]-5,613407338
72509-76-3	-	Felodipine,	[I06] -1,970575347 35898-87-4	-	Dilazep,	[A11] -6,019391899 59865-13-3	-	Cyclosporin	a,	[A09] -5,824208725
6980-18-3	-	Kasugamycin,	[A11] -1,974987292 88495-63-0	-	Artesunate,	[L16] -6,06335834 120092-68-4	-	Manidipine,	[L11] -5,849585017
50-24-8	-	Prednisolone,	[I06] -1,982492139 75330-75-5	-	Lovastatin,	[N05] -6,175711268 69-09-0	-	Chlorpromazine	HCl,	[D11] -5,861944608
101831-37-2	-	Diclazuril,	[N18] -2,412496445 53123-88-9	-	Rapamycin,	[A21] -6,226683313 22916-47-8	-	Miconazole,	[A22] -5,942964735
1054-88-2	-	Spiroxatrine,	[G17] -2,464021131 68844-77-9	-	Astemizole,	[F14] -6,320613344 169590-42-5	-	Celecoxib,	[L18] -6,214257812
123318-82-1	-	Clofarabine,	[A07] -4,679720453 34552-83-5	-	Loperamide,	[C13] -6,447958939 68844-77-9	-	Astemizole,	[F14] -6,593958517
124-94-7	-	Triamcinolone,	[D12] -4,156131038 111974-72-2	-	Quetiapine	fumarate,	[H03] -6,528937604 61825-94-3	-	Oxaliplatin,	[P18] -6,711872524
128794-94-5	-	Mycophenolate	mofetil,	[A03] -3,040684611 50-03-3	-	Hydrocortisone	21-acetate,	[N05] -6,621380758 64211-46-7	-	Oxiconazole	nitrate,	[E16] -6,792794402
129-03-3	-	Cyproheptadine,	[P20] -2,618499386 1841-19-6	-	Fluspirilene,	[C15] -6,675666317 363-24-6	-	Dinoprostone,	[C18] -6,957775607
129722-12-9	-	Aripiprazole,	[N19] -2,086122514 22916-47-8	-	Miconazole,	[A22] -6,684982783 57808-66-9	-	Domperidone,	[D13] -7,066895078
136310-93-5	-	Tiotropium	Br,	[H20] -2,338727467 532-11-6	-	Anethole-trithione	(anetholtrithion),	[N08] -6,715142192 322-35-0	-	Benserazide	HCl,	[O08] -7,14444039
147-94-4	-	Cytarabine,	[B17] -2,089686979 21829-25-4	-	Nifedipine,	[G12] -6,868219637 50-22-6	-	Corticosterone,	[B07] -7,190789059
14976-57-9	-	Clemastine	fumarate,	[J21] -2,079521016 83-43-2	-	Methylprednisolone,	[A14] -6,900965154 14976-57-9	-	Clemastine	fumarate,	[J21] -7,193368207
1744-22-5	-	Riluzole	HCl,	[O19] -2,713082361 93957-54-1	-	Fluvastatin	Na,	[P06] -6,919531501 50-23-7	-	Hydrocortisone,	[N03] -7,417465037
179324-69-7	-	Bortezomib,	[J16] -3,015270441 112965-21-6	-	Calcipotriene,	[J08] -6,982124976 6980-18-3	-	Kasugamycin,	[A11] -7,466715751
18378-89-7	-	Plicamycin,	[F10] -3,167902847 79902-63-9	-	Simvastatin,	[D12] -7,120379632 6090-95-5	-	Conduritol	b	epoxide,	[L20] -7,501642691
19387-91-8	-	Tinidazole,	[B14] -2,19384767 6090-95-5	-	Conduritol	b	epoxide,	[L20] -7,171014555 62571-86-2	-	Captopril,	[O20] -7,566220573
2038-35-9	-	Phenamil,	[E19] -2,186787868 124-94-7	-	Triamcinolone,	[D12] -7,227471021 54965-24-1	-	Tamoxifen	citrate,	[N08] -7,748372573
2114454	-	Camptothecin,	[F08] -3,296464655 50-24-8	-	Prednisolone,	[I06] -7,288258235 50-02-2	-	Dexamethasone,	[M14] -7,797504504
212141-54-3	-	Vatalanib,	[C12] -1,863031286 72509-76-3	-	Felodipine,	[I06] -7,375232216 24280-93-1	-	Mycophenolic	acid,	[A17] -7,984665238
21829-25-4	-	Nifedipine,	[G12] -2,683305711 50-22-6	-	Corticosterone,	[B07] -7,385588653 72509-76-3	-	Felodipine,	[I06] -8,151807525
24280-93-1	-	Mycophenolic	acid,	[A17] -3,048519267 145599-86-6	-	Cerivastatin,	[A12] -7,689297796 378-44-9	-	Betamethasone,	[K11] -8,241101721
25122-46-7	-	Clobetasol	propionate,	[B03] -3,565756495 50-02-2	-	Dexamethasone,	[M14] -7,793755342 58-32-2	-	Dipyridamole,	[M16] -8,242266196
25316-40-9	-	Doxorubicin	HCl,	[H06] -3,150532788 99592-32-2	-	Sertaconazole,	[N15] -7,823956759 25122-46-7	-	Clobetasol	propionate,	[B03]-8,327311915
2919-66-6	-	Melengestrol	acetate,	[N06] -3,708496771 67-73-2	-	Fluocinolone	acetonide,	[J13] -7,845403695 124-94-7	-	Triamcinolone,	[D12] -8,389690181
302-79-4	-	Retinoic	acid,	[D20] -2,226628684 25122-46-7	-	Clobetasol	propionate,	[B03] -7,988057693 50-24-8	-	Prednisolone,	[I06] -8,60027043
33419-42-0	-	Etoposide,	[F14] -3,499571095 378-44-9	-	Betamethasone,	[K11] -7,996017477 5630-53-5	-	Tibolone,	[B10] -8,62906355
34031-32-8	-	Auranofin,	[O18] #DIV/0! 58-32-2	-	Dipyridamole,	[M16] -8,260641052 88495-63-0	-	Artesunate,	[L16] -8,794969568
34552-83-5	-	Loperamide,	[C13] -2,093303875 82640-04-8	-	Raloxifene	HCl,	[F06] -8,518015591 9041-93-4	-	Bleomycin	sulfate,	[P17] -8,795995075
35898-87-4	-	Dilazep,	[A11] -2,083438558 52-86-8	-	Haloperidol	HCl,	[M15] -8,575966221 83-43-2	-	Methylprednisolone,	[A14] -8,907313297
378-44-9	-	Betamethasone,	[K11] -3,073322386 50-23-7	-	Hydrocortisone,	[N03] -8,693503142 128794-94-5	-	Mycophenolate	mofetil,	[A03]-8,978259133
388082-78-8	-	Lapatinib,	[H10] -2,950669511 32222-06-3	-	Calcitriol,	[M04] -8,695449699 18378-89-7	-	Plicamycin,	[F10] -9,272037484
50-02-2	-	Dexamethasone,	[M14] -2,876858819 6980-18-3	-	Kasugamycin,	[A11] -8,787413337 23110-15-8	-	Fumagillone,	[C14] -9,423104294
50-22-6	-	Corticosterone,	[B07] -2,869934473 9041-93-4	-	Bleomycin	sulfate,	[P17] -9,182072291 82640-04-8	-	Raloxifene	HCl,	[F06] -9,451220741
50-23-7	-	Hydrocortisone,	[N03] -2,952012955 71751-41-2	-	Abamectin,	[N04] -9,227092162 82824-01-9	-	Naloxonazine	2HCl,	[F22] -9,61770223
52-86-8	-	Haloperidol	HCl,	[M15] -3,557291946 41294-56-8	-	Alfacalcidol,	[N06] -9,281740272 65646-68-6	-	Fenretinide,	[A18] -9,890495687
532-11-6	-	Anethole-trithione	(anetholtrithion),	[N08]-2,519226247 101831-37-2	-	Diclazuril,	[N18] -9,858517114 52-86-8	-	Haloperidol	HCl,	[M15] -10,18917905
57576-44-0	-	Aclarubicin,	[A14] -4,443454244 33419-42-0	-	Etoposide,	[F14] -10,16807669 53123-88-9	-	Rapamycin,	[A21] -10,37960221
58-32-2	-	Dipyridamole,	[M16] -2,713397016 18378-89-7	-	Plicamycin,	[F10] -10,36683155 68-26-8	-	Vitamin	a	(acetate),	[H19] -10,64390541
58-58-2	-	Puromycin	2HCl,	[F18] -4,407247755 2114454	-	Camptothecin,	[F08] -10,38439828 67-73-2	-	Fluocinolone	acetonide,	[J13] -10,89881841
63675-72-9	-	Nisoldipine,	[L19] -4,373582488 24280-93-1	-	Mycophenolic	acid,	[A17] -10,39786554 60628-96-8	-	Bifonazole,	[K13] -10,90999842
64228-81-5	-	Atracurium	besylate,	[I21] -2,543174205 19356-17-3	-	Calcifediol,	[K22] -10,81083145 99592-32-2	-	Sertaconazole,	[N15] -10,94757686
64439-81-2	-	10-hydroxycamptothecin,	[F22] -4,421122452 57576-44-0	-	Aclarubicin,	[A14] -10,89137923 33419-42-0	-	Etoposide,	[F14] -11,55755237
67-73-2	-	Fluocinolone	acetonide,	[J13] -3,392729164 10212-25-6	-	Cyclocytidine	HCl,	[B15] -10,98716709 83-89-6	-	Quinacrine	2HCl	dihydrate,	[K04]-11,71935787
70288-86-7	-	Ivermectin,	[M09] -4,223805583 63675-72-9	-	Nisoldipine,	[L19] -11,03076084 64439-81-2	-	10-hydroxycamptothecin,	[F22]-11,90258798
71486-22-1	-	Vinorelbine,	[E13] -2,68844862 128794-94-5	-	Mycophenolate	mofetil,	[A03] -11,260195 2114454	-	Camptothecin,	[F08] -12,05472795
71751-41-2	-	Abamectin,	[N04] -3,783970267 64439-81-2	-	10-hydroxycamptothecin,	[F22] -11,64875062 79902-63-9	-	Simvastatin,	[D12] -12,10387524
79902-63-9	-	Simvastatin,	[D12] -2,2285194 25316-40-9	-	Doxorubicin	HCl,	[H06] -12,55865101 10212-25-6	-	Cyclocytidine	HCl,	[B15] -12,45210348
82640-04-8	-	Raloxifene	HCl,	[F06] -3,246125729 82824-01-9	-	Naloxonazine	2HCl,	[F22] -12,80217749 147-94-4	-	Cytarabine,	[B17] -12,74169909
83-43-2	-	Methylprednisolone,	[A14] -3,193503671 147-94-4	-	Cytarabine,	[B17] -13,05973305 101831-37-2	-	Diclazuril,	[N18] -12,98094443
89365-50-4	-	Salmeterol,	[E17] -2,632171275 179324-69-7	-	Bortezomib,	[J16] -13,43047506 64224-21-1	-	Oltipraz,	[E10] -13,32259029
9041-93-4	-	Bleomycin	sulfate,	[P17] -4,228834502 95058-81-4	-	Gemcitabine	HCl,	[P10] -14,18071655 32222-06-3	-	Calcitriol,	[M04] -13,3689594
95058-81-4	-	Gemcitabine	HCl,	[P10] -5,243414738 34031-32-8	-	Auranofin,	[O18] -14,22761407 57576-44-0	-	Aclarubicin,	[A14] -13,52553917
123318-82-1	-	Clofarabine,	[A07] -14,4267973 41294-56-8	-	Alfacalcidol,	[N06] -13,61439792
112965-21-6	-	Calcipotriene,	[J08] -13,63865965
21829-25-4	-	Nifedipine,	[G12] -14,05693049
123318-82-1	-	Clofarabine,	[A07] -14,0604983
25316-40-9	-	Doxorubicin	HCl,	[H06] -14,06383757
19356-17-3	-	Calcifediol,	[K22] -14,30257387
71751-41-2	-	Abamectin,	[N04] -14,39741541
34031-32-8	-	Auranofin,	[O18] -14,52859068
95058-81-4	-	Gemcitabine	HCl,	[P10] -14,542782
179324-69-7	-	Bortezomib,	[J16] -14,72653871
-19,2316631
